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ABSTRACT
Efficacy studies are often done on diseased animals while pharmacokinetic 
studies are done on healthy animals. Disease models are inherently difficult to 
standardize because o f the many variables associated with measuring pharmacokinetic 
parameters in abnormal animals. Information derived from pharmacokinitic studies 
with diseased animals could be useful to determine if  therapeutic doses of a drug or 
antimicrobial becomes less effective or toxic due to changes in distribution and 
clearance.
The objectives of this study were to: characterize a pulmonary infection model 
in swine using Actinobacillus pleuropneumoniae; evaluate the pharmacokinetic changes 
associated with the pulmonary infection model and dexamethasone after the infusion of 
enrofloxacin and urine enrofloxacin and ciprofloxacin concentrations: and the 
comparison endotoxin administration and dexamethasone to the pharmacokinetic 
changes of the infection model.
In the infection study, infected pigs became ill within two hours of inoculation 
and had microscopic lesions of necrotizing, fibrinopurulent pneumonia consistent with 
Actinobacillus pleuropneumoniae infection; plasma interleukin-6 was slightly elevated 
in the infected pigs and not the dexamethasone pigs: clearance of enrofloxacin was 
increased in the dexamethasone treated pigs: volume o f  distribution of the elimination 
phase and at steady state were decreased in the infection: and the urine 
enrofloxacin/creatinine ratios were decreased in the dexamethasone treated pigs.
xi
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In the endotoxin study, the endotoxin treated pigs exhibited toxic signs within 
30 minutes; the plasma interleukin-6 concentrations were markedly elevated in the 
endotoxin treated pigs; the dexamethasone treated pigs showed an increased clearance 
o f enrofloxacin; volumes of distribution was increased in the dexamethasone treated 
pigs; the urine enrofloxacin/creatinine ratios were elevated in the endotoxin group 
compared to control, dexamethasone and endotoxin-dexamethasone groups while the 
ciprofloxacin/creatinine ratios in the endotoxin group was elevated and the 
dexamethasone treated pigs had elevated urine ciprofloxacin/creatinine ratio at 24 h but 
decreased at 48 and 72 h. These results show that the infection model was reliable, 
infection had no effect on enrofloxacin distribution and clearance, dexamethasone 
concurrent administration with enrofloxacin may reduce efficacy because of increased 
clearance and the comparison of the endotoxin model compared to the infection model 
gave incongruous results.
xii
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INTRODUCTION  
Factors Affecting Xenobiotic Disposition
It has been shown that the disposition o f xenobiotic substances may be affected 
by the disease process (Gibson & Skett. 1986; Monshouwer et al.. 1995b). Alterations 
in absorption, distribution, metabolism and excretion depend on the microorganism, 
compound and route of exposure of a drug or antimicrobial (Monshouwer et al., 1995a). 
An alteration o f one of these variables may have a profound impact on pharmacokinetic 
parameters exhibited by a particular drug. All four processes can be affected during an 
infection-induced acute-phase response. The acute-phase response occurs when 
physiological homeostasis is upset by infection, inflammation, tissue injury, neoplastic 
growth, or immunological disorders. The physiological response starts with a local 
reaction at the site o f  injury and progress to a systemic reaction. The local reaction is 
characterized by platelet aggregation, increase vascular permeability and activation and 
accumulation of granulocytes and mononuclear cells. The systemic reaction is 
characterized by fever, anorexia, increased white blood cell-counts. inhibition of gastric 
function, increased release of endocrine hormones and alterations in plasma cation 
concentrations. The term, acute-phase. refers to changes in several plasma proteins.
Delayed gastric emptying can reduce drug absorption from the duodenum and 
jejunum. The rate o f gastric emptying can be affected by anxiety, stress, food and 
infections. In pigs, an experimentally induced acute-phase response decreased the 
absorption rate of orally administered trimethoprim or oxytetracycline (Ladefoged.
1979; Pijpers et al.. 1991). Gastric secretion and gastrointestinal motility can be
1
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affected during infection, which results in altered absorption rate (Groothius et al..
1978; Leenen & van Miert, 1969). The binding of drugs to plasma proteins can 
influence drug disposition. Albumin and a l -acid glycoprotein (AGP) are the main drug 
binding proteins. Inflammation and infection induce an acute-phase response which 
decreases albumin and increases a r acid glycoprotein production (Eckersall et al.. 1996; 
Heinrich et al., 1990; Kushner & Mackiewicz. 1993). Alpha,-acid glycoprotein is an 
important binder o f basic drugs such as propanolol. while albumin binds acidic drugs 
like penicillin. Increased concentrations of a r acid glycoprotein and albumin can alter 
the volume of distribution and drug half-life. The kidney is the most important organ 
for the excretion o f  most drugs below 400 Daltons (Da) molecular weight and drugs 
greater than 400 Da are excreted by the liver. Therefore, renal or hepatic dysfunction or 
diminished renal or hepatic blood flow may affect the excretion rate of drugs 
(Monshouwer et al.. 1995a). Metabolism can also be affected by either infection or 
inflammation.
Domestic animals are especially at risk to infections, because of crowding and 
poor housing conditions where outbreaks of disease are common (Fedorka-Cray et al.. 
1993a). The swine industry is an example o f high density production. Diseases in 
countries raising pigs were high and economic losses were large. Observations from 
laboratory animals and humans provide supporting evidence that infection impairs drug 
disposition, but information is lacking in domestic animals. Infection may induce 
pharmacokinetic changes in domestic animals to the same extent as laboratory species 
and humans. These alterations may have clinical consequences such as increased drug
i
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toxicity or diminished drug efficacy: or decreased toxicity and increased efficacy. 
Decreased half-life, decreased volume of distribution and increased clearance may be 
manifested by decreased efficacy. On the other hand, increased half-life, increased 
volume of distribution and decreased clearance may lead to drug toxicity. Alternatively, 
increased half-life, increased volume of distribution and decreased clearance may signal 
pharmacokinetic changes leading to excessive residue concentrations o f veterinary 
drugs and metabolites in food. The potential for a human food safety problem is likely 
because levels o f  drugs residues may be increased in animal tissues due to decreased 
metabolism of the parent compound.
Infections and Drug iMetabolism 
The main site of drug metabolism is the liver, but lung. skin, kidney and small 
intestine may also metabolize xenobiotic substances. Drug metabolism reactions are 
classified into Phase I and Phase II reactions. Phase I reactions consist o f oxidative and 
reductive reactions that create or alter functional groups and Phase II reactions are 
conjugations. Phase II reactions may depend upon the activities of Phase I enzymes. 
Phase II reactions couple a drug or metabolite to an endogenous substrate such as 
glucuronic acid, glutathione, sulphate, aceytl or glycine. Metabolism of most drugs is 
accomplished by families I to IV of the microsomal cytochrome P450's (Nebert & 
Gonzalez, 1987; Paine. 1991). Hydroxylation. dealkylation. dehalogenation. 
epoxidation and deamination are typical oxidation reactions. In humans studies, 
bacterial, viral and parasitic infections have been shown to impede drug metabolism by 
suppressing cytochrome P450's (Armstrong & Renton. 1993a.b: Azri & Renton. 1987;
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Chang et al.. 1978: Descotes et al., 1985; Farquar et al.. 1983; Galtier et al.. 1986: 
Glazier et al.. 1994: Kokwaro et al.. 1993; Kramer & McClain. 1981; Maffei et al.. 
1981: Renton. 1981.1986; Selgrade et al., 1984; Soykaef al.. 1976). A variety o f 
infections all showed an impairment o f drug metabolizing activities, which 
demonstrates that the source of infection does not necessarily dictate the expected 
effect. Experimental animals exposed to either microbial infection or inflammatory 
stimuli, endotoxin or turpentine, respond by manifesting physiological, hematological 
and metabolic changes that characterize the acute-phase response (Ballmer et al., 1991; 
van Miert. 1990).
Previous work has focused on Phase I metabolism, but only limited information 
is available on the effects o f infection on Phase II metabolism. Malarial infection 
decreased the glucuronidation o f 3'-azido-3' deoxythymidine and paracetamol in rat 
liver microsomes (Ismail et al.. 1992). Ehrlichiaphagocytophilia or Trypanosoma 
infection in goats depressed the glucuronidation of chloramphenicol and sulfadimidine 
metabolites (Anika et al., 1986; van Gogh et al.. 1989). In Salmonella dublin infected 
calves, it was observed that the elimination half-life of chloramphenicol was increased 
(Groothuis & van Miert, 1987). Prolongation of the elimination half-life of paracetamol 
in malaria-infected rats was also shown (Mansor et al.. 1991). Immunosupressed mice, 
infected with Schistosoma mansoni, had prolonged pentobarbital induced sleep-times 
(Tonelli et al.. 1995).
4
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Cytokines and Metabolism
The acute-phase response may be triggered by cytokines released from 
macrophages-monocytes. Interleukins l a  and 1(5 (IL-1 a /p ). tumor necrosis factors a  
and P (TNF-a/p) and interferons a  and P (INF-a/p) are cytokines that inhibit oxidative 
and conjugative drug metabolism in laboratory animals (Craig et al., 1989b; Ghezzi et 
al., 1986a.b; Morgan & Norman. 1990; Renton & Knickle. 1990). The interferon- 
inducer (INF-a), tilorone. was shown to decrease the activity o f several drug 
metabolizing enzymes in the rat (Renton & Mannering. 1976b) such as Bordetella 
pertusis. E. coli. lipopolysaccharide (LPS) and polyinosinic acid-polycytidylic acid 
(poly IC). that induced INF decreased total cytochrome P450 (P450) and related enzyme 
activities (Renton & Mannering. 1976a). Bordatellapertusis and LPS also induced 
tumor necrosis factor-a (TNF-a). interleukin-l (IL-1) and interleukin-6 (IL-6). In 
following years, many reports described the effects of cytokine inducers. polylC and 
LPS effects on cytochrome P450 mediated drug metabolism (Cribb et al.. 1994; 
Delaporte et al., 1993; Ghezzi et al., 1986b; Morgan. 1989; Morgan & Norman. 1990; 
Sakai et al.. 1992; Shedlofsky et al.. 1994; Stanley et al., 1988).
When it was proven that cytokines were involved in infections, cytochrome 
P450 activity was decreased by lowering concentrations o f mRNA and apoprotein to 
suppress drug metabolism. Other studies were performed to directly expose laboratory 
animals to cytokines. Tumor necrosis factor-a, IL-1. IL-6 or interferons depressed 
cytochrome P450 dependent enzyme activities of P450IIC11 and P450I1C12 genes in 
male and female rat livers, respectively (Ghezzi et al., 1986a.b.c; Shedlofsky et al.,
5
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1987: Stanley et al.. 1991; Wright & Morgan. 1991). When administered in 
combination to female rats. IL-1 and dexamethasone significantly depressed total P450 
and P450IIC12 apoenzyme and mRNA (Wright & Morgan. 1991. Interleukin-la alone 
significantly suppressed total P450 content. P450IIC11 apoenzyme and P450IIC12 
mRNA. Interleukin-6 was not as potent, but it did potentiate the effects of 
dexamethasone. In another investigation, the effects o f  IL-1 and IL-6 on P450IIC12 
expression in rat hepatocyte cultures were examined (Morgan et al.. 1994). The effects 
on expression of multiple cytochrome P450 gene products in male rat livers was also 
examined in vitro. Interleukin-1 suppressed the expression of P450IIC12 mRNA and 
protein in cultured hepatocytes. No consistent effect o f IL-6 was observed. Maximal 
suppression of P45II2C12 mRNA after 24 h of IL-1 treatment reached 12 and 32% of 
control concentrations in two separate experiments. Cytochrome P450IIC12 protein 
was suppressed to 28% of control concentrations as early as 12 h after IL-1 treatment. 
Injection of IL-1. low doses o f dexamethasone. or both, in male rats produced decreases 
in total P450 and in P450IIIA2 and P450IIC11 mRNA and protein expression similar to 
effects previously seen for P450IIC12 expression in females. Cytochrome P450IIEI 
mRNA and protein was significantly suppressed only by the combination of IL-1 and 
dexamethasone. Interleukin-6 treatment of male rats down-regulated the P450IIC11 and 
P450IIE1 mRNAs at a dose o f 4.5 pg/kg, which was lower than that required to induce 
haptoglobin mRNA. a prototype acute phase gene product. Cytochrome P450IIC11 
protein content o f the microsomes was also decreased by IL-6 treatment, with a slower 
time-course than for suppression of its mRNA. No significant effects of IL-6 treatment
6
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were seen on P450IIIA2 mRNA or P450IIIA2/1. Therefore. IL-1 and IL-6 treatments. 
in vivo. differentially affect subsets of P450 gene products in rat liver. The effects o f 
LPS. TNF-a and IL-1 on the mixed-fimction oxidase system, in vivo, may be due partly 
to an induction o f IL-6 in vivo (Chen et al.. 1992). The different sensitivities of the 
enzymes to IL-6. but not to IL-1 or TNF-a may be due to the involvement o f two 
distinct mechanisms where ethylmorphine-N-demethylase and ethoxycoumarin-O- 
deethylase were affected; ethoxyresorufin-O-deethylase was minimally affected and 
pentoxyresorufm-O-deethylase was not affected.
The differential effects of IL-1 a  and IL-P may be difficult to explain because 
they both bind to the same biological receptor (Type I) and elicit the same biological 
responses (Kalian et al.. 1986. 1990). For example, IL -la /p  may coordinate the brain- 
endocrine-immune responses to physiological and pharmacological stimuli by binding 
to the same receptor (Takao et al.. 1992). The binding o f radiolabeled IL-1R antagonist 
(IL-ra) in homogenates of mouse hippocampus, spleen and testis was linear over a broad 
range of membrane protein concentrations, saturable, reversible and of high affinity. In 
competition studies. IL-lra. recombinant human IL-1 a . IL-ip and a weak IL-ip analog 
inhibited radiolabeled IL-lra binding to mouse tissues in parallel with their biological 
activities. The binding characteristics and distribution o f IL-lra were comparable to 
those of previously characterized Type I IL-1 receptors. The biological effects of IL-1 P 
have been more extensively studied, because IL -la  is not released into the systemic 
circulation. Nonetheless, differential effects of IL-1 P on cytochrome P450 were 
observed in arthritic rats (Ferrari et al.. 1993b). Interleukin-la may have similar
7
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effects, but this has not been studied. Experimental arthritis and inflammation reduced 
liver cytochrome P450-dependent monooxygenase activities with subsequent 
impairment of drug metabolism. Arthritis was induced on day 0 by type II collagen and 
a low dose (0.2 mg) o f  N-acetylmuramyl-L-alanyl-D-isoglutamine and human 
recombinant IL-1 was administered subcutaneously at the daily dose of 0.02. 0.2 or 2.0 
micrograms to each arthritic rat. from day 21 to 25 and on day 28. Ethoxyresorufin-O- 
deethylation was depressed 6-fold in arthritic rat liver microsomes and the 2.0 pg 
dosage of IL-1 potentiated this depression. Pentoxyresorufm-O-deethylation activity 
was decreased by 50% in arthritic rats, following IL-1 treatment. Progesterone 60- 
hydroxvlation and P450IIIA protein increased by 2-fold in both untreated arthritic rat 
liver microsomes and after the low dose of IL-1. The two higher doses o f IL-1 
decreased this activity to baseline concentrations in the arthritic rats. Laurie acid 
hydroxylation increased 2-fold in arthritic rats and was further potentiated by IL-1. This 
study demonstrated that main liver drug-metabolizing isoenzymes during established 
collagen-induced arthritis in rats were affected by systemic IL-1. Treatment with IL-1 
mimicked or reversed the influence of the inflammatory process on these enzymes.
Actinobacillus Pleuropneumoniae Infection in Swine 
This study tested a specific drug, enrofloxacin. in the presence of a pulmonary 
infection with Actinobacillus pleuropneumoniae (APP). whereas previous studies have 
employed non-therapeutic or classical substrates . such as antipyrine. instead of 
pharmaceuticals to measure pharmacokinetic parameters in diseased animals 
(Monshouwer et al.. 1995a). It is the intent of this study to characterize the disposition
8
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and clearance of enrofloxacin in the infected animal with Actinobacillus 
pleuropneumoniae using a field strain of serotype 1 that has a low virulence (Baarsch et. 
al.. 1995: van Leengoed et. al.. 1987, 1989. 1990; Henselefn/.. 1996). Subsequently, 
the morbidity rate was high, but the mortality rate was low.
Actinobacillus pleuropneumoniae can cause peracute. acute or chronic 
respiratory disease in swine. The host's response to an acute infection includes a 
moderate hyperthermia, lethargy and reduced feed and water consumption. The 
infection occurs in many swine producing countries and causes great economic loss due 
to high morbidity and mortality (Monshouwer. 1996). This study has employed a 
domestic APP field strain. L91-2. belonging to serotype 1 which is common in the 
United States (Baarsch et al.. 1995). The low virulence of the culture was produced by 
serial in vitro passage on solid growth media. In the Netherlands serotype 9. strain 
13261. was employed to perform pharmacokinetic studies. This strain was only passed 
once in mouse lungs to decrease virulence (Monshouwer et al.. 1995a). In the present 
study, only the attenuated field strain. L91-2, was inoculated into swine. High 
morbidity, but low mortality occurred because of the reduced virulence o f the field 
strain, L91-2.
The acute and peracute forms of porcine Actinobacillus pleuropneumoniae 
resemble septic shock in humans. Therefore, an Actinobacillus pleuropneumoniae 
infection model may prove to be useful as a model for septic shock. Bacterial sepsis 
produced by Actinobacillus pleuropneumoniae depends on a variety o f virulence 
factors: capsule, endotoxin, hemolysin and cytotoxins which play important roles in the
9
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pathogenesis (Fedorka-Cray et al.. 1994). Other Gram-negative bacteria, such as 
Escherichia coli. also produce endotoxin. Lipopolysaccharides have been shown to 
induce TNF-a and other inflammatory cytokines which altered pharmacokinetic 
parameters. Endotoxin down-regulated cytochrome P450 and decreased hepatic 
microsomal enzyme activities. Furthermore, endotoxin stimulated transmembrane L- 
arginine transport in pulmonary endothelial cells (Cendan et al.. 1995). 
Lipopolysaccharide stimulation of plasmal membrane L-arginine transport was 
mediated via an autocrine loop involving TNF-a and IL-1. The marked increase in 
carrier mediated L-arginine transport activity produced by LPS. IL-1 and TNF-a may 
represent an adaptive response by pulmonary endothelium to support arginine- 
dependent biosynthetic pathways during sepsis. Lipopolysaccharide stimulation of 
arginine transport was partially mediated through an autocrine mechanism that involves 
IL-1 and TNF.
Definitive studies showing that cytokines affect P450 mediated reaction in food 
and companion animals are lacking. Past research concentrated on viral or bacterial 
infection and vaccinations to achieve changes in drug metabolism in domestic animals 
(Beadle et al.. 1989; Short. 1986). For example, a soft tissue infection model was 
created in horses by infecting subcutaneous tissue chambers with Streptococcus 
zooepidemicus organisms (Beadle et al.. 1989). The horses were treated with cephapirin 
which decreased systemic neutrophilia, pyrexia, anemia and chamber bacterial counts. 
Cephapirin failed to eliminate the infection in the tissue chambers. Another 
subcutaneous tissue chamber model was designed to study the interaction o f Pasteurella
10
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hemolytica. sulfadiazine/trimethoprim and bovine viral diarrhea virus in calves (Clarke 
et al.. 1989b). Bacteria were not cleared from the tissue chambers, despite exceeding 
the in vitro minimum bactericidal antimicrobial concentration in the chamber. The lack 
of antimicrobial effectiveness was related to decreased pH and increased protein 
concentrations in chamber fluids after inoculation. Infection with bovine viral diarrhea 
virus had no effect on the Pasteurella hemolytica response to sulfadiazine/trimethoprim 
antimicrobial therapy. Bovine viral diarrhea virus was thought to suppress host 
responses to inflammation (Clarke et al.. 1989b).
Another tissue chamber study explored the effect o f infection on the distribution 
o f sulfadiazine and trimethoprim in cattle (Clarke et al.. 1989a). Increased total serum 
protein and albumin concentrations, decreased pH. distention of blood vessels and 
erosion of surface capillaries were associated with marked increase in the penetration of 
sulfadiazine and trimethoprim into infected tissue chambers compared to non-infected 
chambers. A concurrent increase in the apparent volume o f distribution for sulfadiazine 
and trimethoprim was associated with increased tissue penetration (Clarke et al..
1989a).
Naturally occurring diseases have provided much insight into the effects of 
infection on pharmacokinetic parameters, but were difficult to control to insure 
reproducibility between groups. Theophylline pharmacokinetic parameters were 
unaltered in horses vaccinated with killed equine influenza vaccine (Short et al.. 1979). 
This apparent contradiction to the previously mentioned studies may be explained by 
vaccination failure with no measurable antibody titer or the failure to induce appropriate
11
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cytokines that would cause pharmacokinetic changes to include down-regulation of 
cytochrome P450. The APP infection model was developed as an experimental 
respiratory disease model (Baarsch et al.. 1995: et al.. I995a.b). The Baarsch model 
was standardized by optical density readings, while the Netherlands model was 
standardized by plating serial dilutions in order to obtain the correct bacterial 
concentration.
An in vitro study was conducted to determine the effect of APP infection on 
Phase I and Phase II hepatic microsomal enzymes in castrated pigs (barrows) 
(Monshouwer et al.. 1995b). Actinobacilluspleuropneumonicie infection produced 
significant suppression of 33% or more of all oxidative activities after 24 h post­
infection. All glucuonyltransferase activities were unaffected by APP infection after 24 
and 40 hours. To further clarify the mechanism o f oxidative suppression of enzyme 
activities. mRNA analysis were performed by dot blot using a human cytochrome 
P450IIIA4 cDNA probe (Monshouwer et al.. 1995b). Infection with APP seemed to 
reduce P450iIIA activity associated with in vitro reduction of 6P-hydroxyIation of 
testosterone, aniline hydroxylation. ethoxyresorufin O-deethylation and 
pentoxyresorufin O-depentylation enzyme activities. While these results were 
interesting, the suppression of model oxidative reactions may not be indicative of 
effects with a therapeutic drug. Furthermore, the use of dot blots to measure total RNA 
may not be as accurate as Northern blots. In another study, the effect o f bacterial acute- 
phase response model was investigated in vivo. Plasma clearances o f antipvrine. 
caffeine, paracetamol and indocyanine green were measured in healthy and APP
12
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
infected pigs (Monshouwer et al., 1995a). The most meaningful change was 
suppression o f oxidative hepatic biotransformation during the acute-phase response 
elicited by APP. Again, the study predicted the fate of a model drug rather than verify 
the fate of a pharmaceutical.
In one study, endotoxin was non-selective in down-regulating cytochrome P450 
metabolism and depressed different forms of several P450's (Monshouwer et al..
1996a), while a separate study indicated that endotoxin was isoform specific (Dr. 
Michael Myers, unpublished). Another report compared the endotoxin model to an APP 
infection model in swine (Monshouwer et al.. I995a.b. 1996a). The lipopolvsaccharide 
model showed a close similarity to the APP infection model based on the large decrease 
o f antipyrine plasma clearance. Total cytochrome P450 content and microsomal P450 
enzyme activities were also decreased 24 h after LPS administration. In swine, 
endotoxin decreased the activities of ethoxyresorufin O-deethyiase. caffeine 3- 
demethylase and testosterone 6p-hydroxyIase which corresponded to rat P4501A1, 
P450IA2 and P450IIIA. respectively. The decreased enzyme activities were 
accompanied by a corresponding decrease in P450IA and P450IIIA apoprotein 
concentrations. In rats and mice, all constitutive P450 isoforms were down-regulated by 
LPS (Chen et al.. 1992: Ferrari et al., 1993a; Morgan. 1993). Western blots were 
performed on P450IA and IIIA. The representative control and treated animals had 
nearly equal band widths in the representative Western blots, which may be interpreted 
that their was no difference between controls and treated pigs.
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Growing swine (35 kg) and finishing swine (85 kg) received intravenous 
endotoxin (2 or 20 (ig/kg) 24 h prior to harvesting the livers. Western blots of 
constitutive P450 showed that endotoxin had no effect on the concentrations o f P450IIE 
or IIIA (Dr. Michael Myers, unpublished). The relative concentrations o f P450IA2 and 
IID6 were unaffected in finishing swine, but were reduced or absent in growing animals. 
Endotoxin challenge completely eliminated detectable cytochrome P450IIA6 and IIB2 
in growing and finishing swine. Endotoxin also eliminated cytochrome P450IA2 and 
reduced the level of IID6 in growing swine. Growing swine had less ethoxyresorufin- 
O-deethylase and coumarin-O-dealkylase than finishing swine and these changes were 
independent of endotoxin dose. Therefore, it was concluded that: cytochrome P450 
expression in swine was dependent upon the age o f the animal: cytochrome P450's was 
not universally down-regulated by endotoxin administration in swine; and. results from 
growing animais may not adequately explain the metabolic fate of drugs in finishing 
swine.
Enrofloxacin
Enrofloxacin. a fluoroquinolone antibiotic, was chosen to assess the influence of 
infection on metabolism, for these primary reasons: First, it was very effective in 
treating porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae 
(Gutierrez et al.. 1993). Forty-two antimicrobial agents were tested in 57 field strains of 
Actinobacillus pleuropneumoniae. The in vitro susceptibility of 839 isolates of 
Actinobacillus pleuropneumoniae showed that danofloxacin had high potency over 
other less effective antimicrobials (Raemdonck et al.. 1994). Cephalosporins and
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quinolones (ciprofloxacin, enrofloxacin and sparfloxacin) were the most active 
antibiotics for treating porcine pleuropneumonia. Enrofloxacin fed in the diet (150 
mg/kg) produced a marked control of Actinobacillus pleuropneumoniae infection with 
reduction of the severity o f thoracic lesions and a reduced prevalence o f the organism in 
the lung at necropsy (Smith et al.. 1991). In a Japanese study, enrofloxacin and 
orbifloxacin were effective when administered subcutaneously. intramuscularly or 
orally administered to swine for pneumonia due to Actinobacillus pleuropneumoniae 
(Nakamura. 1995). In other countries, comparison o f minimum inhibitory 
concentrations tested the effectiveness of 12 antimicrobial agents on swine pathogens, 
including Actinobacillus pleuropneumoniae. in the United States. Canada and Denmark 
(Salmon et al.. 1995). Enrofloxacin had similar minimum inhibitory concentrations 
from one country to another, but variations in the M IC's of the remaining antimicrobial 
agents were observed. Secondly, approval is being sought for the use o f 
fluoroquinolones in food animals (Hannan et al.. 1989: fCung et al.. I993a.b). Thirdly, 
enrofloxacin undergoes N-dealkylation of the ethyl group on the piperazinvl ring, which 
serves as useful marker to determine the effect o f porcine Actinobacillus 
pleuropneumoniae infection on metabolism. Presently, the most likely porcine 
dealkylating P450 subfamily might be IIIA. Inhibitors of IIIA included tiamulin, 
SKF525A, cimetidine and ketoconazole in pig livers (Witkamp et al.. 1994). When 
tiamulin was added to the incubation medium, the N-demethylation rate of 
ethylmorphine and the hydroxylation of testosterone at the 6p- and 1 la-positions were 
strongly inhibited. The microsomal N-demethylation rate of erythromycin and the
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hydroxvlation of testosterone at the 2P-position were inhibited to a lesser degree, 
whereas the ethoxyresorufin-O-deethylation. aniline hydroxylation and testosterone 
hydroxylations at the 15a- and 15p-positions were not affected by tiamulin. In the rat. 
the IIIA subfamily was inducible by steroids (dexamethasone). macrolide antibiotics, 
imidazole antifungals. clotrimazole and phenobarbital (Bachmann et al. 1992: Gonzalez. 
1988; Watkins, 1990). Further support o f oxidative metabolism by P450IIIA was 
presented in a study using APP (Monshouwer et al.. 1995b) where the effect o f APP 
infection on both oxidative and conjugative microsomal enzyme activities was 
investigated in castrated male commercial pigs. All oxidative enzyme activities were 
suppressed by 33%. To further clarify the mechanism of the suppression of oxidative 
enzyme activities, analysis o f mRNA were conducted by dot blot analysis using a 
human cytochrome P450IIIA4 cDNA probe. The reduction in cytochrome P450IIIA 
activity, specific for 6a-hydroxyIation of testosterone, was postulated to be at a pre- 
translational level, as measured by a decrease in the amount o f mRNA. Flavin- 
containing monooxygenases (FMO) are more likely than heme-protein P450s to be 
involved in N-oxidation and N-dealkvlation of enrofloxacin. but absolute proof is 
lacking in swine (Sorgel, 1989). Although, the specific isozyme for the dealkylation is 
unknown, the biotransformation of enrofloxacin to ciprofloxacin may be decreased by 
down-regulation of P450 due to APP infection or endotoxin in this study.
In the past, there has been widespread extra-label use of fluoroquinolones in 
food animals and enrofloxacin, norfloxacin and ciprofloxacin were the ones most 
frequently used in veterinary medicine. Fluoroquinolones have been used, in an extra-
16
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label manner, by veterinarians to treat swine enteric infection, enzoonotic pneumonia, 
septicemia, mastitis-metritis-agalactia and pleuropneumonia (Guitterrez et al.. 1993: 
Kung et al.. 1993a.b). However, the extra-label use of fluoroquinolones in food animals 
was banned in 1997 by the United States Food and Drug Administration. Therapeutic 
use of approved fluoroquinolones in non-food animals was not affected by the ban.
Rationale
The hypothesis of this investigation is: infection with APP or endotoxin 
administration may alter enrofloxacin pharmacokinetic parameters. Therefore, a 
combination of one or more o f the following five conclusions are possible: 1) In 
domestic animals, pharmacokinetic studies have historically been conducted in healthy 
animals, while efficacy studies are conducted in diseased animals. However, infected 
animals may have altered pharmacokinetic parameters when compared to normal 
animals. 2) Target animal safety problems could arise in drug development and 
approval whereby therapeutic doses are actually toxic. 3) Conversely, increased rate of 
clearance could indicate a need for more frequent dosing. Previously effective doses 
may not be adequate to treat an infected animal. 4) Human food safety is an important 
concern. Potential reductions in therapeutic drug clearance in food animals would result 
in elevated residues concentrations even after a proper withdrawal period. Withdrawal 
times are derived from non-infected animals. The purpose o f the present study was to 
determine if the pharmacokinetic parameters of a therapeutic drug (enrofloxacin) are 
altered by APP infection and pleuropneumonia in swine. 5) Infection with APP does 
not alter pharmacokinetic parameters.
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This study was designed to demonstrate that pharmacokinetic alterations can be 
induced by a specific disease, porcine pleuropneumonia, coupled with a specific 
antibiotic, enrofloxacin. in swine. Other investigators have approached this question, 
but have not strongly connected a natural disease with a therapeutic drug to demonstrate 
altered pharmacokinetic parameters.
Few studies have explored the possibility of altered pharmacokinetic parameters 
in infected domestic animals. An Actinobacillus pleuropneumoniae infection model has 
been used, but it is a different serotype (9) than the United States field serotype (1) used 
in this study (Monshouwer et al., 1995a;b). The virulence may vary between the strains 
and influence the experimental results. Variation in virulence may mean a variation in 
bacterial toxins which may directly relate to the amount of P450 down-regulation and 
the suppression o f metabolism. The use of in vitro methods or classic substrates to 
explore pharmacokinetic changes can not accurately predict real world pharmacokinetic 
parameters without using a specific pharmaceutical, test species and microbial disease. 
Dot blot analysis is a good screening tool, but can not compare to the specific molecular 
weight controls o f the protein and mRNA bands found in Western and Northern blots. 
Large doses o f endotoxin were administered in the endotoxin study (Monshouwer et al., 
1996a). However, a single dose of 20 pg/kg o f endotoxin was nearly lethal to swine 
while five doses o f 17 pg/kg at 1 hour (hr) intervals was not lethal in separate study 
(Monshouw'er et al.. 1995a; Myers et al., 1997). A single dose of 17 ug/kg LPS should 
desensitize hepatic microsomal enzymes and create a maximum reduction of 
metabolism (Dr. Michael Myers, unpublished). Furthermore, the results were related to
18
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the weight of the pig; growing pigs respond differently to LPS than finishing pigs (Dr. 
Michael Myers, unpublished). High doses o f LPS should reduce some cytochrome 
P450 activity to undetectable levels.
On one hand, cytochrome P450IIIA is an important constitutive enzyme in the 
pig and total cytochrome P450 content was decreased in infected pigs (Monshouwer et 
al.. 1995b). On the other hand. LPS down-regulation is selective for IIA6 and IIB2. but 
there is no effect on IIE and IIIA (Dr. Michael Myers, unpublished). In the dot-blot. 
two control and two infected animals were used to show that mRNA was reduced in the 
treated pigs (Monshouwer et al.. 1995b). Measurement o f protein by Western and 
Northern blots would be more direct and reflect a more accurate picture of P450 status. 
Unfortunately, there is no statistical analysis o f variability between the control and 
treated animals. The dot blot of total mRNA revealed visual differences in the size and 
intensity of the blot between control and treated pigs. In a group of 23 normal pigs, the 
amount of several cytochrome P450's varied by as much as 6 fold for IIIA (Dr. Michael 
Myers, unpublished). The mean differences in enzyme activities were real, but within 
normal variability with no statistical differences among the 23 control pigs (Dr. Michael 
Myers, unpublished). The Western blot in the endotoxin study requires careful 
interpretation, when the two control pigs were compared to the two LPS treated pigs 
(Monshouwer et al., 1995b). Cytochrome P450IA and IIIA were decreased, but the 
width of the protein bands in the photograph were almost identical. These studies with 
dot blots fall short without specific P450 probes that target purified proteins (controls)
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and use too few animals to allow for adequate quantitative and statistical analysis 
pertaining to dot and Western blots.
Therefore, this study has four objectives to: I) to determine whether endotoxin 
administration will serve as an acceptable model for Actionobacillus pleuropneumoniae 
and other Gram-negative pathogens: 2) determine whether infection with APP alters the 
disposition kinetics and urinary- metabolite profile of enrofloxacin: 3) determine whether 
the potential inhibition o f enrofloxacin metabolism is associated with specific 
cytochrome P450 isozymes; and 4) compare the endotoxin exposure with the porcine 
Actinobacillus pleuropneumoniae infection model.
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CHAPTER I 
LITERATURE REVIEW  
Cytochrome P450 Inhibition
History
Agents that inhibited reticuloendothelial system (RES) phagocytosis also 
prolonged the sleep-times of sodium pentobarbital anesthesia (Samaras & Dietz. 1953). 
Additional research by other investigators showed that increased RES phagocytosis 
increased the barbiturate sleep-times during anesthesia (Di Carlo et al.. 1965; Wooles & 
Borzelleca. 1966; Wooles & Munson. 1971). Sleep-times were used as an indirect 
measure of hepatic microsomal activity and drug metabolism in vivo. This dilemma 
was solved by demonstrating that prolonged barbiturate sleep-time was directly related 
to the depression of the microsomes and was independent o f activation o f RES- 
mediated phagocytosis (Wooles & Munson. 1971). Treated animals had abnormal 
sleep-times lasting 10 days after administration of an RES inhibitor which meant that 
the effect of the activating agents was long-lasting (Wooles & Munson. 1971).
Zymosan was one of the agents that enhanced phagocytic activity and depressed several 
drug metabolizing enzymes; aminopyrine-N-demethvlase. /?-nitroanisole O- 
demethylase and aniline hydroxylase in both male and female mice (Hojo et al.. 1976). 
The effect on enzyme activities was also long-lasting (7 days) after exposure to 
zymosan.
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Cytokines as effectors in the acute-phase response
Infections are clinically manifested by stimulation of RES activity and other 
components o f the immune system such as pro-inflammatory cytokines (Myers and 
Kavvalek. 1995: Whicher & Evans, 1990). The source of infection should be irrelevant 
and infection should depress levels and activities o f  drug-metabolizing enzymes after 
the release of cytokines in the acute-phase response (Myers and Kavvalek. 1995). 
Therefore, infections are well-known inducers of the acute-phase response 
(Monshouwer. 1996). The acute-phase response is characterized by an initial local 
reaction at the site of injury and a subsequent systemic reaction (Kushner. 1982: van 
Miert. 1995: Monshouwer et al., 1995a.b. 1996a). After tissue injury, infection, 
inflammation, neoplastic proliferation, or immunological disorders, the local reaction 
consists of processes such as platelet aggregation, increased vascular permeability and 
activation and accumulation of granulocytes and mononuclear cells. The systemic 
reaction consists o f fever, anorexia, leukocytosis, inhibition of gastric emptying, 
increased endocrine hormone release and alterations in plasma cation concentration. In 
a classical sense, the acute-phase response infers fluctuations of plasma protein 
concentrations at different rates and to different degrees (Gitlin & Colten. 1987). 
Elevated acute-phase proteins include: serum amyloid A. fibrinogen, haptoglobin. C- 
reactive protein and a,-acid glycoprotein (Heinrich et al., 1990; Kushner &
Mackiewicz. 1993). Albumin and transferrin plasma concentrations diminish during the 
acute-phase response and are "negative" acute-phase proteins. Acute-phase proteins are
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mostly synthesized in the liver and aid in the defense against the causes o f tissue 
damage and infection (Volanakis. 1993).
Activated immune cells secrete cytokines that have a complex role in the acute- 
phase response (Monshouwer 1996). Cytokines are peptides or glycoproteins weighing 
from 6 to 60 kiloDaltons (kDa) that act in a non-enzymatic. hormone-like fashion as 
intercellular messengers (Richards et al.. 1995). Cytokines act on a variety of tissues 
and a single cytokine can be released by multiple cell types (Richards et al.. 1995). 
These proteins act in an autocrine or paracrine manner, but they may act systemically in 
an endocrine manner. High affinity for receptors accounts for their potency 
(Monshouwer et al.. 1996b). Over 80 cytokines are known to have a wide variety o f 
functions, but mainly stimulate growth and differentiation. Every cell type expresses 
multiple receptors and responds to many cytokines, which makes it impossible to assign 
unique biological activities. Furthermore, a particular cytokine may have multiple 
biological effects with other cytokines so that there is substantial redundancy in their 
mode of actions (Paul. 1989).
Pro-inflammatory cytokines and infection
Acute-phase responses are readily induced by infection. Pro-inflammatory 
cytokines, such as TN F-a. IL-1. IL-6 and the interferons have important roles in 
response to infections by the host (Whicher & Evans. 1990a). In animals and humans. 
TNF-a is one of the first cytokines to appear after release as an initial burst (Beutler et 
al.. 1985). Generally, peak systemic concentrations were reached one to two hours after 
induction. Interleukin-1 is released after TNF-a and before IL-6 (Fong et al.. 1989).
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Interleukin-6 is released as a secondary burst about one hour after TNF-a and it 
gradually rises for several hours (Fong et al.. 1989; Schalaby et al.. 1989; Van Deventer 
et al.. 1990).
The sequential release of TNF-a. IL.-1 and IL-6 is a common response to Gram- 
negative bacteria, such as Escherichia. Actinobacillus and Pasteurella species. Species 
differences account for many variations to the cytokine cascade, but variations were also 
due to the character and timing o f the stimulatory agent (Monshouwer. 1996). For 
example, interferons are the main cytokine in the acute-phase response induced by viral 
infection, because patients with confirmed viral infections have significantly increased 
INF serum concentrations (Joklik. 1990). Endotoxins (lipopolysaccharide) or poly IC 
are inflammatory stimuli that induce the cytokine cascade. Lipopolysaccharide induces 




Tumor necrosis factor -a  (TNF-a) can alter physiological and immunological 
events as well as induce pathophysiological responses of several disease conditions 
(Myers & Murtaugh. 1995). Tumor necrosis factor has a wide spectrum of physiologic 
functions; mediates hemorrhagic necrosis in tumors, wasting in chronic disease, 
stimulates release of platelet activating factor, activates hepatocytes. increases IL-6 
synthesis and recruits immune and non-immune cells (Edwards et al.. 1994). Usually, 
tumor necrosis factor is released from macrophages and monocytes as a proximal-
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mediator before the release IL-1 and IL-6 in septic shock. Endotoxin increases serum 
TNF-a concentrations by enhancing TNF-a gene transcription approximately 10-fold, 
cellular TNF-a mRNA 100-fold and a 10.000-fold increase in the quantity o f protein 
secreted from activated monocytes.
Early investigators observed that Trypanosoma hrucei infection caused a marked 
hypertriglyceridemia along with anorexia and wasting diathesis. At first, the condition 
was attributed to deficiency of lipoprotein lipase (Kawakami & Cerami. 1981; Rouzer 
& Cerami. 1980). Production of the active factor was induced by endotoxin in sensitive 
mice, but was not induced in endotoxin resistant mice. Serum from sensitive mice that 
had been treated with endotoxin induced the wasting syndrome in resistant mice 
(Kawakami & Cerami. 1981). This factor was called cachectin. In orally fed animals, 
infusion of cachectin/tumor necrosis factor-a caused weight loss and muscular wasting, 
accompanied by anorexia (Matsui et al.. 1993). Despite muscle wasting, there were 
gains in weight, protein and DNA contents of the viscera, but no significant metabolic 
abnormalities. Oral feeding prevented loss of body weight, but cachectin-treated 
animals had reduced nitrogen retention and carcass weight. By contrast, there were 
gains in visceral protein concentrations, which in the liver was due to a marked 
proliferation of biliary epithelium. In addition, cachectin-treated animals receiving feed 
developed hyperglycemia, hyperosmolality, diuresis, dehydration, azotemia and 
cholestasis. In the absence of the effects o f anorexia, cachectin reduced nitrogen 
retention and caused metabolic and multisystem dysfunction, comparable with the 
effects o f clinical sepsis.
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At the turn of the century, it was noted that some tumors underwent hemorrhagic 
necrosis following streptococcal infection (Kawakami & Cerami. 1981). The necrosis 
was caused by TNF-a and not a bacterial component. The serum factor inducing 
hemorrhagic necrosis o f transplantable tumors (TNF) and the macrophage hormone 
associated with cachexia in cancer and certain infectious diseases were shown to be the 
same protein, cachectin (Mullin & Snock. 1990). Because an association may exist 
between TNF-a and the cachectic state, the effect o f TNF-a on the permeability of 
epithelial barriers was evaluated. Tumor necrosis factor was shown to affect the tight 
junctional region between epithelial cells, lowered the transepithelial resistance and 
potential difference and increased the flow of solute between cells and across the 
epithelium. These effects were dose dependent, rapidly reversible and inhibited by a 
monoclonal antibody to TNF-a. This suggested that the release o f TNF-a at various 
sites throughout the body produced a general breakdown in the barrier function of an 
epithelial cell sheet (Mullin & Snock, 1990). Furthermore, the breakdown of the 
epithelial barrier may not only explain cachexia in cancer and chronic infections, but it 
may also explain hemorrhagic necrosis of some tumors.
A selective inhibitor of TNF-a synthesis is pentoxify lline (Strieter et al., 1988). 
Pentoxifylline is a methylxanthine derivative that inhibits phosphodiesterases. The 
subsequent increase in cAMP blocks accumulation of TNF-a mRNA by decreasing the 
rate of transcription, but has no effect on transitional derepression (Han et al., 1990b: 
Noel et al., 1990; Schonharting & Schade. 1989). Pentoxifylline has proven to be too 
toxic for practical use in swine (Dr. Michael Myers, personal communication from Dr.
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Michael Murtaugh). Other methylxanthines suppress TNF-a synthesis: theophylline, 
theobromide. isobutyl methylxanthine (Strieter et al., 1988). These compounds were 
nearly as effective, but molar concentrations were 2 to 5 times greater than 
pentoxifylline. Prostaglandin E2. misprostel. ciprofloxacin and phenylcyclopentenone 
were other agents that increase cyclic AMP, inhibit accumulation o f TN F-a mRNA and 
prevent TNF-a production in monocytes, macrophages and lymphocytes (Edwards et 
al.. 1994: Kunkel et al., 1988: Mahatana et al., 1991). Inhibition of TNF-a may impact 
other cytokines, as TNF-a induces the production and release of IL-l and IL-6.
Dexamethasone and other glucocorticoids inhibit TNF-a mRNA accumulation 
(Beutler et al., 1986; Han et al.. 1990b; Luedke & Cerami. 1990). Dexamethasone may 
alter TNF-a mRNA concentrations by inhibiting early transduction o f proteins, but it 
only inhibits TN F-a if present prior to endotoxin injection. Therefore, dexamethasone 
is of limited benefit during septic shock.
Tumor necrosis factor and interleukin-1 in endotoxemia and sepsis
Tumor necrosis factor has immunological, hematopoeitic. cell differentiation, 
reproduction, antiviral and endotoxic/septic shock effects (Myers & Murtaugh. 1995). 
Tumor necrosis factor, in high doses, produces a variety o f systemic endotoxic/septic 
shock effects to include; hemodynamic, pulmonary, metabolic and pathological events 
(Tracey. 1991). Chronic TNF-a exposure leads to cachexia that was characterized by 
weight loss, protein and lipid depletion and anorexia. Chronic TNF-a administration 
directly affects the hypothalamus to induce fever and the release of corticotropin- 
releasing-factor (Martin & Tracey. 1991). Depletion of body fat. induction o f insulin
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resistance in adipocytes and decreased resting membrane potentials in myocytes are 
direct effects (Goldblum et al.. 1989: Kiorpes et al.. 1990; Parrilo. 1993; Stephens et al.. 
1988a). Anabolic responses of the liver were indirect effects which reflected a cascade 
of cytokine and hormone responses that persist for hours after the TNF-a blood 
concentrations have dissipated (Nemerson. 1992). The effects of intravenous bolus 
injections of TN F-a and IL-ip on hepatic mitochondrial energy metabolism were 
investigated in rats (Shimahara et al.. 1995). The administration of TNF-a and IL-1 (3 in 
rats induced a hypermetabolic state in hepatic mitochondrial energy metabolism, which 
was a pattern similar to sepsis and presumably a compensatory reaction to the increased 
energy consumption
Actinobacillus and Pasteurella species are Gram-negative pathogens that 
produce respiratory bacterial infections in animals (Kiorpes et al.. 1990). Subsequently, 
the lung becomes septic with increased vascular permeability, edema, injury' to 
endothelial cells and death of the animal (Goldblum et al.. 1989; Stephens et al..
1988a). Mortality after sepsis was directly related to the induction of TNF-a and a 
tissue factor which was an inducible cell surface glycoprotein (Henry & Moore. 1988; 
Levi et a l. 1993; Nemerson. 1992: Parrilo. 1993; Taylor et al. 1991). Tumor necrosis 
factor may cause systemic hypotension and altered cell metabolism, while tissue factor 
expression results in a local blood coagulation at the inflammatory site and 
systemically. Coagulation activation occurs through the expression of tissue factor on 
the cell membrane surface o f circulating monocytes and tissue macrophages. Tumor 
necrosis factor may shift the balance between procoagulant and anticoagulant activities
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by initiating the tissue factor pathway of blood coagulation (Aderka, 1991). The most 
severe consequence of the cascade was disseminated intravascular coagulopathy and a 
rapid progression to death (Hoffman et al., 1990: Thomson et al.. 1974: Vestweber et 
al.. 1983). Tumor necrosis factor mediation of lung injury was induced by LPS in 
sheep, dogs, cattle, goats and pigs (Baarsch et al.. 1995; Egawa et al.. 1981: Eichacker 
et al., 1991; Fukushima et al., 1992: Gerros et al.. 1993; van Miert. 1990: van Miert et 
al.. 1992; Redl et al., 1990; van Miert et al.. 1992). Psuedomonas aeruginosa and 
Actinobacillus pleuropneumoniae have both been used in pigs to induce acute lung 
injury in studies designed to measure pulmonary alveolar macrophage cytokines, effect 
o f pulmonary infection on pharmacokinetic parameters and pulmonary dysfunction and 
metabolic acidosis associated with Gam-negative sepsis (Baarsch et al.. 1995: 
Monshouwer et al.. 1995a.b: Windsor et al.. 1994).
Previous studies demonstrated that the administration of the cytokines IL-1 and 
TNF to rats in a fasting state can produce many and. if not most, of the metabolic 
alterations found in patients with sepsis and injury (Ling et al.. 1995). Consequently, 
another study was designed to define the metabolic effects of IL-l and TNF-a during a 
fed state by continuous intravenous feeding for 20 hours and to characterize the unique 
effects of IL-1 among other cytokines by employing the IL-1 receptor antagonist. IL-ra 
(5 mg/kg). The effects were also explored during the endotoxemic condition induced by 
infusion of 200 fig/kg o f endotoxin in rats. The results showed that during feeding IL-1 
was responsible for the increase of glucose flux and plasma insulin, the development of
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insulin resistance and plasma zinc depression. In other words, IL-1 initiated conditions 
that mimicked sepsis and injury that were similar to events in the fasting state.
The changes in energy expenditure have a more complex mechanism. The 
results suggested that certain host responses to cytokines or endotoxin, related to protein 
metabolism, differ between the fed and fasting states. These data may have clinical 
relevance for the insulin-resistant state that develops during severe infection, because 
IL-1 receptor antagonists may be used in conjunction with nutritional therapy to offer 
additional advantages in the treatment of these drastic metabolic disorders.
Cytokines can be produced within the nervous system by various cell types, 
including astrocytes, which secrete them in response to pathological processes such as 
viral infections (Yu et al.. 1995). Astrocytes were known to play an important role in 
the homeostasis of the nervous system by contributing to the regulation o f local energy 
metabolism. Tumor necrosis factor-a and IL -la  markedly stimulate glucose uptake and 
phosphorylation in primary cultures of neonatal murine astrocytes. The effects of TNF- 
a  and IL -la  on glucose uptake and phosphorylation may be mediated by the 
phospholipase A2 signal transduction pathway. These results demonstrated that TNF-a 
and IL -la  can fundamentally perturb the energy metabolism of astrocytes, possibly 
impairing their ability to provide adequate energy substrates for neurons.
Interleukin-1 
History
Three different investigators identified IL-I. The first described a pyrogenic 
factor (endogenous pyrogen) that was produced by activated peritoneal exudate cells
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(Heyman & Beeson. 1949). The second investigator described a factor that was 
synthesized from activated mononuclear phagocytes and acted as a co-stimulator of 
thymocyte proliferation, termed lymphocyte activating factor (Gery & Waksman. 1972: 
Gery et al.. 1971). The third investigator described a soluble mediator, leukocyte 
endogenous mediator, that regulated the acute-phase response (Kampschmidt. 1984). 
The three biological factors were identified and the identical factors were given the 
name, "interleukin-1” (Dinarello. 1984; Kampschmidt. 1984). Additional work 
revealed that IL-1 was produced by every nucleated cell type if  not most cells had IL-1 
receptors on their surface (Dower & Urdal, 1987). Monocytes and macrophages were 
stimulated to produce IL-l by lipopolysaccharide. interferon-y (INF-y). muranyl 
dipeptide, microorganisms, poly IC and complement 5a.
Interleukin-1 in inflammation and host defense
Interleukin-1 is a key promoter of inflammation. There are two forms of 
interleukin-1: IL -la  and IL-1 p. In humans, there was a difference in the time frame that 
the two forms are produced; the a  form was produced early and then the cell switched 
to producing the p form (Dr. Michael Myers, personal communication). Even though 
there was only a 16 to 20% homology between the two forms, they both bound to the 
same Type I receptor (Bomsztyk et al., 1989; Horuk et al., 1989). There was also 
binding to Type II receptors, but without initiating biological activity. Hence. IL-1 type 
II receptors are also termed decoy receptors since they have no biological effects (Dr. 
Michael Myers, personal communication). Adherence of leukocytes to endothelial cells 
and the degradation of cartilage have been examined in detail. In bovine and porcine
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domestic species, IL-1 and other cytokines activate endothelial cells to express surface 
molecules that implement the adhesion and extravasation of IL-1 activated neutrophils 
(Canning & Baker. 1990; Goodman et al., 1991; Johnston et al., 1992; Modat et al., 
1990; Sample & Czuprynski. 1991; Zimmerman et al.. 1992). Interleukin-1 stimulates 
collengenase production and proteoglycan degradation by cartilage explants in vitro 
(Buideetal.. 1992; Conquer et al.. 1992; Mauviel et al.. 1988; Mori et al.. 1989). The 
influence of IL-l on cartilage degradation may be an important part of the inflammatory 
process in arthritic joints (Lederer & Czuprynski. 1995). Lyme disease patients and 
rheumatoid arthritis patients have increased production of IL-1. which further supports 
the role of IL-l as a biological mediator in the pathology of arthritis (Beck et al.. 1989; 
Smith et al.. 1989).
Most o f the literature on IL-1 comes from studies on mice and human cells. 
Veterinary researchers must extrapolate from these studies to a particular species 
(Lederer & Czuprynski. 1995). There was limited literature available on the biological 
effects of IL-1 in cattle, pigs and chickens (Lederer & Czuprynski. 1995). Interleukin- 
l a  and IL-1 (3 are natural porcine isoforms (Huether et al.. 1993; Maliszewski et al., 
1990). These bind with similar high affinity to porcine chondrocytes and synovial 
fibroblasts (Bird & Saklatvala. 1986,1987). Up-regulation of IL-(3 mRNA was observed 
for LPS. phorbol myristate acetate and TNF-a (Huether et al.. 1993). Dexamethasone 
and IL-4 down-regulated mRNA transcription (Huether et al.. 1993). Interferon alone 
did not induce release of IL-1 activity in porcine monocytes, but IL-1 was increased by 
co-stimulation with LPS (Cllarieys et al.. 1990).
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Porcine and human IL-1 have been shown to modulate a host of biological 
responses by porcine cells in vitro. Human IL-1 inhibited proteogylcan synthesis 
without stimulating its degradation by porcine cartilage explants (Nietfeld et al.. 1990). 
Porcine IL -la  decreased collagen synthesis by human rheumatoid synovial cells 
(Mauviel et al.. 1988). Interleukin-1 inhibited progesterone secretion and increased the 
growth of high density cultures o f granulosa cells from small or medium sized ovarian 
follicles, but had no effect on mature granulosa cells (Fukuoka et al., 1989). Little is 
published on the effects of IL-1 on porcine leukocytes. It is known that human IL -la  
induced natural killer (NK) cell lysis of tumor cell targets (Knoblock & Canning. 1992). 
Interleukin-6 
History
Interleukin-6 is a pleiotropic molecule with notable purposes in inflammation, 
hemopoiesis and lymphocyte activation and differentiation (Richards el al.. 1995). 
Rodent models of inflammation have provided in vivo information on the function of 
IL-6. but little data was available in most food-producing animals. Most of the 
investigators have reported work completed in human, rodent and swine systems.
The first observations of IL-6 effects occurred in 1921 when inflamed patients 
yielded blood samples with high erythrocyte sedimentation rates. Erythrocyte 
sedimentation rates are still used today as non-specific markers of inflammation. The 
increased erythrocyte sedimentation rate w'as due to elevation of serum liver proteins. 
Some of these proteins were acute-phase proteins such as fibrinogen. Interleukin-6 w as 
largely responsible for the induction of these proteins from the liver. Early studies that
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sought to isolate and identify IL-1 were obscured by the probable contamination of 
samples with IL-6 and the induction of IL-6 in vivo by crude preparations o f IL-1. It 
was later determined that IL-I induced fever and the production of liver acute-phase 
proteins in rat models of inflammation (Kampschmidt & Upchurch. 1974: 
Kampschmidt et al., 1982). When monocyte or macrophage products were examined, it 
was shown that IL-1 and TNF-a were not fully active (Gauldie et al., 1987b; Koj et al..
1984; Perlmutter et al., 1986). A distinct cytokine . termed hepatocyte stimulation 
factor (HSF). was identified which induced a full spectrum o f hepatic acute-phase 
responses (Bauer et al.. 1984; Baumann et al.. 1987a.b: Darlington et al.. 1986: 
Goldman & Liu. 1987: Koj et al.. 1984; Ritchie & Fuller. 1983; Woloski & Fuller. 
1985). The IL-6 molecule was purified and cloned and was subsequently proven to be a 
potent molecule for regulating hepatocyte responses (Gauldie et al.. 1987a: Hirano et 
al.. 1986).
Acute-phase protein production
It was suggested that mediators responsible for serum acute-phase proteins were 
released by leukocytes at sites of inflammation (Koj, 1974). These mediators acted 
systemically on lymphocytes. The primary role o f IL-6 in vivo was to initiate the 
hepatic inflammatory response. Interleukin-6 serum assays o f animals undergoing an 
inflammatory response revealed a peak concentration of IL-6 at 6-12 h before peak 
concentrations of serum acute-phase proteins (Gauldie et al.. 1992; Jablons et al., 1989; 
Nijsten el al.. 1987; Schreiber. 1987; Schreiber et al.. 1989). The 6 to 12 h time lag
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reflected the time required to synthesize and release cytokines into the systemic 
circulation, interact with hepatic receptors and stimulate hepatic synthesis and secretion.
Treatment with a single low dose (80 to 800 ng) of IL-1 24 h before a lethal 
bacterial challenge o f granulocytopenic and normal mice enhanced non-specific 
resistance (Vogels et al.. 1993). Interleukin-1 induced secretion of acute-phase proteins, 
liver proteins w hich possess several detoxifying effects. The role o f these proteins in 
the IL-1-induced protection was investigated. Inhibition of liver protein synthesis with 
D-galactosamine completely inhibited the IL-1-induced synthesis of acute-phase 
proteins. D-galactosamine pretreatment abolished the protective effect o f  IL-1 on 
survival completely in neutropenic mice infected with Pseudomonas aeruginosa or 
partially in non-neutropenic mice infected with Klebsiella pneumoniae. Pretreatment 
with IL-6. a cytokine induced by IL-1. did not reproduce the protection offered after IL- 
1 pretreatment, nor did it enhance or deteriorate the IL-1-enhanced resistance against 
infection. A protective effect o f IL-1 via effects on glucose homeostasis during the 
acute-phase response was investigated by comparing plasma glucose concentrations in 
IL-1-treated mice and control mice before and during infection. Although glucose 
concentrations in IL-1-pretreated mice were somewhat higher in the later stages o f 
infection, no significant differences from concentrations in control mice were present 
and the glucose concentrations in control and treated animals never fell to hypoglycemic 
values. Interleukin-1-induced non-specific resistance was mediated neither by the 
induction o f IL-6 nor by the effects o f  IL-1 on glucose homeostasis. Acute-phase
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proteins generated after IL-1 pretreatment seem to play a critical role in the IL-l- 
induced protection to infection.
Immune effects
Interleukin-6 is a multifunctional cytokine whose circulating concentrations are. 
under physiological conditions, below detection, but whose production was rapidly and 
strongly induced by several pathological and inflammatory stimuli (Poli et al.. 1994). 
Interleukin-6 has been implicated in a number o f cell functions connected to immunity 
and hematopoiesis. Cells o f the immune system that were affected by IL-6 were: B 
lymphocytes, helper T lymphocytes, cytokine T lymphocytes and NK cells (van Snick. 
1990). In vitro. B lymphocytes require IL-6 for late stage differentiation o f B cells 
(Muraguchi et al.. 1988). Interleukin-6 augmented secondary antibody responses in 
vivo (Takatsuki et al.. 1988). Interleukin-6 played a major role in the development of 
antigen specific humoral responses, but there were no supporting experiments in food- 
producing animals. Interleukin 6 may also synergize with IL-1 to regulate the initial T- 
cell activation (van Snick. 1990). Lastly. IL-6 may increase the lysing activity of 
natural killer cells (Luger et al.. 1989).
Interleukin-6 deficient mice were unable to mount a normal inflammatory 
response to localized tissue damage generated by turpentine injection (Fattori et al.. 
1994). The induction o f acute-phase proteins was dramatically reduced, mice did not 
lose body weight and only suffered from mild anorexia and hypoglycemia. In contrast, 
when systemic inflammation was elicited through the injection of bacterial 
lipopolysaccharide. these parameters were altered to the same extent both in wild-type
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and IL-6-deficient mice, demonstrating that under these conditions IL-6 function was 
dispensable. Moreover, LPS-treated IL-6-deficient mice produce three times more 
TNF-a than wild-type controls, suggesting that increased TNF-a production might be 
one of the compensatory mechanisms through which a normal response to LPS was 
achieved in the absence of IL-6. Different patterns o f cytokines were involved in 
systemic and localized tissue damage which identified IL-6 as an essential mediator of 
the inflammatory response to localized inflammation. Interleukin-6 may regulate 
(locally) bone turnover and are essential for the bone loss caused by estrogen deficiency 
in mice (Poli et al.. 1994).
Changes in the parameters of specific and non-specific immunity after challenge 
of the immunized animals with Marburg virus were characterized (Ignat'ev et al.. 1994). 
Mediators of the immune response. TNF-a and rNF. were shown to play different roles 
in the development of the disease and "protection" o f animals. The survival rate o f the 
immunized animals after the challenge with Marburg virus was determined by the 
intensity and level of the immune response after challenge rather than by the 
concentrations o f post-vaccination immunity at the time of the challenge.
Hematopoiesis
Interleukin-6 interacted with IL-3 to enhance stem cell differentiation (Wong & 
Clark. 1988). Strong inducing effects on megakaryocyte colony formation were 
impressive (Akira et al.. 1990; Kishimoto. 1989). Interleukin-6 and IL-11 may have a 
use in supporting cancer patients, but high concentrations of IL-6 cause pathological
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increases in proliferation o f hematopoietic myeloid cell lineage on multiple myeloma 
and Castleman's disease (Akira et al., 1990; Zhang et al.. 1990).
Anti-inflammatorv mediators
The initiation o f the acute-phase response by IL-6 has been well characterized 
(Bauman & Gauldie. 1990; Gauldie, 1991; Koj. 1985; Richards & Gauldie. 1995;
Travis & Salvesen, 1983). On the other hand. IL-6 has been shown to inhibit the release 
o f pro-inflammatory cytokines IL-1 and TNF-a from monocytes in vitro (Aderka et al.. 
1989; Mancilla et al., 1990). In vivo. LPS induced inflammation in the rat lung was 
reduced by IL-6 (Guo et al., 1992; Ulich et a l , 1991). Interleukin-6 also inhibited joint 
inflammation in a collagen-induced arthritis model (Ikuta et al.. 1991). Tissue 
inhibition of metalloproteinases-1 was enhanced by IL-6. The balance of 
metalloproteinases and tissue inhibitors of metalloproteinases-1 help govern the net 
catabolism of connective tissue matrices in normal physiological processes and in 
pathological conditions involving joints and lungs (Lotz & Gueme. 1991).
Other systemic functions of IL-6 in inflammation include actions in the brain. 
Interleukin-6 was shown to enhance ACTH production in vitro and to increase ACTH 
in serum of rats (Perlstein et al., 1993; Woloski et al.. 1985). These ACTH effects 
probably cause increases in glucocorticoids in serum after inflammatory stimuli. 
Increased glucocorticoids may modulate numerous functions such as decreased cytokine 
production, suppression of lymphocyte responses and enhancement of regulation of 
various acute-phase protein genes (Richards et al., 1995). In addition. IL-6 has also 
been shown to increase body temperature (Akira et al.. I990a.b). Thus, IL-6 has a
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major role in several aspects o f the systemic inflammatory response. Analysis of these 
activities in mice, rats and rabbits and correlation with IL-6 levels in humans, suggest 
that similar activities of IL-6 may occur in pigs, cattle and poultry in vivo. However, 
this has not been determined.
Xenobiotic Immunomodulation by Cytokines 
Cytokines in acute and chronic disease
Interleukin-1. IL-6 and TN F-a act synergisticallv to induce fever, initiate acute- 
phase protein synthesis, activate neutrophil and macrophage antimicrobial activity, 
decrease serum iron and zinc concentrations and induce tissue catabolism (Dinarello. 
1986; Hardie & Kruse-Elliot. 1990; Le & Vileck. 1987; Whicher & Evans. 1990b). 
These were beneficial events in the formation o f an effective inflammatory and immune 
response to invading microorganisms and in tumor surveillance. The inflammatory 
reaction was beneficial for humans when its effects were limited to the pathogens 
(Hakim. 1993). The insufficiency o f  a component of the inflammatory reaction such as 
the production of reactive oxygen species (ROS). which was seen in chronic 
granulomatous disease, leads to severe and recurrent bacterial infections. In other 
situations, inflammatory reactions were deleterious because they were directed against 
normal tissues instead, or in addition to. pathogens.
In some instances, the behavior of the phagocytes was modified, because they 
have been primed by inflammatory molecules such as TNF, LPS. interleukins or 
interferons. Priming often led to a decreased speed of locomotion of the leukocytes 
with an increased susceptibility to their stimuli. The combination o f these effects leads
39
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
to a premature release by the phagocytes o f their killing and degradative factors. 
Production of ROS such as that seen during irradiation, drug metabolism, or ischemia 
followed by reperfusion induced inflammatory reactions with a secondary amplification 
of ROS production. Acute ROS production can also lead to thrombosis, whereas 
chronic ROS production induced a chronic inflammatory reaction o f the endothelium 
with atherosclerosis as a possible consequence. Reactive oxygen species may either 
positively or negatively control the activity of inflammatory molecules. The 
multiplicity of the cross reactions between ROS and inflammation suggests a search for 
new therapeutic drugs that disconnect these two events.
In contrast, pro-inflammatory cytokines also have adverse effects in both acute 
and chronic diseases (Dinarello. 1986: Hardie & Kruse-Elliot. 1990: Lahdevirta et al.. 
1988: Le & Vileck. 1987; Morris & Moore. 1991; Sprouse et al.. 1987; Whicher & 
Evans. 1990b). Tumor necrosis factor and IL-1 were involved in the induction of shock 
associated with Gram-negative sepsis, trauma and bums (Dinarello. 1991; Eichacker et 
al.. 1991: Hardie & Kruse-Elliot. 1990: Tracey & Cerami. 1989; Whicher & Evans. 
1990b). Pathogenic sequellae associated with IL-1 and TNF-a release included 
hypotension, depressed myocardial function, vascular leakage, microvascular 
thrombosis, tissue neutrophilic infiltration and necrosis and multiple organ failure. 
Chronic production of pro-inflammatory cytokines caused cachexia found in 
inflammatory and neoplastic disorders (Bistrian et al.. 1992; Cotran. 1987; Grunfeld & 
Feingold. 1992: Le & Vileck. 1987; Tracy & Cerami. 1992). The cachexia was a result
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of increased oxidation of amino acids, muscle proteolysis and accelerated synthesis of 
acute-phase proteins in the liver.
Tumor necrosis factor and IL-1 were also involved in tissue injury associated 
with inflammation through interaction with neutrophils and endothelial cells. (Cotran. 
1987; Le & Vileck, 1987; Ward. 1991 a.b). Both cytokines sustain the mobilization of 
mature neutrophils from bone marrow and activate the neutrophils. Exposure of 
endothelial cells to TNF-a or IL-1 induced expression of leukocyte adhesion molecules 
and contact between endothelial cells and neutrophils exposes endothelial cells to toxic 
oxygen radicals and proteases. Tumor necrosis factor and IL-1 enhanced the 
susceptibility of endothelial cells to injury by increasing concentrations of xanthine 
oxidase and iron inducing the generation of oxygen radicals and promoted conversion 
into intracellular hydroxyl radicals. Tumor necrosis factor and IL-1 increased the 
amount and surface expression o f tissue factor by endothelial cells. Tissue factor 
expression promoted thrombus formation at the site of inflammation and may play a 
role in disseminated intravascular coagulopathies during shock and sepsis.
Acute inflammation is a natural response to tissue injury during sepsis. 
Excessive tissue destruction, shock, multiple organ failure and death are deleterious 
effects caused by pro-inflammatory cytokines. Therapeutic regimes to limit 
inflammatory responses may be life saving if accompanied by an antibiotic.
Approaches to limit inflammation include: inducing neutropenia, blocking neutrophil 
migration from the blood, antioxidants, iron chelators, antiproteases, inhibitors or 
antagonists of IL-1 and TNF-a and inhibitors of IL-1 and TNF-a production, inhibitors
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of cyclooygenase isozymes (COX-1 and COX-2) (Cotran. 1987; Landoni & Lees. 1996; 
Le & Vileck, 1987; Ward, 191a.b). Therapeutics, such as ibuprofen. which prevent 
effector cells from reaching the site o f inflammation or which inhibit synthesis of pro- 
inflammatory cytokines have the most promise for prevention of tissue injury 
(Eichacker et al.. 1992; Mullen et al., 1993; Nacy et al.. 1990; Stephens et al.. 1988b).
Pro-inflammatory cytokines regulate local inflammatory reactions, but may also 
gain access to the circulation and evoke systemic effects known as the acute-phase 
response (van Miert, 1995). A study was performed to improve the understanding of 
the pathophysiology o f pro-inflammatory cytokines in ruminants using TNF-a. IL -la /p  
and INF-a/y (van Miert. 1995). The following aspects were perceived from this study:
a) cytokine therapy given before or just after microbial challenge induces in vivo 
antimicrobial activity, cytokines potentiate in vivo antimicrobial activity of antibiotics:
b) cytokines may act as biological response modifiers for enhancing specific immunity 
to vaccines and c) cytokines may affect drug absorption, disposition and metabolite 
formation in disease states.
Cytokine therapy in conjunction with antibiotics was further explored in a study 
using Staphylococcus aureus (Sanchez et al.. 1994a.b). A bovine blood 
polymorphonuclear neutrophil system was used to determine the ability of cytokines, 
alone or in combination with various antibiotics, to enhance the intracellular killing of 
Staphylococcus aureus sequestered within these phagocytes. Pretreatment of blood 
polymorphonuclear neutrophils with human recombinant TNF-a. bovine macrophage 
supernatant TNF-a. or human recombinant IL-ip enhanced the killing of S. aureus by
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the phagocytes compared with that of untreated polymorphonuclear neutrophils. This 
enhancement was dose-dependent and required 30 minutes o f contact between the 
cytokine and the blood polymorphonuclear neutrophils. However, mammary gland 
polymorphonuclear neutrophils, macrophages and blood monocytes showed no 
enhanced killing activity following pretreatment with TNF. Pretreatment of 
polymorphonuclear neutrophils with TNF-a and subsequent exposure to various 
antibiotics after infection with S. aureus enhanced intracellular bacterial killing by 
certain antibiotics, including paldimycin. rifampin and ciprofloxacin, but not antibiotics 
that do not normally kill intracellular S. aureus. Cytokine therapy may be a useful 
adjunct to antibiotic therapy in the treatment o f bovine staphylococcal infection and 
mastitis.
Tumor necrosis factor plays a central role in the initiation of inflammation and 
inhibitors of TN F-a production would be a logical choice as inhibitors of inflammation 
(Cavaillon & Cavaillon. 1990). Production of TNF-a can be blocked at two 
pharmacological sites. The first site, blocked by drugs such as dexamethasone and 
cyclosporin A. halted pre-translational derepression without significantly inhibiting 
transcription (Han et al.. 1990a: Trinchieri. 1991: Weinberg et al., 1992). Blocking at 
the second site for compounds that increased cAMP. such as pentoxifylline, 
prostaglandin E2. forskolin and dibutyrl cAMP. prevented translation of TNF-a (Han et 
al.. 1990a: Trinchieri. 1991). Increased concentrations o f cyclic AMP blocked 
accumulation of TN F-a mRNA. as cyclic AMP caused a decrease in the rate of 
transcription (Han et al., 1990a; Noel et al.. 1990). It had no effect on post-
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transcriptional control o f mRNA. The mechanism for this effect was not clearly 
defined, but may involve the retention o f a  necessary transcription factor (NF-kP) in the 
cytoplasm due to the phosphorylation of an associated inhibitor protein (I-kP).
Blocking TNF-a mRNA by increasing cAMP concentrations may require more than a 
therapeutic dose of pentoxifylline. A pharmacological dose of pentoxifylline had no 
protective effects on the acute-phase response reactions induced by a pyrogenic dose of 
Escherichia coli LPS (van Duin et al., 1995). However, both dexamethasone which 
blocks arachadonic acid release and cyclosporin A have been reported to prevent IL-1 
production (Cavaillon & Cavaillon. 1990).
Chlorpromazine (CPZ) inhibited TN F-a production and protected against 
endotoxic shock in mice (Menzozzi et al.. 1994). The effect of pretreatment with CPZ 
(4 mgdcg intraperitoneally 30 min before endotoxin) was compared with dexamethasone 
(3 mg/kg) after induction o f endotoxin-induced cytokines (IL -la. IL6. IL-10 and TNF) 
in the serum of mice. The inhibitory effect o f CPZ and dexamethasone on serum and 
spleen-associated TNF-a release was studied. Induction of IL-1 and IL-6 was inhibited 
by dexamethasone but not by CPZ. Dexamethasone did not affect IL-10. while CPZ 
potentiated its induction. Chlorpromazine also inhibited spleen-associated TNF-a 
induction in LPS-treated mice, suggesting an effect on the synthesis o f  TNF. 
Chlorpromazine inhibited TNF-a induction by Gram-positive bacteria (heat-killed 
Staphylococcus epidermidis) and by anti-CD3 monoclonal antibodies. Intraperitoneal 
administration of CPZ also inhibited the induction of brain-associated TN F-a induced 
by intra-cerebroventricular injection o f LPS. Therefore. CPZ was a more specific
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inhibitor o f TN F-a production than dexamethasone. In particular. CPZ increased the 
induction of IL -10. which is a "protective" cytokine known to inhibit LPS toxicity and 
TNF-a production. Chlorpromazine inhibited TNF-a production in vivo, irrespective of 
the TNF-a stimulus used to induce TNF. Finally, dexamethasone can potentiate TNF-a 
production when administered 24 h before LPS which is called "rebound'’. CPZ did not 
induce the "rebound” effect of dexamethasone when administered 24 h before LPS but 
it did inhibit TN F-a production after 24 h . Chlorpromazine has potent 
immunomodulatory effects in vivo: it induces humoral autoimmunity in up to 50% of 
patients, inhibits delayed-type hypersensitivity reactions and suppresses lethal immune 
hyperactivation in animal models of septic shock (Tarazona et al.. 1995). In an in vivo 
model o f acute superantigen-driven immune activation, CPZ independently down- 
regulated the production o f various T cell-derived cytokines (IL-2. IFN-y. IL-4. TNF-a 
and GM-CSF) and up-regulated the secretion o f IL-10. The mechanism by which CPZ 
and related drugs enhance humoral autoimmune reactions, block cellular immune 
responses and prevent lethal septic shock in vivo may explain the mechanism of action 
of CPZ in endotoxic shock.
The effect of different inhibitors o f cytochrome P450 on TNF-a production can 
repress TNF-a production (Fantuzzi et al.. 1993). Metyrapone and SKF525A (100 and 
50 mg/kg, i.p.. respectively) suppressed serum TNF-a induced by co-treatment with 
LPS. (2.5 micrograms/mouse). Inhibition was independent of endogenous 
corticosteroids since it was also observed in adrenalectomized mice. In vitro production 
of TNF-a by endotoxin-stimulated human monocytes was also inhibited by metyrapone
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and SKF525A. Since lipoxygenase (LO) inhibitors also block TN F-a production and 
metyrapone was reported to inhibit LO. it was suggested that inhibition by metyrapone 
and SKF525A might be due to inhibition of either LO or a cytochrome P450 implicated 
in the oxidation of endogenous substrates involved in the inflammatory response. 
Glucocorticoids
Dexamethasone and other glucocorticoids inhibited TN F-a mRNA 
accumulation (Beutler et al.. 1986; Han et al.. 1990b; Luedke et al., 1990). 
Dexamethasone was believed to alter TNF-a mRNA levels by inhibiting early 
transduction proteins. This may explain why dexamethasone inhibited TNF-a 
production only if present prior to administration of endotoxin. It also explains why 
dexamethasone was o f limited benefit during septic shock. Thalidomide also 
destabilized TNF-a mRNA and reduced its half-life from approximately 30 to 17 min. 
The effect of thalidomide was selective for TNF-a (Moreira et al., 1993). Its 
mechanism of action was distinct from those o f the glucocorticoids and pentoxifylline, 
thus accounting for the synergistic effects of these drugs.
Glucocorticoids acts both at the transcriptional and post-transcriptional level to 
inhibit TNF-a synthesis (Han et al.. 1990a; Trinchieri. 1991). Endotoxin induced TNF- 
a  gene expression was associated with an increase in NF-kB nuclear factors binding kB 
motifs. Tumor necrosis factor action was mediated through receptor signaling 
pathways, as microinjection of TN F-a into the cell has no effect (Niitsu et al.. 1985). 
Tumor necrosis factor rapidly induced production of diacylglycerol (DAG) from 
membrane phospholipids as a result o f activation of a phosphatidylcholine-specific
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phospholipase C (PC-PLC) following binding to the type I receptor. Diacylglycerol 
formation did not result in changes in cellular Ca~+ or inositol trisphosphate (Shutze et 
al.. 1991). Diacylglycerol produced by PC-PLC resulted in the activation of two 
additional signal pathways, protein kinase C (PK.C) and acidic sphingomyelinase which 
breaks down cellular sphingomyelin to produce ceramide (Schutze et al.. 1992). Protein 
kinase C triggered the activation of the proto-oncogenes c-myc. c-fos and c-jun.
The sphingomyelin/ceramide pathway functions to activate NF-kB. Activation 
of NF-kB resulted when the inhibitory subunit I-kB was released from the cytoplasmic 
complex containing the p50 and p65 (rel A) subunits. This dimer was then translocated 
to the nucleus. Ceramide produced from neutral sphingomyelinase also may activate 
NF-kB (Yang et al.. 1993). Neutral sphingomyelin (SM) was directly activated by the 
TNF-a receptor (Kim et al.. 1991). Neutral SM broke down membrane sphingomyelin 
to ceramide. which activated a membrane-bound. 97 kDa-protein kinase. This activated 
kinase then phosphorvlated substrates containing the motif X-Ser/Thr-Pro-X which was 
the consensus sequence for the action of mitogen-activated protein (MAP) kinases. 
Tumor necrosis factor binding resulted in the phosphory lation of 42- and 44-kDa MAP 
kinases (Vietor et al.. 1993: Raines et al.. 1993). Tumor necrosis factor activation of 
the MAP kinases are responsible for production of arachidonic acid through the 
activation of both a secreted phospholipase A2 (sPLA2) and a cellular phospholipase
A2 (cPLA2) (Lin et al.. 1993: Hoek et al.. 1993). Arachidonic acid metabolites play a
role in the induction of c-fos and cell cytotoxicity (Jones et al.. 1993: Chang et al..
1992; Reid et al.. 1991).
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Glucocorticoids strongly inhibited translational derepression of TNF-a (Han et 
al.. 1990a). A highly conserved region in the 3* untranslated mRNA region may be 
responsible for post-translational control. The 3' untranslated region contains the 
(UUAU)n sequence common to many cytokine mRNAs. which may regulate messenger
RNA stability (Jongeneel, 1992). Stimuli that induced NF-kB translocation to the 
nucleus and binding to the promoter region were potent inducers o f TNF. Endotoxin 
was a strong inducer o f NF-kB in macrophages and phorbol mvristate acetate (PMA). 
the classic inducer o f protein kinase C activity and TNF-a itself, also elicited the 
appearance of NF-kB in the nucleus. Various transactivator viral proteins, such as the 
Taxi gene of HTLV-I. activated the TNF-a promoter through the NF-kB enhancer 
element (Albrecht et al.. 1992). These observations showed that the activation of NF- 
k B  was a major route by which TNF-a expression was induced in target cells. Since 
NF-kB was a universal transcription factor and was activated by numerous conditions, 
including bacterial products, viruses and their products, cytokines, mitogens and 
physical and oxidative stresses, it was not surprising that expression of TNF-a has been 
implicated in many physiological and pathophysiological processes (Baeuerle &
Henkel, 1994).
Another mechanism of TNF-a suppression may be through lipocortin induced 
inhibition of phospholipase A2 (Goulding & Guyre. 1992). Many of the anti­
inflammatory effects o f glucocorticoids were dependent on lipocortin 1 synthesis. 
Lipocortin 1 is a calcium binding protein in the annexin family. Lipocortin inhibited 
phopholipase A2 which resulted in decreased production o f platelet activating factor.
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leukotrienes and prostaglandins (Fradin et al., 1988). The binding of lipocortin to 
neutrophils and monocytes reduced chemotaxis and attenuated the release o f oxygen 
radicals and eicosanoids (Goulding & Guyre. 1992).
Efficacy of glucocorticoids in endotoxic shock
Synthetic glucocorticoids, such as dexamethasone and non-steriodal anti­
inflammatory drugs, such as phenylbutazone, are often used as immunosuppressors in 
veterinary practice (Bertini et al.. 1989; Edwards et al.. 1994). The scope o f treatment 
extends from mild allergic reactions to septic shock. Glucocorticoids inhibit TNF-a 
mRNA transcription and prevent translation when corticosteroids were administered 
prior to LPS administration. A lag time is needed for blocking mRNA transcription and 
translation. Cytokines. TNF-a in particular, may contribute to inflammation through 
eicosanoid activation. Arachidonic acid metabolites seem to function as secondary 
messengers to escalate the inflammatory processes. Pretreatment with the 
cyclooxygenase inhibitor, ibuprofen. and other non-steriodal anti-inflammatory agents 
prior to endotoxin exposure may dampen cytokine-mediated prostaglandin responses.
At the same time, negative feedback inhibition of cytokine production by prostaglandins 
is also blocked. The specific actions of these therapeutic steroids and non-steroids on 
cytokine mediated alteration in cytochrome P450 metabolism of antibiotics was 
discovered in the present decade. Efficacy of the veterinary immunomodulators in 
domestic animals has often been assumed, because of extrapolation from human and rat 
data (Myers & Kawalek. 1995).
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Dexamethasone attenuation of experimental endotoxin-induced acute respiratory 
failure in pigs has been evaluated (Olson et al., 1988). Dexamethasone (5 mg/kg) was 
given intravenously 18 and 1 hour before administration o f endotoxin. The 
hemodynamic alterations attributed to endotoxin infusion were attenuated and 
leukotriene B4 was blocked (Weiss. 1995). These preliminary data suggested that 
modulation of inflammatory cytokines may be beneficial in attenuating acute infectious 
pneumonia and septic and endotoxic shock. Perhaps combinations of drugs, such as a 
phosphodiesterase inhibitor and a cvclooxygenase and/or lipoxygenase inhibitor may 
prove to be effective.
Cytochrome P450 Subfamilies and Isozymes 
Rat
The following cytochrome P450s subfamilies have been identified in the rat: IA.
11 A. IIB, IIC. IID. HE. IIG. Ill A. IVA. IVB. IVF. VII. XIA. XIB. XVII. XIX and XXVII 
(Nelson et al., 1993). Analysis o f interspecies differences of P450 primary sequence 
showed a strong evolutionary conservation of the mammalian IA genes (Wrighton & 
Stevens. 1992). In the rat. IA1 was constitutively expressed at low levels in the liver 
and in extrahepatic tissues, such as the lung (Ryan & Levin. 1990). After treatment 
with polycyclic aromatic hydrocarbons (PAH), such as 3-methylcholanthrene. IA1 
concentrations were increased by induction. The second gene of the P450IA subfamily 
vvas IA2. which plays a major role in the rat with the bioactivation of a multitude of 
carcinogens and mutagens (Guengerich. 1988: Nebert et al.. 1987).
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The P450IIA subfamily has been extensively studied in the rat. This subfamily 
had three members (Gonzalez. 1988; Nebert et al.. 1991). The IIA1 isozyme was the 
most extensively studied and was originally referred to as testosterone 7a-hydroxylase 
(Ryan et al.. 1979). The second rat form was IIA2. Although it was highly related to 
IA1 by amino acid sequence, it did not demonstrate the same degree of specificity with 
respect to testosterone hydroxylation (Arlotto et al.. 1989). Furthermore. IIA1 and IIA2 
were not expressed similarly in the untreated rat and were not induced by PAH (Arlotto 
et al.. 1989: Ryan & Levin. 1990; Ryan et al.. 1979). The third rat IIA subfamily 
member . IIA3 was expressed exclusively in the lung, where the concentrations of 
mRNA encoding IIA3 were induced by 3-methylcholanthrene (Kimura et al.. 1989).
The P450I1B6 subfamily were the major forms o f P450 induced by 
phenobarbital and the most widely studied in humans (Adesnik & Atchison. 1985: Ryan 
& Levin. 1990). Phenobarbital induced IIB1 and IIB2 in the rat. where only IIB2 was 
expressed in untreated rats (Adesnik & Atchison. 1985: Ryan & Levin. 1990). The 
substrate specificity of these two forms overlap, but the activity of IIB1 is greater than 
IIB2 for the majority of substrates (Guengerich et al.. 1982; Ryan & Levin. 1990).
Most of the P450IIC subfamily was composed o f  a large number of forms that 
were historically referred to as the constitutive P450s (Ryan & Levin. 1990). This 
designation includes most o f  the rat forms that were expressed in a gender-specific 
manner. As of 1992. seven rat IIC genes had been identified.
The HE subfamily is a very important metabolic system in regards to toxicology. 
In the rat. the HE subfamily contains only one member. IIE1 (Nerbert et al.. 1991).
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This P450 was unusual, because it was induced by many common small organic 
molecules (Wrighton & Stevens, 1992). Furthermore. IIE2 often catalyzed the 
conversion of numerous low molecular weight agents to metabolites that were more 
chemically reactive than the parent compound. Therefore. IIE2 was first isolated as the 
low Km N-nitrosodimethylamine N-demethylase. which was induced after treatment 
with pvrazole, acetone, isoniazid, ketone, isopropanol and ethanol (Patten et al., 1986; 
Ryan et al., 1985). Rat IIE1 was also induced by physiological status, such as fasting, 
diabetes and obesity that result in accumulation of acetone or ketones. It has been 
demonstrated that rat HE 1 was responsible for the metabolic activation o f a large 
number of halogenated toxins to include: carbon tetrachloride, enflurane. alcohols. N- 
nitrosodimethylamine. aniline, benzene, acetone and acetominophen.
The final P450 subfamily involved in hepatic drug metabolism is the IIIA 
subfamily. The various members o f this subfamily have been widely studied, because 
they were shown to be responsible for the metabolism of clinically and toxicologically 
important agents. The IIIA subfamily is inducible by steroids, macrolide antibiotics, 
imidazole antifungals. clotrimazole and phenobarbital (Bachmann et al. 1992; Gonzalez. 
1988: Watkins. 1990). Two genes were identified in the rat. IIIA 1 and IIIA2 (Hardwick 
et al.. 1983; Gonzalez et al., 1986). However, it is important to know that various 
purification procedures and immunochemical characterizations indicate that three or 
four proteins may be present in the P450III family (Halpert. 1988: Hostetler et al., 1987: 
Graves et al.. 1987). It was found that rat III Al was induced by glucocorticoids, such 
as dexamethasone and was not expressed in untreated adult rats (Gonzalez et al.. 1986;
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Wright & Paine. 1994) On the other hand. IIIA2 was not induced by glucocorticoids 
and was expressed only in adult male rats. Finally, both IIIA 1 and IIIA2 were induced 
by phenobarbital (Gonzalez et al., 1986). These forms of rat P450 were specifically 
responsible for erythromycin N-demethylation. steroid 6p-hydroxylation and the 
formation of a stable metabolic intermediate complex with triacetyloleandomycin 
(Wrighton et al.. 1985; Sonderfan et al., 1987). The stable metabolic intermediate 
complex with triacetyloleandomycin inhibited IIIA1 and IIIA2. Hepatocytes from 
female rats lack P450IIIA2 (Fau et al., 1994). Hepatotoxicity due to flutamide. an 
androgen, was lower in female rats than in male rats. Flutamide led to the covalent 
binding of reactive electrophilic metabolites in male rat hepatocyte proteins. The 
female rat did not produce reactive electrophilic metabolites which resulted in lower 
covalent binding to proteins. In a like manner, male rats had reduced covalent binding 
and lactate dehydrogenase release from hepatocytes after piperonyl butoxide. a P450 
inhibitor, administration. The toxicity in male rats was increased by P-naphthoflavone 
which induces P450IA. It was concluded that flutamide was toxic to rat hepatocytes as 
a result of the P450-mediated (IIIA and IA) formation of electrophilic metabolites. To 
date, much less is known about the regulation of expression or substrate specificity o f 
other rat IIIA subfamily members, as compared to humans.
Swine
The following cytochrome P450 families and subfamilies have been identified in 
the pig: XIA1. XVII and XXIA1 (Nelson et al., 1993). Compared to the rat. swine 
P450 subfamilies and isozymes have not been extensively studied (Axen et al., 1994).
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Therefore, there is very little published information concerning substrates, inducers and 
inhibitors. A small number of studies have appeared in the literature and seem to deal 
primarily with the P450IIIA subfamily. One o f these studies investigated the 
simultaneous use of the antibiotic, tiamulin, with certain ionophoric antibiotics 
(monensin. salinomycin) which may give rise to a toxic interaction in pigs and poultry 
(Witkamp et al.. 1994). The effects of tiamulin on hepatic cytochrome P450 activities 
in vitro were tested using pig liver microsomes. When tiamulin was added to the 
incubation medium, the N-demethvlation rate o f ethylmorphine and the hydroxylation 
of testosterone at the 60- and 1 la-positions was strongly inhibited. Tiamulin inhibited 
these activities more than SKF525A or cimetidine. but less than ketoconazole. The 
microsomal N-demethylation rate o f erythromycin and the hydroxylation o f testosterone 
at the 20-position were inhibited to a lesser degree, whereas the ethoxyresorufin-O- 
deethylation. aniline hydroxylation and testosterone hydroxylations at the 15a- and 
150-positions were not affected by tiamulin. Complexation by tiamulin o f cytochrome 
P450 resulting in a loss o f CO-binding capacity was not demonstrated. Thus, it was 
suggested that a selective inhibition of cytochrome P450 enzymes was present in pigs, 
probably those belonging to the P450IIIA subfamily. The mechanism of this interaction 
was unclear. However, interactions between tiamulin and those veterinary drugs or 
endogenous compounds which undergo oxidative metabolism by P450 enzymes must 
be considered.
A second study involving P450IIIA was conducted (Monshouwer et al.. 1995b). 
The effect of APP infection on both Phase I (oxidative) and Phase II (conjugative)
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microsomal enzyme activities was investigated in castrated male conventional pigs.
After 24 h. Actinobacillus pleuropneumoniae infection resulted in a significant 
suppression of 33% or more o f all oxidative enzyme activities determined. After 40 h . 
the activities were still suppressed, but did not differ from the results after 24 h . On the 
contrary, all glucuronosyltransferase activities measured were not affected by APP 
infection after both 24 and 40 h . To further clarify the mechanism of the suppression of 
oxidative enzyme activities, analysis o f mRNA were conducted by dot-blot analysis 
using a human cytochrome P450IIIA4 cDNA probe. The results indicated that APP 
infection suppressed oxidative enzyme activities. The reduction in cytochrome 
P450IIIA activity, specific for 6a-hydroxylation o f testosterone, was postulated to be at 
a pre-translational level, as measured by a decrease in the amount o f mRNA.
In another study, a cytochrome P450XXVII catalyzing la-hydroxylation of 25- 
hydroxyvitamin D3 was purified from pig liver mitochondria (Axen et al.. 1994). It 
also catalyzed 27-hydroxylation of 25-hydroxy vitamin D3 and 25-hydroxyIation of 
vitamin D3. The ratio between the la -. 27- and 25-hydroxylase activities remained 
essentially constant during the purification. This was an example of a constitutive P450 
subfamily in porcine liver.
Cytokine Mechanism of Action on Cytochrome P450 
Interferons
Interferon induction was thought to be the most likely suppresser of P450. 
because all agents that induce INF. such as the antiviral drug tilorone. depressed mixed- 
function oxidase (Leeson et al.. 1976: Renton & Mannering. 1976b). The down
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regulating effect of 12 different INF inducing agents on P450 content and reactions 
supported this hypothesis. Tilorone, Mengo RNA virus. Escherichia coli 
lipopolysaccharide. B. pertussis vaccine, hepatic RNA, poly IC and statolon. from a 
fungal mycophage. were tested. In addition to the interferons, these agents induced the 
production and release of several other cytokines: IL-1, IL-6 and TNF-a.
Testing of purified and hybrid interferons in mice showed that there was a 
relationship between INF concentrations and changes in P450 activity and 
concentrations (Ghezzi et al., 1986a.b). Interferons administered in vivo inhibited 
microsomal metabolism, in vitro, o f benzo(a)pyrene. hexobarbital, 7-ethoxycoumarin. 
benzamphetamine and zoxazolamine (Ghezzi et al.. 1986a.b.c). Murine in vivo and 
human in vitro studies showed increased hexobarbital sleep-times and decreased 
metabolism of antipyrine. p-nitroanisole. theophylline. 16P hydroxylation of 
androstenedione and acetominophen (Craig et al.. 1989a; Franklin & Finkle. 1986; 
Moochhala & Lee. 1991; Moore et al.. 1983;Okuno. 1990; Smith et al.. 1983; Taylor et 
al.. 1985).
Interferon influenced constitutive P450 expression both at the steady state 
mRNA and P450 apo-protein biosynthesis level (Craig et al.. 1990). Messenger RNA 
concentrations were depressed 6-8 h after exposure to INF and reached maximum 
suppression at 24 h post-treatment. Cytochrome P450 apo-protein did not diminish 
until 8-12 h post-treatment. Reduced P450 mRNA mirrored decreased concentrations 
o f hepatic P450 protein (Craig et al.. 1990; Morgan, 1989.1991; Stanley et al.. 1991).
In a more recent rat study, the response o f constitutive enzymes activities to down-
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regulation of INF was not influenced by any of the induction protocol using 
polyinsonoic acid-polycytidylic acid (Anari et al., 1995). The interferon inducers 
depressed the constitutive and induced activities o f ethoxyresorufin O-deethylase. 
benzyl-oxyresorufin O-dealkylase and p-nitrophenol hydroxyalse at all concentrations 
of induction. Cytochrome P450 induction did not invariably confer resistance to 
interferon-medicated down-regulation of the enzymes. Furthermore, the mechanism of 
induction did not determine the response to INF. It was concluded that species and 
duration or level of induction were the major influences on the observed response of 
P450 enzymes to INF down-regulation.
Interleukin-1, interleukin-6 and tumor necrosis factor-a
Interleukin-1. IL-6 and TNF-a are cytokines produced during an inflammatory 
response, including endotoxin challenge (Bertini et al.. 1988.1989: Myers & Kawalek. 
1995). Interferons. TNF-a and IL-6 all down-regulated P450 by affecting hepatic P450 
concentrations and activity. Interferons are potent blockers o f P450 synthesis, but 
definitive proof is lacking that interferons are the primary agents: they may even 
enhance degradation o f P450s. Heat-stable LPS induced serum factor could also 
depress P450 after heat-inactivation of all interferons (Egawa et al.. 1981). It was 
decided that the heat-stable factor was not interferon which led to the discovery of other 
blockers of P450 synthesis. Dextran sulfate induced production of a factor that 
decreased hepatic P450 concentrations and inhibited in vitro aminopvrine and benzo- 
(a)-pyrene metabolism (Peterson & Renton, 1986). The serum samples from the
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animals contained no detectable INF. The serum factor could have been a combination 
of IL-1. IL-6 and TN F-a (Myers & Kawalek, 1995).
More recent research suggests that IL-6 may have an inhibitory effect on 
cytochrome P450IIIA and may alter drug metabolism (Liao et al., 1996). Cyclosporine 
is a drug used to prevent rejection of transplanted organs and is metabolized by 
P450IIIA. Thus, the inhibitory effect o f IL-6 may alter cyclosporine concentrations 
which, in turn, may increase its adverse effects, such as nephrotoxicity. Interleukin-6 
was administered in vivo to rats, resulting in decreased steady state concentrations of 
mRNA and apoprotein for P450 IIC12. microsomal ethylmorphine-N-demethvlase and 
ethoxycoumarin-O-deethylase activities (Williams et al., 1991; Wright & Morgan.
1991).
IL-1 also depressed P450 by inhibiting gene expression (Myers & Murtaugh. 
1995). Ethyoxycoumarin-O-deethylase activity decreased in microsomes from mice 
treated in vivo with IL-1. but did not affect activity when added to microsomes from 
untreated animals. In a study to compare cytokines, cultured rat hepatocytes were used 
to measure the relative activities of human IL-6, IL-1 a  and -P and INF-y (Clark et al.. 
1995. 1996). These cytokines were used to inhibit phenobarbital and/or 3- 
methylcholanthrene induction of cytochrome P450IIB1. P450IIB2. P450IA1 and 
P450IA2. All cytokines produced a concentration-dependent inhibition of 
phenobarbital induction of benzyloxyresorufin O-dealkylase activity. All cytokines 
were less effective in inhibiting the 3-methylchoIanthrene induction of ethoxyresorufin 
O-dealkylase. These results suggested that inducible isoforms of P450 differ in their
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susceptibility to regulation by cytokines. Cytokines possess differential activity to 
inhibit the induction o f P450 isoforms, where IL-1 P and IL-6 were the most effective.
The mechanism for the inhibition of drug-metabolizing enzymes by IL-1 p was 
investigated (Ferrari et al.. 1993a). Interleukin-1 treatment on various drug- 
metabolizing enzymes in male and female rats induced both cytochrome P450IIIA1 
activity and protein in females. In males. IL-1 repressed P450IIIA2 activity without 
decreasing the protein. Cytochrome P450IA1 activity was impaired in males, but was 
retained after dexamethasone pretreatment. Interleukin-1 did not change P450IIB1/2 
activity and protein, but counteracted their induction by dexamethasone. Uridine 
diphospho-glucuronosyltransferase. P450IA2 (bilirubin), activity and its induction by 
dexamethasone were not affected by IL-1 treatment. Both P450IIC11 and epoxide 
hydrolase activities were repressed by IL-1 treatment, as well as dexamethasone 
treatment. The incongruity between the variations of the activities and the protein of 
P450IIIA2 suggested a post-translational regulation. Interleukin-1 treatment mimics 
glucocorticoid effects for P450IIC11. IIIA 1 and for microsomal epoxide hydrolase, but 
not for P450IA1 and IIB1/2. Cytochrome P450IA1 was impaired in males, but its 
activity was restored after dexamethasone pretreatment. Both P450IIC11 and epoxide 
hydrolase activities were repressed by IL-1 treatment, but were not altered by 
dexamethasone.
In a study using rat hepatocytes in primary culture. IL-1P strongly inhibited 
basal ethoxyresorufin O-deethylase and pentoxyresorufin O-deethylase activities and 
fully blocked their induction by pentobarbital in a dose-dependent relationship while IL-
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6 only slightly antagonized pentobarbital-induced pentoxyresorufin activity (Abdel- 
Razzak et al., 1995). This demonstrated that IL-1 (3 can suppress basal P450 activities, 
as well as pentobarbital-inducible expression of five cytochrome P450 mRNA's in 
cultured hepatocytes. A previous experiment provided the first demonstration that 
various cytokines act directly on human hepatocytes to affect expression of major P450 
genes and that a wide range o f responses can be observed among the enzymes for a 
given cytokine, suggesting that different regulatory mechanisms may be involved 
(Abdel-Razzak et al., 1993).
Interleukin-1 triggered the down-regulation o f several hepatic cytochrome P450 
gene products, but the cellular signaling pathways involved are not known (Chen et al.. 
1995). The role o f sphingomyelin hydrolysis to ceramide in the suppression of 
P450IIC11. a major constitutive form of cytochrome P450. by IL-1 was examined. 
Treatment of rat hepatocytes cultured on matrigel with IL -la  caused a rapid turnover of 
sphingomyelin and an increase in cellular ceramide. with no change in cellular 
phosphatidylcholine. The ceramide was composed mainly o f a D-erythro-sphingosine 
backbone, suggesting that it was derived from sphingolipid hydrolysis rather than from 
increased de novo synthesis. Treatment o f the cells with either N-acetyl-D-erythro- 
sphingosine (C2-ceramide) or bacterial sphingomyelinase suppressed the expression of 
P450IIC11 and induced the expression of the interleukin-1-responsive a,-acid 
glycoprotein mRNA. In contrast, the acute-phase gene p-fibrinogen. which was 
induced by IL-6 but not by IL-1. did not respond to C2-ceramide. N-Acetyl-D-erythro- 
sphinganine mimicked the effect of C2-ceramide on P450IIC11. but not on a,-acid
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glycoprotein expression. These results were consistent with a role for ceramide or a 
related sphingolipid in mediating the down-regulation of P450IIC11. the induction of 
a r acid glycoprotein and perhaps other cellular effects of IL-1 in hepatocytes.
Interleukin-1 is known to repress a number o f hepatic drug-metabolizing 
enzymes in rats and humans (Parmentier et al.. 1993). The effect o f interleukin-ip on 
lauric acid 12-hydroxylase (IVA family) was studied in cultured fetal rat hepatocytes 
after clofibric acid induction. Dexamethasone was used as an agent promoting 
differentiation and long-term maintenance of active hepatocytes. Dexamethasone and 
clofibric acid in combination allowed maximal (13.5-fold) induction of IVA 1. Lauric 
acid 12-hydroxylase activity was found to increase with time in culture. Interleukin-ip 
adversely affected P450IVA clofibric acid-induced activity, totally eliminating the 
effect of induction at doses exceeding 5 ng/ml. This repression was dose-dependent. 
The mechanism by which interleukin-ip prevents the development o f cytochrome 
P450IVA activity was unclear.
The cytokine. TN F-a . is a primary inflammatory' mediator after liver injury. 
Several cytokines impair the regulation of cytochrome P450 genes in liver, but the 
specificity of these effects remains unclear (Nadin et al.. 1995). Tumor necrosis factor- 
a  depressed ethoxycoumarin-O-deethylase activity and the steady state concentrations 
of mRNA and apo-proteins for P450IIC12 and IID6 (Bertini et al.. 1988; Chen et al., 
1992; Wright & Morgan, 1991). Microsomal ethylmorphine-N-demethylase and 
ethoxycoumarin-O-deethylase (P450 IIC12) were inhibited by exogenous IL-6 in rats. 
Messenger RNA steady state concentrations were depressed along with decreased apo-
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protein (Williams et a l, 1991; Wright & Morgan. 1991). The effects o f  recombinant 
murine TNF-a on the expression o f specific constitutive P450s in male rat liver was 
investigated (Nadin et al.. 1995). Tumor necrosis factor-a down-regulated P450IIC11 
and IIIA2 in male rat liver at a pre-translational level, whereas two other constitutive 
P450s. IIA 1 and IIC6, seem refractory to TNF-a. Thus, impaired P450 regulation by 
TNF-a resembled the combined effects of autologous interferons on IIIA2 and 
interleukins on IIC11.
Inhibition of cytochrome P450 was not limited to hepatic microsomes but can 
occur in other tissues, such as Leydig cells (Li et al.. 1995). Testosterone biosynthesis 
in Leydig cells depended on the action of 17 a-hydroxylase/C 17-20 Ivase cytochrome 
P450 (P450cl7). which was encoded by the Cypl7 gene. Tumor necrosis factor-a 
inhibits cAMP-stimulated testosterone production in mouse Leydig cells. The 
inhibition of testosterone production was parallel to the inhibition of P450cl7 
messenger RNA and protein concentrations. Tumor necrosis factor-a stimulated PK.C 
a-translocation was further demonstrated by indirect immunofluorescence assay. 
Phorbol myristic acid, a known activator of protein kinase C and TNF-a a  had a similar 
inhibitory effect on P450cl7 expression, testosterone production and P450XVII 
activity.
Dexamethasone is a well known inhibitor o f TN F-a production when given 
shortly before lipopolysaccharide (Fantuzzi et al., 1995). However, dexamethasone 
may potentiate TNF-a production when administered 24-48 h before LPS. This may be 
due to induction of P450IIIA. which was known to produce nitric oxide (NO). This
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suggests that P450IIlA-generated NO might be involved in TN F-a induction. Nitric 
oxide is becoming more recognized as a signaling molecule in many organs, although 
its role in the liver remains to be fully elucidated (Milboume & Bygrave. 1995). Liver 
cells produced NO in response to a variety o f stimuli including infection with 
Corynebacterium parvum . LPS and cytokines. Within the liver. NO modulated some 
fundamental intracellular functions such as protein synthesis, mitochondrial electron 
transport and components o f  the citric acid cycle. Drug metabolism and blood storage 
may be other intracellular roles of nitric oxide. Additionally. NO acts to protect the 
liver from immunological damage in models of hepatic inflammation. Inflammatory 
stimulation of the liver led to the induction of nitric oxide (NO) biosynthesis (Stadler et 
al.. 1994). The interference o f NO with specific P450-dependent metabolic pathways 
was investigated, because NO binds to the catalytic heme moiety o f cytochromes 
P450IA. The results indicated that inhibition o f NO biosynthesis in patients suffering 
from systemic inflammatory response syndromes may help to restore biotransformation 
capacity of the liver.
Although nitric oxide synthetase (NOS) is a cytochrome P450-like hemoprotein 
with additional sequence homology to cytochrome P450 reductase, the role of the 
cytochrome P450 system in cytokine-mediated NO synthesis is unknown (Kuo et al..
1995). Inhibition of P450IIIA activity was associated with a concentration-dependent 
decrease in cytokine-mediated NO production. Concentrations o f NOS mRNA and 
protein were not altered. The NOS enzyme assay was notable for stable concentrations 
of intermediate. N-OH-L-arginine and decreased production o f the final end product. L-
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citrulline. Cytochrome P450IIIA isoform may play a post-translational role in cytokine- 
mediated NO synthesis in this model of isolated rat hepatocytes in primary culture. Rat 
liver microsomes catalyzed the oxidative denitration of N omega-hydroxy-L-arginine 
(NOHA) by hydrogenated nicotinamide adenine dinuleotide phosphate (NADPH) and 
0 2 with formation of citrulline and nitrogen oxides like NO and N 0 2- (Boucher et al..
1992). Classical inhibitors o f NO-synthetases. like N omega-methyi-and N omega- 
nitro-arginine. failed to inhibit the microsomal oxidation of NOHA to citrulline and 
N 0 2-. On the contrary, classical inhibitors of hepatic cytochromes P450 like CO, 
miconazole, dihydroergotamine and troleandomycin. strongly inhibited this 
monooxygenase reaction. Oxygenation of NOHA by NADPH and 0 2 with formation of 
citrulline and NO can be efficiently catalyzed by cytochromes P450, including the IIIA 
subfamily.
Endotoxin and infection effects on drug metabolism
Endotoxin
Active infection with bacterial proliferation was not necessary for changes in 
drug biotransformation. Heat-killed or formalin-fixed Corynebacterium parvum and 
bacillus Calmette-Guerin, an immunomodulator. depresses hepatic P450 drug 
metabolism (Farquar et al.. 1976: Soyka et al.. 1976). Endotoxin from other Gram- 
negative and positive bacterial cell walls are potent inhibitors o f hepatic mixed-function 
oxidase (Azri & Renton, 1987; Gorodischer et al., 1976; Lavicky et al.. 1988; Sasaki et 
al., 1984; Sonawane et al., 1982; Stanley et al., 1988; Williams & Szentivanyi. 1983: 
Yoshida et al., 1982). Escherichia coli. Bordatella pertussis, diphtheria toxoid and
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tetanus toxoid all contain cell wall endotoxins that alter P450 activity (Ashner et al., 
1992.1993; Fantuzzi et al., I994a.b). Pertussis toxin was a necessary component for the 
sustained effects o f  diphtheria-tetanus-pertussis vaccine on hepatic drug metabolism 
which suggested a role for INF-y in this process (Ashner et al.. 1993). Bacterial 
endotoxin such as Escherichia coli or B. pertussis endotoxin decreased P450 activities 
in mice (Fantuzzi et al., 1994b; Sasaki et al.. 1984). Endotoxin treated rats experienced 
a dramatic decrease in steady state concentrations o f P450IIC12 mRNA and apo-protein 
(Morgan. 1989). The mechanism for these effects was thought to be suppression of 
cytochrome P450 activity and concentrations by TNF. interleukins, interferons and 
other cytokines (Myers & Kawalek. 1995). The common theme that emerges from the 
preceding studies was that infections, whether viral, bacterial, or parasitic, all depressed 
P450-mediated metabolism. The next question was how were these vastly different 
agents all affected by the mixed-function oxidase system? In a series o f papers, it was 
shown that both poly IC and tilorone decreased the levels of enzymatically-active P450. 
cytochrome b5 and 5-aminoIevulinic acid synthetase (ALA-S) (El Azhary &
Mannering, 1979). Conversely, heme oxygenase activity increased following treatment 
with poly IC. 6-Aminolevulinic acid synthetase was the rate-limiting enzyme 
controlling heme biosynthesis, whereas heme oxygenase degrades heme (Tephley et al., 
1973; Maines. 1988). Administration of interferon inducers such as poly IC and 
tilorone seemed to simultaneously decrease heme synthesis and increase heme 
degradation.
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Functional P450 consists o f  both the P450 apoprotein and the heme moiety with 
independent synthesis o f  both components. Either component could be the target of the 
interferon-inducing agents. The turnover rate o f the heme moiety had a biphasic 
pattern, indicating that different P450 molecules have different turnover rates (Levin & 
Kuntzman. 1969). Poly IC and tilorone increased the turnover rate o f short-lived P450 
molecules, but did not affect the long-lived variants (El Azhary et al., 1980). However, 
a transient increase in heme ievels was also noted. This suggested, but did not prove, 
that the ultimate target was the synthesis of the P450 apoprotein.
Xanthine oxidase had been proposed as being another mechanism for the 
depression of P450 levels and was observed after animals were treated with interferon 
or interferon inducers (Myers & Kawalek. 1995). Added support for this hypothesis 
came from studies showing an inverse relationship between production of interferon and 
depression of P450 protein levels and P450-mediated enzymatic activity (Singh et al..
1982). Strains of mice that produced high levels o f interferon had low levels of P450 
following challenge with Newcastle disease virus, whereas mouse strains that produced 
lower levels of interferon exhibited a small effect on P450 concentrations. The 
differences in P450 levels between these two strains o f mice correlated to 
ethylmorphine-/V-demethylase activity and high interferon-producing strains exhibiting 
the lowest levels o f enzymatic activity. The induction o f xanthine oxidase paralleled the 
levels o f interferon produced (Deloria et al., 1983). High interferon-producing mice had 
levels of xanthine oxidase that were higher than those found in mice producing lower 
levels of interferon. The inhibiting effect on P450 levels and its monooxygenase
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activity was greatest in high interferon-producing mice (Deloria et al.. 1983).
Formation of lipid peroxides (Ali et al., 1985) has also been proposed as one possible 
mechanism to explain the decrease in the P450 levels following interferon induction. 
However, inhibiting lipid peroxidation failed to prevent poly 1C induced P450 loss 
(Mannering et al.. 1989).
Additional studies revealed that incubation with free radical scavengers 
superoxide dismutase and iV-acetylcysteine protected the P450 enzymes from the effects 
o f added xanthine oxidase (Ghezzi et al.. 1985). In vivo treatment with allopurinol. an 
xanthine oxidase inhibitor, or iV-acetylcysteine canceled the effect of poly IC on both 
P450 and xanthine oxidase. However, while allopurinol protected against the effects of 
poly IC. it also decreased the basal concentrations o f P450 and xanthine oxidase. 
Although there were effects of xanthine oxidase on P450 levels, there was no significant 
effect on P450-mediated ethoxycoumarin O-deethvlase activity (Ghezzi et al.. 1985). 
Chickens cannot form xanthine oxidase and it was shown that polv IC treatment of 
chickens did not affect P450 levels (Moochhala & Renton. 1991). Nonetheless, 
brooder-raised chickens may have very low levels o f P450-mediated enzymatic activity 
when compared with pen-raised birds (Dr. Joseph Kaw'alek. unpublished). Using 
animals with such low activity would minimize any changes in P450 concentrations that 
may have been affected in these chickens. In addition, they could not show a protective 
role for the free radical scavenger iV-acetylcysteine, or that added xanthine oxidase 
affected the in vitro activity of liver microsomes.
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The above results were subsequently contradicted using mice, rats and hamsters 
(Reiners et al., 1990; Cribb & Renton. 1993). While no one group showed a role for 
xanthine oxidase, an earlier study had been designed to feed diets containing tungstate 
to inactivate xanthine oxidase in mice (Mannering et al., 1988). In the tungstate study, 
a role for either xanthine oxidase or lipid peroxides in the poly IC mediated decrease in 
hepatic P450 was not discovered. Therefore, it was concluded that induction of 
xanthine oxidase and reduction in P450 content were coincidental and not causally 
related. Based on these observations, the decreases in P450 and its related activities 
were probably not a consequence of xanthine oxidase activity in rodents (Reiners et al.. 
1990; Cribb & Renton. 1993).
In a more recent in vivo study using pigs instead of rodents, multiple intravenous 
(i.v.) doses of LPS (17 pg/kg) induced a mild acute-phase response in swine within 2 h 
of the first injection (Monshouwer et al.. 1996a). Antipvrine plasma clearance was 
decreased in the LPS treated pigs (control: 8.5±0.8; LPS: 2.2±0.7 ml/min/kg) and 
decreased ethoxyresorufin O-deethylase. caffeine, 3-demethylase and testosterone 6P- 
hydroxylase activities which corresponded to P450IA1. P450IA2 and P450IIIA 
respectively, in rats. The P450IA and P450IIIA apoprotein concentrations were also 
decreased. The results suggested that the effect on cytochrome P450 was relatively 
non-selective in the pig and affects several P450 isozymes. High systemic 
concentrations o f TNF-a and IL-6 were associated with decreased antipvrine clearance 
in LPS treated pigs. Microsomal 1-naphthol glucuronosyl transferase activity was not 
altered in LPS treated pigs.
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Endotoxin elicits a broad, non-specific cascade o f events in vivo. a variety of 
potent mediators and cytokines were secreted, primarily, by activated cytokines and 
monocytes (Kielian & Blecha, 1995) The over-production of these effector molecules, 
such as IL-1 and TNF-a. contributed to the pathophysiology o f endotoxic shock. 
Cellular recognition o f LPS involved several different molecules, including a cluster o f 
differentiation antigen. CD 14. A thorough understanding of the interaction of LPS with 
cells o f the immune system is necessary before effective preventative or therapeutic 
measures can be designed and tested to limit the host response to endotoxin. The CD 14 
antigens function as a receptor for lipopolysaccharide binding protein complexes 
(Kielian et al.. 1995). Lipopolysaccharide has a varying effects on CD14 expression in 
vitro which required that the evaluation of CD14 expression in response to LPS with a 
fully differentiated macrophage phenotype, the porcine alveolar macrophage. The 
investigators found that LPS activation of porcine alveolar macrophages for 24 h 
increased CD14-like receptor expression. The degree o f CD14-like up-regulation was 
related to LPS concentration. However, activation did not require the presence of serum 
at concentrations o f LPS.
Infection
Infection from viral, bacterial, or parasitic sources depressed drug metabolizing 
activity of diseased animals (Myers & Kawalek. 1995). Pharmacokinetic changes were 
often overlooked when drug toxicity or decreased efficacy occur during an infection, 
especially in veterinary medicine. Influenza infections altered the metabolism of 
theophylline and cytomegalovirus increased the toxicity o f parathion. but not all viral
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vaccines affected cytochrome P450 (Fisher et al.. 1981; Selgrade et al.. 1984). Both 
heat-killed and formalin-fixed infection with Corynebacterium parvitm in rats and mice 
decreased hepatic P450-mediated drug biotransformation (Farquar et al.. 1983: Soyka et 
al., 1976). Malaria-infected rats have exhibited decreased ability to metabolize aniline, 
ethylmorphine,/7-nitroanisole and hexobarbital (McCarthy et al.. 1970). Plasmodium 
berghei were irradiated and injected into mice (Song et al.. 1995). There were 
significant decreases in mouse hepatic cytochrome P450 and benzo(a)pyrene 
hydroxylase activity, but no effect on N-demethylase activity. Antipvrine and 
metronidazole were administered as a cocktail to young male Wistar rats to investigate 
the effect of malaria infection due to the rodent parasite Plasmodium berghei and 
Escherichia coli endotoxin-induced fever on the metabolism o f the two compounds in 
vivo (Kokwaro et al.. 1993). Malaria infection had no effect on clearance of antipyrine 
or on formation clearance of any of its metabolites. However, the clearance of 
metronidazole was reduced by approximately 20% compared with controls as a result o f 
decreased formation o f hydroxymetronidazole. Fever decreased clearance of both 
antipyrine and metronidazole by approximately 36% and 23%, respectively. These 
results demonstrated that both malaria infection and fever influenced P450-dependent 
drug metabolism and the effects seen were isozyme-selective Parasitic infection with 
Fasciola hepatica or viral infection with influenza A and B, poliovirus, as 
cytomegalovirus depressed mixed-function oxidase activity (Chang et al., 1978;
Descotes & Evreux. 1986; Descotes et al.. 1985; Kraemer & McClain. 1981; Kraemer 
et al.. 1982; Maffei et al., 1981; Renton, 1981; Selgrade et al.. 1984). In mice infected
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with Fasciola hepatica. there was a loss of respiratory control in isolated liver 
mitochondria at 4 weeks post-infection (Somerville et al.. 1995). A similar time course 
was demonstrated for a reduction in hepatic microsomal cytochrome P450 content. In 
another parasitic study using Schistosoma mansoni. the intensity o f infection determined 
alterations in hepatic drug metabolism, as indicated by measuring zoxazolamine 
paralysis times (Naik & Hasler. 1995).
The A. pleuropneumoniae infection model was well characterized and has 
become a standard respiratory disease model in pigs (Baarsch et al., 1995: Kamp & van 
Leengoed, 1989). Hepatic microsomes. in vitro. from APP infected pigs were used to 
determine enzyme activities for the model substrates: aniline-hydroxylation. 
ethoxyresorufin O-deethylation. pentoxyresorufin O-depentylation and testosterone- 
hydroxylation at the 20. 60. 1 la .  15a and 150 positions (Monshouwer et al., 1995b).
All oxidative enzyme activities were depressed by 33% twenty four hours after infection 
and indicated that the depression was not selective. UDP-glucuronosyltransferase 
activities were not affected. The dot blots showed a reduction in total mRNA in two 
infected pigs, but this study was somewhat lacking in experimental design. The human 
cytochrome P450IIIA4 cDNA probe was used to detect mRNA in a mixture of mRNA 
on the dot blot. There was no control for the possibility that the IIIA4 cDNA probe 
might cross-react with mRNA in other P450 subfamilies, resulting in a false positive. 
Additionally, only two control and two treated pigs were used, which makes statistical 
analysis difficult.
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In a subsequent experiment, the investigator attempted to verify in vitro findings 
by performing an in vivo pharmacokinetic experiment with APP infected pigs using 
model drugs (Monshouwer et al.. 1995a). The plasma clearance of antipyrine and 
caffeine represented a decrease in oxidative drug metabolism and differed greatly from 
the infected pigs compared to the controls (72% and 68%. respectively). The effect of 
the infection on the glucuronidation of paracetamol was minimal in infected pigs (39% 
depression). The clearance of indocyanine green and creatinine were unaffected which 
indicates normal hepatic blood flow and renal excretion. Antipyrine. caffeine and 
paracetamol were negligibly bound to plasma proteins so it was unlikely that the 
decrease in clearance was from changes in protein binding. Cytochrome P450 enzymes 
responsible for the reduction of oxidative metabolism were not pursued, but the results 
suggested non-selective action in vivo. The possible mechanism for decreased 




Actinobacillus pleuropneumoniae is the most common causative agent o f swine 
pleuropneumonia, a highly contagious and sometimes fatal, respiratory tract disease of 
pigs known as porcine pleuropneumonia (Nicolet. 1994). The disease was first reported 
in 1957 and was followed by worldwide reports of APP outbreaks in commercial swine 
herds (Fedorka-Cray et al.. 1993a; Pattison et al., 1957). Morbidity approaches 100% 
with 50% mortality, 55% increase in the feed conversion ratio and a 40% decrease in
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average daily gain (Mackinnon. 1993). In controlled studies o f swine infected with A. 
pleuropneumoniae, 60% died 18 to 56 h after exposure (Kung et al., 1993a.b). Control 
and prevention measures for porcine pleuropneumonia were often ineffective, because 
of the complex nature o f the disease (Fedorka-Cray et al.. 1993a: Maclnnes &
Rosendal. 1982; Sebunya & Saunders. 1983). Subsequently, pork producers have 
suffered great economic loss.
Actinobacillus pleuropneumoniae is a facultative anaerobe that is non-spore 
forming, encapsulated, nonmotile. Gram-negative pleomorphic coccobacillus (Kilian & 
Biberstein. 1984). Biochemical characteristics o f the organism include: urease positive: 
able to ferment mannitol. xylose and ribose; with variable fermentation of lactose 
(Kilian & Biberstein. 1984; Nicolet. 1994). A rough to smooth morphologic transition 
may occur after passage in artificial medium. (Fedorka-Cray et al.. 1993a; Gunnarsson. 
1979). Colonies exhibit P hemolysis on blood agar plates, but some isolates were non­
hemolytic (Kamp & van Leengoed. 1989; Morrison et al., 1985; Sebunya & Saunders.
1983). Some field isolates have been identified with fimbria by negative staining 
(Utrera& Pijoan. 1991).
Actinobacillus pleuropneumoniae was originally believed to be Haemophilus 
parahaemolyticus. because of the requirement o f nicotinamide adenine dinucleotide 
(NAD) for growth (Biberstein et al., 1977; Kilian & Biberstein, 1984; Niven & 
Levesque. 1988). In 1978. distinguishing biochemical and cultural characteristics were 
identified between porcine and human strains and a new strain, Haemophilus 
pleuropneumoniae, was named (Kilian et al., 1978). In 1983, DNA hybridization was
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performed between Haemophilus pleuropneumoniae and Haemophilus influenza and the 
percent binding indicated no measurable relationship (Pohl et al., 1983). The DNA 
hybridization and phenotypic characteristics did indicate that Haemophilus 
pleuropneumoniae was closely related to Actinobacillus lignieresi. The Haemophilus 
pleuropneumoniae was transferred to the genus Actinobacillus with 2 biovars: a V 
factor biovar 1 dependent on nicotinamide adenine dinucleotide and a V factor 
independent biovar 2. The two strains were very similar except for the NAD 
requirement and morbidity in biovar 2 induced pleuropneumonia was less than the 
morbidity caused by strains o f biovar 1 (Kilian et al.. 1978).
Epidemiology
Only pigs are known to be naturally susceptible to Actinobacillus 
pleuropneumoniae (Fedorka-Cray et al.. 1993a). The organism has not been found in 
rodents, birds, or humans and does not persist in the environment (Fedorka-Cray et al.. 
1993a; Nicolet. 1994). Serotypes 1. 5 and 7 are frequently found in the United States 
and are common in the Midwest; serotypes 3. 4. 8 and 9 are infrequently found 
(Fedorka-Cray et al.. 1993a; Sebunya & Saunders. 1983). Serotypes 1. 2. 3 5 and 7 are 
common in Canada and serotypes 1, 2, 5. 7 and 9 are common in Europe (Rapp et al.. 
1985; Rosendal & Boyd, 1982; Sanford & Josephson. 1981; Schultz et al.. 1983). In a 
recent study, bronchoalveolar lavage was performed in 128 pigs from five fattening 
units showing acute pneumonia, subclinical pneumonia and chronic purulent pneumonia 
(Tapner et al., 1996). Using cultural methods. APP could only be isolated from six 
samples. In contrast, there were frequent positive reactions to APP antigens with
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immunofluorescence microscopy. Thus, immunofluorescence was a better screening 
method.
Occurrence of swine pleuropneumonia in previously non-infected herds can be 
linked to introduction of asymptomatic carrier pigs (Greenway. 1981). Chronically 
infected pigs that are asymptomatic may develop signs of the disease during transport 
(Greenway. 1981). Actinobacillus pleuropneumoniae is spread by direct contact or by 
aerosol transmission (Fedorka-Cray et al., 1993a). Nasal secretions can contain 109 
colony forming units/milliter (CFU/ml) which quickly spreads the disease between pigs 
(Rosendal & Mitchell. 1982). Stress factors of overcrowding, transportation and abrupt 
temperature changes also increased the incidence of the disease (Sebunya et al., 1983b). 
The increased susceptibility to APP can be predicted by the absence of toxin- 
neutralizing antibodies to haemolysin and cytotoxin (Cruijsen et al.. 1995a.b). Autumn 
through early spring is the period o f greatest incidence o f APP (Fedorka-Cray et al.. 
1993a.: Sebunya et al., 1983b).
Intense industrialization o f pork production has been suggested as contributing 
to the rapid rise of APP infected herds (Fedorka-Cray et al., 1993a). Pigs older than 12 
weeks o f age are the most vulnerable and immunologically naive herds are the most 
severely affected (Sebunya et al., 1982.1983b: Shope. 1964). A recovered pig can 
remain an asymptomatic carrier for months and provide low exposure o f APP to the 
herd. This allows the herd to establish a level of immunity that decreases the incidence 
of new and acute infections. Chronically infected herds have some individuals that 
remain seronegative. Seronegative sows did not pass on colostral immunity to suckling
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piglets and the offspring will remain susceptible to infection. Piglets become vulnerable 
when exposed to crowding and poor ventilation (Fedorka-Cray et al.. 1993a: Sebunya et 
al.. 1982).
Signs, pathology and lesions
Actinobacillus pleuropneumoniae infection can cause death within 12 h after 
exposure (Fedorka-Cray et al., 1993a). Clinical signs include: anorexia, fever, severe 
respiratory distress, cyanosis, coughing and dyspnea. Discharge of blood tinged foam 
from the nose and mouth is common in acutely infected pigs (Fedorka-Cray et al.. 
1993a). The severity of the disease is influenced by the virulence of the strain, size of 
inoculum, protective immunity and stress (Greenway. 1981; Rosendal. 1985; Sebunya 
et al.. 1983b; Shope. 1964; Jacobsen et al., 1996).
The disease can occur in the peracute. acute, subacute or chronic form (Fedorka- 
Cray et al.. 1993a: Nicolet. 1994: Udeze et al., 1987). In the peracute form, death 
occurs within 24 to 36 hours. Sudden death in piglets without previous clinical signs 
has been reported (Fedorka-Cray et al.. 1993a; Sebunya et al.. 1983b; Shope, 1964).
The acute form may progress from severe clinical disease to death within a few days or 
it may resolve into the chronic form depending on the severity of lung lesions and 
response to antibiotic therapy (Fedorka-Cray et al., 1993a; Nicolet. 1994) In the early 
stages o f the disease, common microscopic changes included pulmonary necrosis, 
hemorrhage, neutrophil infiltration, macrophage and platelet activation, vascular 
thrombosis, widespread edema and fibrinous exudate (Bertram. 1985. 1986. 1988: 
Liggett & Harrison. 1987). Following the acute response to APP infection, macrophage
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infiltration, marked fibroplasia around areas of necrosis and fibrinous pieuritis were 
characteristic in later stages of the disease (Hani et al.. 1973). Antibiotic therapy was 
efficient only in the initial phase of the disease, when there was the best chance to 
reduce mortality (Nicolet. 1994). Actinobacillus pleuropneumoniae was susceptible to 
(3-lactams, mainly penicillin and cephalosporins: chloramphenicol: cotrimoxazole: and 
tetracyclines, but resistance has developed to ampicillin. streptomycin, sulfonamides, 
tetracyclines, chloramphenicol, tiamulin and a combination of lincomycin and 
spectinomycin (Anderson & Williams, 1990; Gilbride & Rosendal. 1984; Hsu. 1990: 
Vaillancourt et al.. 1988). Resistance was most frequently seen in serotypes 1 .3 .5  and 
7. Presently, the quinolone derivatives or the semisynthetic cephalosporin, ceftiofur 
sodium, have been shown to be very effective after experimental challenge with APP 
(Kobisch et al.. 1990; Stephano et al.. 1990).
Gross lesions common in acute APP infections consisted of serofibrinous 
pieuritis and fibrinous and necrotizing hemorrhagic pneumonia (Sebunya et al.. 1983a). 
Lesions were usually distributed bilaterally in the caudal lobes o f the lungs (Sebunya et 
al.. 1983a). In chronic infections, fibrinous pieuritis and necrotic foci that very in size 
were evident. The necrotic foci, in recovered animals, serve as a nidus of infection for 
months and infected animals were considered to be carriers (Fedorka-Cray et al..
1993a).
Sequential studies have been conducted to record histological lesions caused by 
Actinobacillus pleuropneumoniae infection (Liggett & Harrison, 1987). Neutrophil 
infiltration and fibrinous exudate are present in the early stages of the disease (Bertram,
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1988). Bacteria occur as individual cells or groups throughout the exudate (Fedorka- 
Cray et al., 1993a). Coagulative necrosis was evident 12 to 18 h after infection in areas 
of concentrated suppuration (Liggett & Harrison. 1987). Macrophage infiltration and 
areas of marked fibroplasia were evident around necrotic tissue as the disease 
progressed (Bertram, 1988). Neutrophils occurring in various stages of degradation 
suggested that vascular damage may be mediated by neutrophil degeneration and release 
of lysomal contents (Liggett & Harrison. 1987). Sequestration of necrotic pulmonary 
tissue and development of pleural adhesions were common sequellae to the acute 
response (Bertram. 1988: Fedorka-Cray et al.. 1993a). Complete healing, locally 




Some of the 12 identified serotypes o f APP cause more severe disease than 
others (Brandreth & Smith. 1987: Fedorka-Cray et al., 1994: Jensen & Bertram. 1986: 
Rosendal & Boyd. 1985). Inoculation with as few as 10,000 virulent bacteria can cause 
death in 12 hours and 100 bacteria caused lung abscesses in swine (Perry et al., 1990). 
Virulence factors on the cell surface or secreted by the bacteria were responsible for the 
disease process.
The structure and chemical composition o f the 12 APP serotypes have been 
described (Fedorka-Cray et al., 1994). Capsules consist o f polymers of two or three 
sugars or amino acids, techoic acid polymers linked by phosphate diester bonds or
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oligosaccharide polymers linked by phosphate bonds (Fedorka-Cray et al.. 1994). The 
presence o f phosphate or carboxylic acid creates a negative charge on the capsule and 
was important for the evasion o f APP cells from phagocytic cells. Serotype specificity 
o f APP was attributed to capsular antigens (Inzana. 1991; Inzana & Mathison. 1987).
The capsule protected the bacterium from host defenses, such as opsonization 
and phagocytosis and complement mediated killing by classic and alternate pathways 
(Inzana. 1991). However, not all encapsulated strains have been shown to be virulent 
(Jacques et al.. 1988a: Jensen & Bertram. 1986: Rosendal & Boyd. 1985). Capsule 
deficient mutants of APP serotypes 1 and 5 were less virulent in pigs than their 
encapsulated parent strains (Inzana et al.. 1988: Rosendal & Maclnnes. 1990). Injection 
o f capsular material alone neither produced disease nor pulmonary lesions nor disease in 
pigs (Fenwick et al.. 1986c). Purified capsule produced a poor antibody response, but 
conjugation with protein improved immunogenicity and gave partial protection to 
pleuropneumonia caused by APP (Inzana. 1990: Inzana et al.. 1988). Passive transfer of 
non-specific capsular antiserum to swine provided a level o f protection similar to 
immunization with killed bacteria (Inzana et al.. 1988). Other virulence factors 
accounted for the variation in virulence. The presence of lipopolysaccharides and 
exotoxins were known to vary between A. pleuropneumoniae serotypes and strains 
(Byrd & Kadis. 1989; Frey & Nicolet. 1990: Kamp & van Leengoed. 1989). Adhesins. 
hemagglutinins, fimbriae and pili. played an unknown role in the pathogenesis of APP 
(Fedorka-Cray et al.. 1994).
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Subsequently, to explore the attachment of APP to mucosal surfaces, an 
investigator endobronchially inoculated seven pigs with APP serotype 1 and the pigs 
developed subacute necrotizing pleuropneumonia (Narita et al., 1995). When the pigs 
were treated with high doses o f atropine (0.25 mg/kg) and xylacaine spray using a 
bronchoscope, mucus secretion was suppressed along with ciliary activity. The animals 
showed severe pleuropneumonia and two treated pigs died within 36 h after inoculating 
320 CFU/2ml of APP serotype 1. The findings suggested that the attachment of APP to 
the mucosal surfaces may be a critical in the pathogenesis o f pneumonic lesions. 
Lipopolysaccharide
Lipopolysaccharide is a macromolecule that is part of the outer membrane of 
Gram-negative bacteria (Stanier. 1976). Lipopolvsaccharides are composed of a 
complex lipid material, lipid A. which is attached to the core polysaccharide. The core 
is comprised of sugars, including 2-keto-3-deoxyoctonate. attached to O-specific side 
chains. The O-specific side chains protrude out from the cell surface of the bacterium 
and endow strain specific antigenic properties on certain Gram-negative bacteria. O- 
specific side chains have repeating units that convey a phenotypic characteristic of 
smooth, side chains present, or rough, side chains absent. Each strain shares a common 
core O antigen within each serotype. Serotype 5 can have both partially rough and 
smooth strains, because the length of the side chain can vary (Altman et al.. 1990; Frey 
& Nicolet. 1990). Serotype specific and cross reactive epitopes in the LPS have been 
identified for APP (Fenwick & Osbum. 1986).
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Lipopolysaccharides have similar structures among the Gram-negative bacteria 
and similar biological effects have been inferred (Fenwick. 1990). Lipopolysaccharide 
induced the release of pro-inflammatory cytokine mediators. The mediators activate 
various cells to include macrophages and neutrophils which played a primary role in 
acute inflammation. Purified APP lipopolysaccharide induced non-necrotizing 
pneumonia with neutrophil infiltration (Udeze et al.. 1987). The deleterious effect of 
LPS was inflammation and not the associated necrotic lesion development (Idris et al.. 
1992; Udeze et al.. 1987). Necrotic lesion development seems to depend on the 
presence of exotoxins that lyse neutrophils and release toxic substances that severely 
damaged tissue.
Supporting evidence for the involvement of endotoxin with A. 
pleuropneumoniae virulence was demonstrated in a study using pigs vaccinated with the 
J5 bacterin from a mutant of Escherichia coli 0111: B4 (Udeze et al.. 1987). The 
vaccinated pigs survived Actinobacillus pleuropneumoniae infection challenge, whereas 
four of the five control non-vaccinated animals died following infection with APP. 
Antibodies against lipid A and possibly to core antigens o f LPS. may have a protective 
effect against septicemia and death caused by pleuropneumonia infections (Udeze et al..
1987). J5 protection against septicemia and death in porcine pleuropneumonia was 
indirect evidence that APP endotoxin contributed to pathogenicity. Lipopolysaccharide 
isolated from A. pleuropneumoniae induced a pulmonary lesion and the severity of the 
lesion may be a function of the composition of the LPS molecule. The heat stable 
endotoxin and the heat labile extracellular hemolysins act in concert to produce lung
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lesions. Endotoxin alone did not induce the full array of lung lesions observed in the 
acute form o f natural and experimental infections. Lipopolysaccharide and exotoxins 
may act together as virulence factors in mediating the disease process (Fenwick & 
Osbum. 1986; Fenwick et al., 1986a.b). Hemolysin and cytotoxin may also contribute 
to the pathogenesis of lung lesions (Udeze et al., 1987).
Another virulence factor may be the affinity o f APP endotoxin for porcine 
respiratory tract secretions (Belanger et al., 1994). The affinity for a crude preparation 
o f porcine respiratory tract mucus o f isolates of the Pasteurellaceae family 
{Actinobacillus. Haemophilus and Pasteurella spp.) and of some unrelated Gram- 
negative bacteria was examined. To identify the receptors recognized by the 
lipopolysaccharidic adhesin of APP. affinity chromatography was used. Two 
proteinaceous bands (10 and 11 kDA) were recovered. This suggested that two low- 
molecular-mass proteins present in porcine respiratory tract secretions bind APP 
endotoxin. In a latter study. LPS from all APP isolates tested, bound pig hemoglobin 
and lipid A was involved in this binding (Belanger et al.. 1995). Some APP isolates 
were able to use hemoglobin for growth. This indicated that binding of hemoglobin to 
LPS might represent an important means by which APP acquires iron in vivo from 
hemoglobin released from erythrocytes Iysed by the action o f its hemolysins. Two 
outer-membrane proteins were involved in the uptake of iron from transferrin by certain 
Gram-negative bacteria, including Actinobacillus pleuropneumoniae. transferrin- 
binding proteins 1 and 2 (Daban et al., 1996).
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Recently. 40 and 48 (kDa) outer membrane proteins have been identified from 
Actinobacillus pleuropneumoniae. serotype 5 (Bunka et al. 1996; Cruz et al.. 1996). 
Vaccine prepared from the outer membrane of serotype 5 provided protective immunity 
in swine challenged with either serotype 5 or serotype 1. The outer membrane protein 
was common to all 12 capsular serotypes o f APP. but was not present in the outer 
membranes o f related species of Gram-negative swine pathogens. It was inconclusive 
whether or not antibodies to the 48 kDa outer membrane antigen contribute to cross- 
protective immunity to control porcine pleuropneumonia caused by APP. Live non­
capsulated mutants of A. pleuropneumoniae may provide safe and cost-effective 
protection against swine pleuropneumonia (Inzana et a l. 1993). These observations 
support the possibility that non-capsulated mutants o f other encapsulated, toxin- 
producing bacteria may also prove to be efficacious live-vaccine candidates.
Bacterins for Actinobacillus pleuropneumoniae have proven to be ineffective 
(Fedorka-Cray et al., 1993b). Current bacterins may provide only partial protection in 
swine following infection APP. Vaccination failure o f whole cell bacterins has been 
attributed to antigenic variation within a capsular serotype, due to antigenic variation 
within LPS (Jolie et al., 1995). This lack o f cross-protection, within a capsular subtypes 
1A and IB. provides partial explanation for vaccination failures observed under field 
conditions. The efficacy of a cell-free concentrate from mid-log phase growth cultures 
of APP serotype 1 to four commercial bacterins were compared (Fedorka-Cray et al. 
1993b). This cell-free preparation contained carbohydrate, endotoxin and protein and 
had hemolytic and cytotoxic activity. Similar, but not identical, responses were
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observed when antisera generated against the bacterins was used. This study indicated 
that an acellular vaccine, containing multiple virulence factors, can provide complete 
protection from mortality and significantly reduced morbidity to homologous challenge 
(Fedorka-Cray et al., 1993b). Swine were protected by a subunit vaccine that did not 
create unacceptable tissue reaction at the immunization site after challenge with APP. 
serotype 1 (Walker et al.. 1995).
A study in mice used specific monoclonal antibodies (MoAbs) to Actinobacillus 
pleuropneumoniae serotypes 1 and 2 which recognized serotype-specific antigens (Saze 
et al.. 1994: Oishi et al., 1993). It was revealed that the two serotype-specific MoAbs 
HI-18 and H22-7 recognized O-polysaccharides of the lipopolysaccharide from APP 
serotypes 1 and 2. respectively. These results showed that LPS from APP bacterial cells 
was one of the structural substances in the serotype-specific antigens and an important 
component as one of the antigens protecting against the homologous serotype strain.
The combined vaccine of serotypes 1. 2 and 5 from APP was tested for its ability to 
confer protection in pigs (Oishi et al., 1995). Clinical signs o f pleuropneumonia were 
not observed after intratracheal challenge with A. pleuropneumoniae.
Exotoxins
Bacterial exotoxins are soluble proteins secreted by live organisms (Rutter.
1988). Toxin release contributed to the disease process, especially for organisms 
infecting mucosal surfaces (Shewin. 1988). The presence o f exotoxins was 
demonstrated by administering sterile culture supernatants o f  APP to pigs (Fedorka- 
Cray et al.. 1994). Pulmonary lesions were similar to those found in natural infections.
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Lung lesions were produced by all o f the exotoxins, except one. PTX/ClvIII. which was 
not essential for the pathogenicity o f the organism (Fedorka-Cray et al., 1994). In an 
attempt to gain insight into the events that take place during APP infection, the effects 
o f bacterial toxicity on porcine neutrophil functions and viability was evaluated (Udeze 
et al.. 1992). Incubation of phagocytes with opsonized APP resulted in phagocylic 
uptake of less than or equal to 4%. At the same bacterium-to-phagocyte ratio, levels o f 
lactate dehydrogenase activity of 74 and 81% were detected in the extracellular medium 
after 1.5 and 3 h o f incubation, respectively. Furthermore, the ingested bacteria were 
not killed by the phagocytes. These effects were ascribed to hemolysin produced by the 
bacteria, because the presence of hemolysin-neutralizing antibody prevented overt 
cellular damage, significantly increased phagocytic uptake and resulted in an 
approximately 10-fold decrease in the number of ingested bacteria. Cytolytic doses o f 
isolated hemolysin caused dose-related loss of cell viability, diminished bactericidal 
activity of toxin-treated phagocytes for Escherichia coli and decreased the ability o f the 
phagocytes to undergo a respiratory burst upon stimulation with phorbol myristic 
acetate. In contrast, sublytic doses of the hemolysin activated the phagocytes and 
caused them to respond to phorbol myristic acetate with increased generation o f 
superoxide anion. Heated (100 degrees C. 5 min) hemolysin preparations did not 
produce similar effects and it was concluded that the observed effects were not due to 
contaminating endotoxin. The data indicated that APP hemolysin was a potent 
antiphagocytic virulence factor by virtue o f its leukocidal activity.
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Two hemolytic and cytolytic toxins (Hly/Clyl and Hly/CIyll) were believed to 
be important in disease progression and are related to the repeat toxin (RTX) family of 
exotoxins o f other Gram-negative microorganisms. These toxins include the leukotoxin 
in Pasteurella haemolytica. the exotoxin in A. sais and the a  hemolysin produced by 
some strains o f Escherichia coli (Devenish et al.. 1989: Lian et al., 1989). The derived 
amino acid sequence of Hlyl showed 42% homology with the hemolysin of 
Actinobacillus pleuropneumoniae serotype 5. 41% homology with the leukotoxin of 
Pasteurella haemolytica and 56% homology with the Escherichia coli a-hemolysin 
(Frey et a i. 1991). The 13 glycine-rich repeats and three hydrophobic areas of the Hlyl 
sequence show more similarity to the E. coli a-hemolysin than to either the APP 
serotype 5 hemolysin or the leukotoxin. while the last two were more similar to each 
other. Two types o f RTX hemolysins, therefore, seem to be present in APP. one (Hlvl) 
resembling the a-hemolysin and a second more closely related to the leukotoxin. The 
structural gene encoding Actinobacilluspleuropneumoniae-RTX-toxin I (ApxIA) was 
cloned from serotype 10. as a major hemolytic and cytolytic toxin of the organism (Nagi 
et al.. 1993a). The gene from serotype 10 was 98% identical to that from serotype 1 at 
both the DNA and amino acid levels. Results of DNA sequencing showed serotypes 1.
9 and 11 to be the original form of the ApxIA gene and the allelic variant was found in 
serotypes 5a. 5b and 10. The gene products, ApxIA proteins, have different secondary 
structures at the carboxyl terminal region. Using the AppA gene encoding 
Actinobacillus pleuropneumoniae-KYX-toxm  II (ApxII) as a probe, it was demonstrated 
by Southern hybridization that AppA-sequence was present in all 12 serotypes except
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10 (Nagi et al., 1993b). After DNA sequencing, this region was determined to be part 
of the HlylA gene that encoded a 105 kDa hemolysin (Apxl). The presence of the low 
homology region was evident in serotype 10 compared to the AppA gene locus (HlylA) 
found in serotypes 1, 5a. 5b. 9 and 11 which all had strong hemolytic activity with 
sheep red blood cells and were highly virulent in mice. This suggested that Apxl may 
be associated with the virulence phenotype of the organism. Another investigator 
proposed a new and uniform designation for the App-RTX-toxins consisting of 
hemolysins, cytolysins, pleurotoxins and their genes (Frey et al.. 1993). The 
designation of Apxl. Actinobacillus pleuropneumoniae RTX-toxin I. was proposed for 
serotypes 1. 5a. 5b. 9. 10 and 11, which was previously named hemolysin I (Hlyl) or 
cytolysin I (Clyl). This protein was shown to be strongly hemolytic and cytotoxic 
towards pig alveolar macrophages and neutrophils. The genes o f the Apxl operon 
would have the designations: ApxIC. ApxIA. ApxIB and ApxID for the activator, the 
structural gene and the two secretion genes respectively. The designation of ApxII was 
proposed for the RTX-toxin which was produced by all serotypes except 10 and was 
previously named APP. HlvII. Clyll or Cyt. This protein is weakly hemolytic and 
moderately cytotoxic. The genes of the ApxII operon would have the designations of 
ApxIIC for the activator gene and ApxIIA for the structural toxin gene. In the ApxII 
operon. no genes for secretion proteins have been found. Secretion of ApxII seemed to 
occur via the products o f the secretion genes ApxIB and ApxID of the Apxl operon.
The designation. ApxIII. was proposed for the non-hemolytic RTX-toxin of the 
reference strains for serotypes 2. 3. 4. 6 and 8. which was previously named cytolysin
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Ill (Clylll). pleurotoxin (Ptx). or macrophage toxin. The previous studies and toxin 
designations were corroborated by another study where structural analysis demonstrated 
that intact Apxl operons, consisting of the four contiguous genes. ApxICABD, were 
present in serotypes 1. 5. 9. 10 and 11 (Jansen et al., 1993a). However, Apxl operons 
with a major deletion in the ApxICA genes were present in serotypes 2. 4, 6 . 7, 8 and 
12; serotype 3 did not contain Apxl operon sequences. All Apxl operons were 
transcriptionally active despite the partial deletion of the operon in some serotypes. 
Next, the APP RTX-toxin III gene (ApxIII) was cloned (Jensen et al., 1993b). Two 
genes. ApxIIIC and ApxIIIA. coded for proteins ApxIIIC and ApxIIIA. respectively, 
which were 53 and 50% identical to the prototypic RTX proteins HlyC and HlyA of E. 
coli. It was assumed that the ApxIIIA gene coded for the structural RTX-toxin and that 
the ApxIIIC gene coded for its activator. In addition, it was found that ApxIII could be 
secreted from E. coli by the heterologous RTX transporter proteins. HlyB and HlyD.
The deduced amino acid sequence o f ApxIIIA was 50% identical to that of ApxIA and 
41% identical to that of ApxIIA. Beside Apxl and ApxII. ApxIII was determined to be 
the third RTX toxin produced by A. pleuropneumoniae.
The virulence of the RTX hemolysins (Apxl and ApxII) of the swine pathogen 
Actinobacillus pleuropneumoniae was investigated using hemolysin-deficient mutants 
(Tascon et al.. 1994). Two types o f haemolysin mutants with single insertions of the 
transposon were obtained from a serotype I strain producing both Apxl and ApxII. One 
presented a complete loss of hemolytic activity because o f the absence o f Apxl and 
ApxII production. The other displayed weaker hemolysis than the wild type and
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produced only ApxII. In the non-hemolytic mutant, the transposon had inserted in 
ApxIB. a gene involved in the exportation of Apxl and ApxII toxins. The weakly 
hemolytic mutant resulted from the disruption o f the structural gene for Apxl. Both 
mutations in the Apxl operon were associated with a significant loss o f virulence for 
mice and pigs, demonstrating that hemolysins were involved in APP pathogenicity. The 
non-hemolytic mutant was non-pathogenic and the weakly hemolytic mutant retained 
some virulence for pigs, suggesting that both Apxl and ApxII were needed for full 
virulence.
Actinobacillus pleuropneumoniae strains that secrete three different exotoxins 
(Apxl. ApxII and ApxIII) have been implicated in the etiology o f porcine 
pleuropneumonia (Chang et al.. 1993). To understand the role o f these toxins in the 
pathogenesis of this disease, the hemolysin gene (ApxII )was cloned, which encodes a 
110-kDa polypeptide with hemolytic and cytotoxic activity. To clone the third toxin 
gene (ApxIII). a new genomic library using APP serotype 2 chromosomal DNA was 
constructed. A series o f five overlapping recombinant phage clones carrying the gene 
(ApxIII) for this 120-kDa antigen were identified using a DNA probe containing 
sequences from the Pasteurella haemolytica IktBD genes. Sequence analysis of a 
region of the cloned DNA revealed four open reading frames encoding proteins with 
predicted masses of 20.4, 112.5. 80.3 and 54.7 kDa. These genes, designated ApxIIC. 
ApxIIIA. ApxIIIB and ApxIIID. respectively, were similar in sequence to the RTX 
(repeat of toxin) toxin family. The toxin produced by the cloned gene kills BL-3 cells 
and was not hemolytic in vitro. Mutants of Actinobacillus pleuropneumoniae serotype
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1 that were devoid of RTX toxins did not activate or kill porcine neutrophils (Jansen et 
ai, 1995; van de-Kerkhof et al... 1996). The Actinobacillus pleuropneumoniae RTX- 
toxins Apxl. ApxII and ApxIII were important virulence factors o f this swine pathogen 
and emphasized the importance o f Apxl and ApxII in pathogenesis. The Apx toxins 
may be deleterious to defense cells of the host, enabling the bacterium to infect the host.
The hemolytic RTX toxins o f 27 isolates of APP representing all serovars have 
been isolated in Australia (Tarigan et a i, 1994.1996). The quantity o f protein secreted 
by these isolates was not significantly different between serovars. Hemolytic activity 
was detected only in the unconcentrated supernatants from cultures o f serovar 1 and 5 
isolates. Hemolytic activity in supernatants of serovar 2. 3 and 7 isolates was detected 
only after the supernatants were concentrated. The hemolytic activity o f the culture 
supernatant depended on the type of composition of media and adaptability of the 
bacteria to in vitro culture. A low number o f in vivo passage after several in vitro 
passages cultures of APP characterized by waxy colonies, produced significantly 
weaker hemolytic activity than initial APP.
Non-Swiss albino (CF1) male mice were used as a model to study the 
pathological effects of specific toxic components o f APP on the respiratory system 
(Idris, et al., 1993). Mice were divided into five groups of ten each and were inoculated 
by the intranasal route with whole-cell APP serotype 1. cell-free culture supernatant 
fluid (CFCSF) containing hemolysin protein, purified lipopolysaccharide. heat-treated 
CFCSF. or PBS solution. Pulmonary lesions were evaluated at 6 and 12 h after 
inoculation. Mice inoculated with whole cells. CFCSF and LPS developed severe
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purulent bronchiolitis and alveolitis. Focal pulmonary necrosis was also observed in 
these three groups but was most consistent in the CFCSF-inoculated mice. 
Ultrastructurally. lungs from mice inoculated with whole cells, LPS and CFCSF were 
characterized by severe degenerative changes in type I and type II pneumocytes. 
Alveolar spaces contained cellular debris and fibrin. Endothelial cells were swollen and 
selected pulmonary capillaries were occluded with platelets and fibrin. Infiltrating 
neutrophils were often swollen, vacuolated and degranulated. Although inoculation 
with relatively large numbers of APP were required to kill mice, the mouse lung was 
quite sensitive to the toxic components produced by these bacteria. The elaboration of 
these two toxic components by APP may be responsible for the characteristic 
pulmonary inflammatory and necrotic lesions observed in infected swine.
Fluoroquinolones 
Biotransformation
The predominant site of fluoroquinolone biotransformation is the piperazine ring 
(Figures 1.1 and 1.2). (Neu. 1989. 1992). The oxoquinolones represent the major 
metabolites o f ciprofloxacin, enoxacin and norfloxacin (Lode et al.. 1990). It has been 
postulated that fluoroquinolones producing 4-oxo metabolites were stereochemically 
similar to theophylline or caffeine and inhibit methylxanthine metabolism (Robson, 
1992: Sakar et a i. 1990; Staib et ai, 1989; Fuhr et al.. 1992,1993). The potential for 
interaction with theophylline was not identical for all gyrase inhibitors (Sorgel &
Kinzig, 1993). Enoxacin is the strongest inhibitor of theophylline and caffeine 
metabolism, followed by tosufloxacin. ciprofloxacin and pefloxacin. Fleroxacin.
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ofloxacin, rufloxacin and sparfloxacin have none or negligible effects. A likely 
mechanism for this interaction is the inhibition o f subsets o f  the cytochrome P450 
enzyme. Piperazine ring-cleaved compounds and naphthyridine nuclei were shown to 
be most active inhibitors o f cytochrome P450IA2 (Figure 1.1). The effect of various 
substituents was also tested, leading to an equation that predicted inhibition of 3- 
caffeine 3-demethylation. Piperazine ring-cleaved compounds were more inhibitory 
than parent compounds and a nitrogen at position 4 or 7, respectively, reduced or 
increased inhibitory activity. Data on interactions of rifampin and cyclosporine with 
gyrase inhibitors were conflicting. Rifampin increased the clearance of fleroxacin but 
did not change the elimination half-life significantly. Although norfloxacin may 
interfere with metabolism of the S enantiomer o f warfarin, fleroxacin did not affect 
pharmacokinetic parameters of either the R or S enantiomer or the anticoagulant 
response.
Ciprofloxacin is the main metabolite o f  enrofloxacin resulting from ethyl 
dealkylation at the para nitrogen on the piperazinyl ring (Figure 1.2) (Outman & 
Nightingale. 1989). Desethylene-ciprofloxacin (Ml)  resulted from dealkylation of the 
ethyl group from the piperazinyl ring. Sulfo-ciprofloxacin (M2) was produced when the 
para nitrogen on the piperazinyl ring was sulfated. Oxo-ciprofloxacin (M3) occurred 
with the oxidation o f the ortho position in relation to the para nitrogen on the 3' carbon 
of the piperazinyl ring. Formyl-ciprofloxacin (M4) was formed by an aldehyde group 
on the para nitrogen o f the piperazinyl ring.
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Figure 1.1. The basic structure of the quinolones relates to the inhibition of 
methylxanthine metabolism. The N-C=N-C-N-C moiety is found in pipemidic acid and 
enoxacin. but not lomefloxacin or enrofloxacin.
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Figure 1.2. The fluoroquinolone, enrofloxacin, and some o f its metabolites.
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Flavin-containing monooxvgenase
Usually, flavin-containing monooxygenases catalyze the formation of N-oxides 
from tertiary aliphatic amines like the 4-methvl-1-piperazinyl gyrase inhibitors (Sorgel.
1989). Like the cytochrome P450's. flavin-containing monooxygenases are oxidative 
enzymes involved in Phase I biotransformations and can be referred to as mixed- 
fiinction amine oxidases (Sipes & Gandolfi. 1991). The FAD-flavoprotein is present in 
the endoplasmic reticulum and is capable of oxidizing nucleophilic nitrogen using 
NADPH and oxygen. Flavin-containing monoxvgenase competes with the cytochrome 
P450 system in the oxidation of amines, where FMO activity is high in humans and 
pigs, but low in rats. Tertiary amines are converted to amine oxides, secondary amines 
are converted to hydroxyl amines and nitrones and primary amines are converted to 
hydroxy lam ines and oximes. The catalytic mechanism for flavin-containing 
monoxvgenase is known in some detail for porcine liver (Poulsen & Ziegler. 1979: 
Beaty & Ballou. 1980. 1981 a.b). The flavin-containing monooxygenases are not under 
the same regulatory control as cytochrome P450's (Sipes & Gandolfi. 1991). While 
P450's can be induced by phenobarbital and 3-methylcholanthrene. FMO was 
repressed. Steroid sex hormones seem to regulate FMO enzymes with testosterone 
decreasing and progesterone increasing the cellular concentrations. Unlike P450's. 
xenobiotic substrates were not oxygenated for the reduction of flavin by NADPH or for 
the reaction of dioxygen with the reduced flavin (Poulsen & Ziegler. 1979: Beaty & 
Ballou. 1980. 1981 a.b). The key to FMO catalytic activity was the 4a- 
hydroperoxyflavin intermediate and was formed by the reaction of oxygen with
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reduced flavin. The 4a-hydroperoxvflavin intermediate was stable, which was a feature 
unique to this type o f monoxvgenase. The hydroperoxyflavin was also the oxygenating 
intermediate and oxygen was transferred from the hydroperoxyflavin to the substrate. 
The oxygenation reaction was identical in a model mechanism with similar products to 
the oxidation o f nucleophiles by synthetic protein-free N-5-alkyI. 4a-hydroperoxyflavin 
(Ziegler. 1988). There was no evidence for intermediates during oxygen transfer in 
either the porcine model or enzymatic reactions. This suggested that activation of 
substrate was not required and explains the nature of products formed and for the broad 
range of xenobiotics oxygenated by flavo-protein monooxygenases. Therefore, only 
xenobiotics with electron-rich centers can serve as substrates. However, the substrate 
must gain access to the enzyme-bound hydroperoxyflavin. Hydroperoxyflavin was 
common to all forms of the enzyme, so it was evident that steric differences in access 
may be responsible for differences in substrate specificity.
Substrate specificity of the enzyme-bound oxygenating intermediate should be 
limited to organic nitrogen compounds with functional groups that are readily oxidized 
by organic peroxides (Ziegler. 1988). Hydroperoxyflavin was not a strong oxidant for 
the attack of nitrogen atoms in amides, carbamides. imines. nitrones. oximes. 
isocynates, nitriles. or heterocyclic aromatic amines (Poulsen & Ziegler. 1979; Beaty & 
Ballou. 1980. 1981a,b). Amines, hydroxylamines. hydrazines and sulfur functional 
groups were more susceptible to oxidation and xenobiotics containing these groups 
were suitable substrates. Amine functional groups are quite common in alkaloids and 
synthetic drugs which makes the number of substrates in this category very large. Most
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all lipophillic acyclic (nortryptyline. promazine) or cyclic (perazine, nicotine) secondary 
and tertiary amines, respectively, tested were substrates. Flavin-containing 
monoxvgenase had a loose specificity for amines and precise fit into the catalytic cavity 
was not essential for biotransformation of substrates. Subsequently, the enzyme 
catalyzes both acyclic and cyclic amines with equal efficiency.
The piperazinyl ring on enrofloxacin has two tertiary nitrogens (Figure 1.2).
The most likely position for N-oxidation and dealkylation by FMO would be the 
nitrogen at the para position, possibly because there would be less steric hindrance. The 
metabolism of enrofloxacin by FMO is supported by work with tertiary amines related 
to brompheniramine, an antihistamine (Cashman et al.. 1993). The metabolism of 
racemic, (D)- and (L)-brompheniramine was studied in microsomes and with highly 
purified FMO from porcine liver. The main metabolite was the metabolite containing 
aliphatic nitrogen N-oxide. but some N-demethylation was observed. Furthermore, 
brompheniramine was extensively N-oxygenated by the highly purified FMO from hog 
liver. N-oxygenation o f bromapheniramine was enantioselective in both microsomes 
and highly purified FMO. The Km for N-oxygenation o f  (D)-brompheniramine was 
markedly lower than the Km for (L)-brompheniramine. (D)- and (L)-zimeldine were 
less conformationally flexible model compounds o f brompheniramine and both 
compounds were found to be steroselectively N-oxygenated by the highly purified FMO 
from hog liver. The results suggested that (D)-brompheniramine and (L)-zimeldine 
have the aliphatic tertiary amine nitrogen atom and aromatic ring center at a defined
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distance and geometry and were more efficiently N-oxygenated than their respective 
isomers.
Antimicrobial mechanism of action
The primary target o f quinolone activity in prokaryotic cells was DNA gyrase 
(Vance-Bryan et al., 1990). This enzyme, a type II topoisomerases. was required for 
DNA replication, transcription o f certain operons. repair and recombination. In vitro. 
the quinolones inhibit gyrase mediated DNA supercoiling and promote double stranded 
DNA breakage at specific sites. New details of the molecular interactions of quinolones 
with their target DNA gyrase and DNA have come from the nucleotide sequences of the 
gyrA genes from resistant mutants of Escherichia coli and wild-type strains of other 
bacteria and studies o f gyrase A tryptic fragments (Hooper & Wolfson 1991). The 
importance of an amino-terminal domain in quinolone action was supported by 
observations of alterations in DNA super-twisting that were associated with altered 
quinolone susceptibility, possibly by indirect effects on DNA gyrase expression. 
Specific binding of relevant concentrations of norfloxacin to a complex of DNA gyrase 
and DNA in the presence of ATP. the cooperativity o f DNA binding and the crystalline 
structure of nalidixic acid led to a model in which quinolones bind cooperatively to a 
pocket of single-strand DNA created by DNA gyrase. Quinolones vary in their relative 
activity against DNA gyrase and its eukaryotic homolog. topoisomerase II. The action 
of the fluoroquinolones on the eukaryotic enzyme was associated with genotoxicity. 
Inhibition of bacterial DNA synthesis by quinolones may correlate with minimum 
inhibitory concentrations (MICs) in some species, but comparisons of drug
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accumulation and inhibition o f  DNA synthesis in permeabilized cells among species 
have been difficult to interpret. In addition to interaction with DNA gyrase. the specific 
factors necessary for bacterial killing by quinolones include oxygen and new protein 
synthesis.
Pharmacokinetic characteristics
The fluoroquinolones are characterized by a large volume of distribution, which 
is reflected by good tissue penetration and long biological half-life in dogs, pigs and 
humans (Greene & Budberg. 1993; Kung et al.. 1993a.b; Lode et al.. 1990; Vancutsem 
et al.. 1990). The gastrointestinal absorption in mammals is rapid and substantial; the 
duration of action is long and the excretion mainly through the kidney (Vancutsem et 
al.. 1990). Their adverse effects were not severe when compared to the beneficial 
features fluoroquinolones exhibit. The targets for adverse effects are: central nervous 
system, urinary tract. DNA (genotoxicity). skin (phototoxicity), reproductive, digestive 
tract and the juvenile cartilage (Takayama et al.. 1995; Vancutsem et al.. 1990). Neither 
blood concentration nor pH affected low serum protein binding (Greene & Budberg. 
1993; Kung et al.. 1993a.b; Lode et al.. 1990). Low serum protein binding promoted 
rapid elimination by renal and extrarenal mechanisms with high total and renal 
clearances. There was transluminal enteric excretion as well as nephron tubular 
secretion (Wolfson & Hooper. 1991: Vance-Bryan et al.. 1990). The transluminal 
elimination of ciprofloxacin implied that the drug was eliminated across the intestinal 
wall without significant biliary elimination (<1%) (Bergan. 1989). In fact, transluminal 
elimination compensates for loss of renal elimination. All fluoroquinolones, except
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pefloxacin and enrofloxacin. undergo limited metabolism (Wolfson & Hooper. 1991: 
Vance-Bryan et a l. 1990). Water solubility promotes excellent bioavailability and 
rapid distribution. In humans, pharmacokinetic characteristics include a large volume 
o f distribution for fluoroquinolones (1.74 to 5.0 L/kg), a two compartment model after 
oral dosing and a three compartment model after i.v. dosing (Lode et a l. 1990). The 
two peripheral compartments consist of one with a rapidly equilibrating high clearance 
rate and the other slowly equilibrating with a slow clearance rate that prolongs the half- 
life (Lode et a l. 1990).
The large volume of distribution is not counterbalanced by rapid elimination of 
quinolones for most species. In pigs, the half-life is 6 to 8 h for the elimination of 
ciprofloxacin, which is much slower than other reported half lives (Kung et a l.
1993a.b). Ciprofloxacin may have potential clinical use in veterinary medicine, because 
of its breadth and intensity o f activity against Gram-negative pathogens and no cross 
resistance with P-Iactams or aminoglycosides occurs (Nouws et a l. 1988). Pigs were 
administered an i.v. injection o f 3.06 mg/kg of ciprofloxacin. The volume of 
distribution, elimination half-life and total clearance were: 3.83 L/kg. 2.57 h and 17.3 
ml/min/kg respectively. Twenty four hours after i.v. dosing, the urinary drug 
concentration in pigs was 8.9 pg/ml and plasma protein binding for ciprofloxacin in 
pigs was 23.6 %. The renal clearance of ciprofloxacin was 10 times higher than the 
creatinine clearance and indicated a predominately tubular secretion pattern o f the drug. 
Urinary recovery for pigs following i.v. administration was 47.9%. No glucuronide 
conjugates o f ciprofloxacin or its metabolites (M, or M2) were detected in the plasma or
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urine of the pigs (Nouws et al., 1988). The low protein binding of ciprofloxacin was 
attributed to interference o f fatty acids in the drug binding by albumin or fewer binding 
sites on albumin and a  i-acid glycoprotein (Belpaire. 1986).
The relationship o f  the physicochemical properties o f gyrase inhibitors to their 
hepatic and renal elimination pathways was analyzed (Sorgel & Kinzig, 1993). Luminal 
fluid concentrations of gyrase inhibitors were affected by an active process and 
inhibited by agents, such as probenecid, that inhibit tubular secretion of anions (Bergan. 
1989; Sorgel & Kinzig. 1993). Probenecid may inhibit base transport in the proximal 
tubule and inhibit quinolone transport as well. Available evidence suggested that all 
gyrase inhibitors were secreted as anions by the proximal tubules. Cimetidine. which is 
cationic at physiologic pH. inhibited base transport in the proximal tubule and inhibit 
base transport o f  gyrase inhibitors. Reabsorption also affected tubular concentrations. 
The N4'-methylated derivatives were the most lipophilic and addition or removal of the 
methyl group can. but did not always, affect reabsorption. The data indicated that all 
gyrase inhibitors undergo tubular secretion as either acids or bases and that some also 
were significantly reabsorbed. Hepatic handling and resultant excretion of metabolites 
were also influenced by the presence or absence of N4'-methylation. A step in the 
hepatic handling o f  N4'-methylated gyrase inhibitors that leads to N4'-oxidation has not 
yet been found in rufloxacin.
Enrofloxacin in veterinary medicine
In the USA. approved use of enrofloxacin is limited to dogs; approval for use in 
food-animals is currently being sought for several fluoroquinolones (Greene &
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Budberg, 1993: Vancutsem et al., 1990). even though extra-label use of other approved 
fluoroquinolones has been banned by the U.S. Food and Drug Administration. The 
activities of danofloxacin. a novel fluoroquinolone and two other antimicrobials were 
determined in vitro against field isolates o f seven Mycoplasma species of veterinary 
importance isolated from cattle, swine and poultry in five European countries (Cooper 
et al., 1993; Giles et al., 1991; McGuirk et a i. 1992). It was concluded that 
danofloxacin is highly active in vitro for the antibiotic control of all of the Mycoplasma 
species tested and thus showed great potential for the treatment of respiratory and other 
infections caused by Mycoplasma species in cattle, pigs and poultry. Marbofloxacin is a 
new fluoroquinolone that was developed exclusively for veterinary use (Spreng et ai. 
1995) Marbofloxaicn showed a broad spectrum of activity for the treatment of Gram- 
negative and Gram-positive bacterial diseases in dogs and cats. The post-antibiotic 
effect durations were found to be almost equal to the durations of enrofloxacin and 
ciprofloxacin. Marbofloxacin has been recently approved in 1997 in the United 
Kingdom for salmonellosis and colibacillosis in cattle (Dr. Michael Myers, personal 
communication).
Enrofloxacin is available in some countries as a injectable for parenteral use and 
as a food additive (Greene & Budberg. 1993). Enrofloxacin is the first antibacterial of 
this family to be available to veterinary medicine in the United States (Vancutsem et al..
1990). In swine, quinolones are effective for treating difficult respiratory diseases: 
mycoplasmal pneumonia and arthritis; enteric infections such as diarrhea of suckling, 
weaning or fattening pigs (coli diarrhea); septicemia caused by pathogenic Escherichia
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coli (edema disease) or Salmonella spp.; mastitis-metritis-agaiactia and urinary tract 
infections (Vancutsem et al., 1990; Wendt. & Sobestiansky 1995). Enrofloxacin is 
effective for the control of diseases caused by Escherichia coli and Haemophilus. 
Mycoplasma, Pasteurella, Eubacterium suis, Actinobacillus suis, Actinomyces 
pyogenes, Corynebacterium pseudotuberculosis. Erysipelothrix rhusiopathiae. 
Haemophilus pctrasuis, Haemophilus somnus, Pasteurella haemolytica, Pasteurella 
multocida, Rhodococcus equi. Streptococcus equi. Streptococcus suis. Streptococcus 
zooepidemicus and Salmonella spp in the United States (Hariharan et al., 1995; Prescott 
& Yielding. 1990; Vancutsem et al., 1990; Wendt. & Sobestiansky 1995).
Streptococcus suis types 1 and 2 were most commonly isolated via direct swabbing of 
palatine tonsils of healthy nursery pigs on 35 farms throughout the United States (Dee et 
al.. 1993). All isolates o f Streptococcus suis were susceptible to enrofloxacin. 97% of 
the isolates were susceptible to ceftiofur and 94% were susceptible to ampicillin. 
However, only 80% of the isolates were susceptible to penicillin and only 18% were 
susceptible to tetracycline.
While vaccine protection has not been rewarding for the control of porcine 
pleuropneumonia caused by APP. antimicrobial therapy has proven to be effective . 
Treatment for infection usually lasts 8 to 10 days in swine using quinolones. In 
controlled studies of swine infected with APP, 60% of the pigs died 18 to 56 h after 
experimental inoculation (Glawischnig et al., 1989; Schroder. 1989). Enrofloxacin was 
administered intramuscularly for 3 days at 2.5 to 5 mg/kg beginning 8 h post-infection 
or 5 mg/kg starting 12 h post-infection. Clinical improvement began 12 h after therapy
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was initiated and recovery was facilitated in all treated animals (Bauditz. 1987; 
Stephano et al.. 1987).
In a recent study, the pharmacokinetic parameters o f enrofloxacin in clinically 
normal dogs and mice and drug pharmacodynamics in neutropenic mice with 
Escherichia coli or Staphylococcal spp. infections were investigated (Meinen et al.. 
1995; Walker et al.. 1992). Enrofloxacin dosages ranged from 0.78 to 50 mg/kg of 
body weight in dogs and 6.25 to 200 mg/kg in mice. It was determined that 
enrofloxacin total dose rather than the dose frequency was significant in determining 
drug efficacy. Pharmacokinetic parameters were analyzed by multivariate stepwise 
linear regression analysis. The calculations revealed that the area under the 
concentration-time curve was more important than the time above minimum inhibitory 
concentration. So. enrofloxacin killing of Escherichia coli and Staphylococcus was 
plasma concentration-dependent and not time-dependent.
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Previous experiments by other investigators were designed to demonstrate 
efficacy and pharmacokinetic changes using non-infected animals. However, animals 
may have altered drug disposition and clearance when infected with pathogenic 
organisms. The infectious disease may alter the drug pharmacokinetic changes and 
efficacy studies often do not examine drug pharmacokinetic parameters. Therefore, 
evidence of a potential problem will not be detected. Few studies have explored the 
possibility of drastically increased toxicity or reduced efficacy in domestic animals to 
the same extent as rodent and human studies (Monshouwer. 1996: Monshouwer et al.. 
1995a.b. 1996a.b: Myers & Kawalek. 1995: Pijpers et al.. 1990.1991: Short. 1986: 
Short et al.. 1986). Endotoxin has been shown to reduce the elimination rate of 
antipyrine and trimethoprim in swine and decreased the total clearance of tiliazad 
mesylate in beef calves (Ladefoged, 1979: Rose et al.. 1993).
Target animal safety problems could arise in the drug development and approval 
process whereby therapeutic doses are actually toxic in the infected animal (Ladefoged. 
1979: Rose et al.. 1993). Conversely, increased rate o f clearance could indicate a need 
for more frequent dosing. Doses that were previously efficacious may not be sufficient 
to treat an infected animal. Human food safety is a concern. However, increased drug 
clearance and decreased half-life in food animals would result in decreased residue 
concentrations that are well below tolerance concentrations and withdrawal times.
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The goal o f  the infection study was 1) to characterize pharmacokinetic changes 
associated with APP infection in swine after receiving enrofloxacin and 2) to evaluate 
the pulmonary infection model compared to the endotoxin model and 3) to characterize 
the systemic level o f cytokines that may be associated with pharmacokinetic changes. 
Plasma concentrations of IL-6 were determined from 0 to 72 h after infection. Plasma 
concentrations o f IL-ip were determined for 0. 2, 6 and 12 h after infection. Plasma 
concentrations o f enrofloxacin and ciprofloxacin were determined for pharmacokinetic 
analysis from 24 to 72 h after infection. Urine enrofloxacin and ciprofloxacin were also 
measured and normalized with urine creatinine concentrations for samples collected 48 
and 72 h after infection. Gross necropsies were performed on all pigs which included 
lung weights and tissues collection for histopathology.
Materials and Methods 
Animal management
The experiment consisted of 24 crossbred. Landrace x Yorkshire, castrated pigs 
that were procured from a local vendor. All o f  the pigs were weighed prior to 
intravenous catheterization and were within a 25 to 35 kg weight range. Housing 
consisted of a heated building with a concrete floor and all animals were fed 3 kg/day 
from a single batch of a commercial corn-based ration without antibiotics. The pigs had 
been fed a commercial ration that was medicated with tylosin before procurement. All 
pigs were examined upon arrival and were clinically healthy at the start o f the study.
All procedures were approved by the Food and Drug Administration, Center for
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Veterinary Medicine, Office o f Research. Institutional Animal Care and Use 
Committee.
Experimental design
The design consisted of a 2 x 2 factorial o f treatments groups (Table 2.1). 
Actinobacillus pleuropneumoniae (gift from Dr. Michael P. Murtaugh. University of 
Minnesota. St. Paul. Minnesota) was one treatment. The second treatment was 
dexamethasone (0.5 mg/kg, Phoenix Pharmaceuticals. St. Joseph. Missouri). The 
bacteria were administered bv endotrachael infusion at zero hour into two of the four 
groups as a comparison to endotoxin that was administered by i.v. bolus in the next 
experiment. Intranasal inoculation in previous studies had resulted in a low infection 
rate while endotrachael inoculation produced a 100% infection rate. Four groups of six 
pigs were intravenously catheterized and placed in stainless steel metabolism cages over 
a one month period. Two groups were procured at a time and one group was placed in 
metabolism cages for four days followed by the second group. This process was 
repeated with another two groups of pigs. The Actinobacillus pleuropneumoniae was 
administered as a single endotrachael infusion to two groups while the other two groups 
received a sham saline infusion (Table 2.1). One infected group and one sham group 
received i.v. dexamethasone at -18 h . 0 h and 12 h . A bolus dose of 5 mg/kg 
enrofloxacin (Baytril . Bayer, Shawnee Mission. Kansas) was administered 
intravenously 24 h after saline or bacterial infusion to all four groups of pigs.
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Table 2.1. Experimental design for the Actinobacillus pleuropneumoniae infection 
study.
Treatment Sham Infection Infection
No Dexamethasone
Sham Infection Infection
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Bacteria
Animals were endobronchially inoculated with Actinobacillus 
pleuropneumoniae serotype 1. strain L91-2. a field strain isolated from an outbreak in 
Iowa(Baarsch et. a i .  1995: van Leengoed et. al.. 1987. 1989. 1990). The virulence of 
strain L91-2 was reduced by serial in vitro passage on solid growth media. Single 
colonies were passaged four times or until atypical morphology was evident. Colonies 
were creamier in appearance and two to three times larger and had a more rapid growth 
rate compared to non-passed microorganisms.
Logarithmically growing bacteria were employed to prepare inocula for the pigs. 
Cultures of APP bacteria were grown on agar plates from frozen stock (-70°C) that had 
been preserved in broth culture and 80% glycerol. The agar media consisted of 43 
grams of Casman's agar (Difco Laboratories, Detroit. Michigan) dissolved in 1000 ml 
of water and autoclaved for 20 minutes. The media was allowed to cool to 50°C and 50 
ml of heat inactivated horse serum was added. After the addition of 2 ml (5 g/L) of 
sterile NAD (Sigma. St. Louis. Missouri) the agar was poured into sterile plates. After 
incubating at 37°C for 12 hours, a single colony wras picked from the Casman's plate 
and inoculated into 3% tryptic soy broth (Difco Laboratories. Detroit. Michigan) 
containing 1% NZ amine (Sigma, St. Louis. Missouri), 0.1% yeast extract and 0.001% 
NAD and incubated at 37°C for 4-6 h while shaking at 215 rpm. The NAD was added 
to the broth after autoclaving and just before inoculation of the bacteria.
The cells were washed with 5% bovine serum albumin (BSA) in phosphate 
buffered saline (PBS. pH 7.4) after centrifugation at 1500g for 10 minutes. The washed
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cells were diluted to 0.4 optical density (550 run) which corresponded to approximately
2.0 x 10 CFU/ml. Viable cell-counts before inoculation were confirmed by plating on 
Casman's agar and reading the plate counts on the day following endobronchial 
inoculation. The cells were further diluted in PBS-BSA to about 2 x 104 CFU/ml. Six 
milliliters o f the 2 x 104 CFU/ml bacterial inoculum was delivered through a rigid 
polypropylene tubing (1 m x 1 mm I.D.) into the bronchial lumen using a 12 ml syringe. 
Air was flushed into the polypropylene tubing after the inoculation of the bacteria. 
Non-infected animals received 6 ml o f PBS-BSA.
Blood collection
A cranial vena cava catheter was implanted in each animal 24 h prior to bacterial 
inoculation or saline inoculation. Plastic tubing (0.6 mm I.D. x 1 m) was inserted 
through a 14 gauge (14 cm in length) stainless steel cannula (Brocht et al.. 1989; van 
Leengoed et al.. 1987). The animals were restrained without anesthesia while inserting 
the cannula 2.5 cm lateral to the point of the sternum at a 45° angle. The catheter was 
secured at the point o f skin penetration with surgical silk. The end of the catheter was 
extended to the back of the neck and protected with 15 cm of Elastikon2' (Johnson &
S)Johnson. Raritan. New' Jersey) and two rolls of Vetrap (3M Animal Care. St. Paul. 
Minnesota). A 19 gauge tubing adapter (Becton/Dickson. Sandy. Utah) was inserted 
into the end of the catheter and fitted with an injection cap (Becton/Dickson, Sandy. 
Utah).
Blood samples were collected through a saline-heparin lock (10 units/ml. Sigma. 
St. Louis, Missouri) in order to measure plasma concentrations o f enrofloxacin.
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ciprofloxacin (Sigma, St. Louis. Missouri) IL-6 and TNF-a. Cytokine blood samples 
were collected in heparin tubes (Monovette. Sarstedt, Germany) at 0. 1. 2. 3,4, 6. 8, 10. 
12.24, 36. 48. 60 and 72 h after sham infection or infection. High-performance liquid 
chromatography (HPLC) samples were also drawn in heparin tubes at 0. 0.25. 0.5. 1. 2. 
3, 4. 6, 8, 12. 24, 30 and 48 h after i.v. administration of enrofloxacin at 24 h post­
infection or sham infection. The samples were placed on ice before transporting to the 
laboratory and centrifuged (Jouan CR 412. Winchester. Virginia) at 1500g for 10 
minutes. The centrifuged plasma was harvested and aliquoted for storage at -70°C. 
Pharmacokinetic analysis 
Plasma sample preparation
Plasma samples were analyzed for enrofloxacin and ciprofloxacin by mixing 100 
pi of sample with 300 pi of a 2: 1 mixture of 0.05 N sodium hydroxide (Sigma. St. 
Louis. Missouri) and acetonitrile (HPLC grade. Burdick & Jackson. Muskegon. 
Michigan) containing 333 pg/L of pipemidic acid (Tyczkowska et al.. 1994). The final 
internal standard concentration of the fortified samples was 250 ng/ml pipemidic acid. 
After vortexing for 10-15 seconds, a 200 pi aliquot was placed in a 30.000 molecular 
weight cut-off microfilter (Microcon 30®. Millipore. Burlington. Massachusetts) and 
centrifuged (Eppendorf 5402. Brinkman Instruments, Westbury, New York) at 14.000g 
in a 45° fixed-angle rotar for 1 h . Approximately 150 pi was recovered and placed in 
tapered glass sample vials (Sulpelco. Bellefonte. Pennsylvania). Ten microliters of the 
clear ultrafiltrate was injected into the liquid chromatograph.
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Urine sample preparation
Urine samples were collected 24 h after infection or sham infection and at 0. 24 
and 48 hours after enrofloxacin administration. The urine samples were aliquoted into 
cryovials and stored at -70°C. After thawing at room temperature, sample dilution was 
accomplished by adding 100 pi o f the sample to 400 pi of diluent (2: 1 mixture of 0.05 
N. sodium hydroxide and acetonitrile) in siliconized microcentrifuge tubes (Costar, 
Cambridge, Massachusetts) and mixed by vortexing. A 50 pi aliquot was taken from 
the 1:4 urine dilution and added to a sample vial containing 950 pi o f the following 
mixture: 750 pi of 0.05 N sodium hydroxide and acetonitrile (2: 1): 200 pi o f distilled 
water with 263 pg/L of pipemidic acid. The pipemidic acid had been added from a 5 
mg/L stock solution that was diluted with the 2: 1 mixture o f 0.05 N sodium hydroxide 
and acetonitrile. The pipemidic acid, water and sodium hydroxide/acetonitrile were 
mixed in a single batch prior to addition to the sample vial. The final urine dilution in 
the sample vial was 1: 99 after mixing the 50 pi of the 1:4 diluted urine to the 950 pi of 
internal standard, water and 2: 1 mixture of 0.5 N sodium hydroxide/acetonitrile. The 2 
ml glass sample vials (Sulpelco. Bellefonte, Pennsylvania) were placed in the HPLC for 
10 pi injections.
Urine creatinine
Urine creatinine was used to normalize the urine concentrations o f enrofloxacin 
and ciprofloxacin (Palmisano et. al.. 1995). This approach avoided the need to collect 
and measure the volume of 24 hour urine samples, because o f the occasional 
contamination with drinking water or accidental loss of a portion of the 24 hour urine
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sample. Urine creatinine was assayed using a Urine Creatinine Kit (Sigma, St. Louis, 
Missouri). The urine samples were first diluted ten to thirty times with water. Working 
standard dilutions were prepared by diluting 150 mg/L stock standard with water 
resulting in a standard curve consisting o f 0. 25. 50, 75. 100 and 150 mg/L. Sample and 
standards were prepared in triplicate by adding 30 pi to 300 pi of alkaline picrate 
solution into each well of a microplate including the standard curve wells on each plate. 
The plates were mixed for 30 seconds and let stand at room temperature for 10 minutes. 
The plates were read at 500 nm using a microplate spectrophotometer (Spectra Max 
250. Molecular Devices. Sunnyvale. California)
The standard curve on each of the four test plates was linear, "y" (absorbance) 
versus “c" (concentration. mg/L): y=0.007 c + 0.221. R=0.9995; y=0.007 c + 0.189, 
R=0.9995; y=0.007 c + 0.191. R=1.0: and y=0.007 c + 0.185. R=0.9995. The 
coefficient o f variation was less than 7% and 10% for the standar ds and samples, 
respectively.
Recovery of the internal and external standards
Pooled pig plasma from an unrelated study was used to explore recovery of 
ciprofloxacin and enrofloxacin. Ten serial dilutions (1: 1) o f ciprofloxacin and 
enrofloxacin were prepared in the range of 313 pg/L to 80 mg/L using water. The final 
concentrations o f the 10 standards ranged from 15.6 pg/L to 4 mg/L after adding 50 pi 
of each stock standard to 950 pi of pooled pig plasma. The fortified plasma samples 
were analyzed for enrofloxacin and ciprofloxacin by mixing 100 pi of the fortified 
plasma with 300 pi o f a diluent consisting of: a 2: 1 mixture o f 0.05 N sodium
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hydroxide and acetonitrile with 333 pg/L pipemidic acid as the internal standard 
(Tyczkowska et al.. 1994). The final internal standard concentration of the fortified 
samples was 250 pg/L pipemidic acid. After vortexing for 10-15 seconds, a 250 pi 
aliquot was placed in a 30.000 molecular weight cut-off microfilter and centrifuged at 
14.000g in a 45° fixed-angle rotary for lh. Approximately, 200 pi of the ultrafiltrate 
was recovered and placed in tapered glass sample vials. Ten microliters o f the clear 
ultrafiltrate was injected into the liquid chromatograph Average analyte recovery from 
five replicates at each of the 10 concentrations ranged from 91% to 104% for pipemidic 
acid. 94% to 107% for ciprofloxacin and 94% to 106% for enrofloxacin. The plasma 
peak height counts were compared to the average o f five replicates of aqueous internal 
standard and external standards that were prepared in water without microfiltration. The 
coefficients of variation for each of the 10 concentration recoveries ranged from 1.9% to 
11% for the percent o f recovery of pipemidic acid, ciprofloxacin and enrofloxacin. 
Aqueous standard curves for plasma
Aqueous standard curves for plasma were constructed by first preparing 
enrofloxacin and ciprofloxacin working standards consisting o f eleven dilutions: 0. 
0.156. 0.313. 0.625. 1.25. 2.5. 5.0. 10.0. 20. 40 and 80 mg/L. Each working standard 
was diluted 20 times to final concentrations ofO, 0.0078. 0.0156. 0.0313. 0.0625. 0.125, 
0.25, 0.5. 1. 2 and 4 mg/L. for enrofloxacin and ciprofloxacin. The final dilution for 
HPLC analysis was prepared by adding 50 pi o f working standard to 950 pi o f the 
following mixture: 750 pi o f 0.05 N sodium hydroxide and acetonitrile (2: 1); 200 pi of 
distilled water with 263 pg/L of pipemidic acid. The pipemidic acid had been added
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from a 5 mg/L stock solution that was diluted with the 2: 1 mixture o f 0.05 N sodium 
hydroxide and acetonitrile. The pipemidic acid, water and sodium 
hydroxide/acetonitrile were mixed in a single batch prior to addition to the sample vial. 
The final internal standard concentration of the standards and fortified samples was 250 
ng/ml of pipemidic acid. The standards were not filtered through the 30.000 molecular 
weight cut-off filters.
The linearity o f the response, "y" (ratio of peak height counts) versus ”c '  
(concentration. mg/L) were tested over eight standard solutions. The typical response 
standard curves for plasma samples were linear as represented by the equations: y=12.8 
c + 0.135. R=0.9995 for enrofloxacin; and y=10.2 c - 0.323. R=0.9984 for 
ciprofloxacin. Five replicates of each of the 10 standard concentrations (7.8 pg/L to 4 
mg/L) for ciprofloxacin and enrofloxacin yielded coefficients o f variation ranging from 
2% to 6% for ciprofloxacin and 0.8% to 13% for enrofloxacin.
Aqueous standard curves for urine
Aqueous standard curves for urine were constructed by first preparing 
desethylene-ciprofloxacin. enrofloxacin and ciprofloxacin stock standards. 
Desethylene-ciprofloxacin stock standard (6.25 mg/L) was diluted (1 :1) into the 
enrofloxacin and ciprofloxacin stock standard (20 mg/L). Working standards were 
prepared by simultaneous 1:1 serial dilutions of the three standards in the stock solution. 
The working standards concentrations were: 0. 0.0244. 0.0488. 0.0975. 0.195. 0.39.
0.78. 1.56 and 3.13 mg/L for desethylene-ciprofloxacin and corresponding dilutions: 0.
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0.078. 0.156. 0.313. 0.625, 1.25. 2.5, 5.0 and 10.0 mg/L of enrofloxacin and 
ciprofloxacin.
Each working standard was diluted 20 times with 0.05 N sodium 
hydroxide/acetonitrile (2:1) to final concentrations o f 0. 3.9. 7.8. 15.6. 31.3. 62.5. 125. 
250 and 500 pg/L, for enrofloxacin and ciprofloxacin and 0. 1.22. 2.44. 4.88. 9.75. 19.5. 
39. 78 and 156 pg/L. for desethylene-ciprofloxacin. The final solution for HPLC 
analysis was prepared by adding 50 pi of working standard to 950 pi o f the following 
mixture: 750 ul of 0.05 N sodium hydroxide and acetonitrile (2: 1): 200 pi o f distilled 
water with 263 pg/L of pipemidic acid. The pipemidic acid had been added from a 5 
mg/L stock solution that was diluted with the 2: 1 mixture of 0.05 N sodium hydroxide 
and acetonitrile. The pipemidic acid, water and sodium hydroxide/acetonitrile were 
mixed in a single batch prior to addition to the sample vial. The final internal standard 
concentration of the standards and fortified samples was 250 ng/ml o f pipemidic acid. 
The internal standard, water and sodium hydroxide/acetonitrile were mixed in a single 
batch prior to addition to the sample vial. The standards were not filtered through the
30.000 molecular weight cut-off filters.
The linearity of the response, "v” (ratio of peak height counts using the internal 
standard, pipemidic acid) versus concentration, "c” (mgT. for desethylene- 
ciprofloxacin, ciprofloxacin and enrofloxacin) were tested over eight standard dilutions. 
The typical response standard curves for urine samples were linear as represented by the 
equations: y=16.0 c - 0.0379. R=0.9997 for enrofloxacin; y=l 1.8 c + 0.00253.
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R=0.9997 for ciprofloxacin; and y=123 c + 0.0434, R=0.9997 for desethylene- 
ciprofloxacin.
Five replicates of each of the 8 concentrations (3.9 - 500 pg/L for ciprofloxacin 
and enrofloxacin and 1.22 - 156 pg/L for desethylene-ciprofloxacin) o f standard yielded 
coefficients of variation ranging from 0.7% to 2.9% for desethylene-ciprofloxacin, 2% 
to 11 % for ciprofloxacin and 1 % to 9% for enrofloxacin. respectively. The minimum 
detection concentrations for pipemidic acid, ciprofloxacin, enrofloxacin. and 
desethylene-ciprofloxacin were 33. 10. 12 and 1 ng/ml, respectively. The actual 
minimum detection level was 40, 49 and 4 ng/ml for ciprofloxacin, enrofloxacin and 
desethylene-ciprofloxacin. respectively because of a four-fold plasma dilution. The 
actual minimum detection limit for urine was 200. 240 and 20 ng/ml for ciprofloxacin, 
enrofloxacin and desethylene-ciprofloxacin. respectively because o f a 20-fold urine 
dilution. The minimum detection limit was based on a signal-to-noise ratio of 3. 
High-performance liquid chromatography
Ten microliters injections o f samples and standards were loaded into a 
Rheodvne injector valve using a an autosampler that was incorporated into the liquid 
chromatograph (Perkin Elmer Integral 4000. Perkin Elmer. Norwalk, Connecticut). The 
column was a reverse phase C-18 column with dimensions of 250 mm c 3.2 mm and a 5 
pM particle size protected by a guard column (Primasphere^. Phenomenex, Torrance. 
California). The mobile phase for the plasma samples consisted of 19% acetonitrile and 
81% 0.15 M citric acid (Sigma. St. Louis. Missouri) with a flow rate o f 0.5 ml/min with 
a 10 minute run time for plasma. The mobile phase for the urine samples consisted of
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18% acetonitrile and 82% 0.15 M citric acid with a flow rate o f 0.5 ml/min with a 14 
minute run time. The UV detector was set at 280 nm and the fluorescence detector (LS- 
4, Perkin Elmer. Norwalk, Connecticut) settings were 276 nm and 450 nm for excitation 
and emission, respectively. The peak height data was integrated by Turbochrom9 
(Version 4.2. Perkin Elmer-Nelson, San Jose. California). The resulting plasma 
concentrations were then subjected to nonlinear regression analysis using a 
noncompartmental model (WinNonlin Version 1.1. Apex, North Carolina). 
Interleukin-6 bioassay
Interleukin-6 assay was performed as previously described using the murine IL- 
6 dependent 7TD1 cell line (ATCC No. CRL 1851. Rockville. Maryland) to assay the 
swine plasma (Myers et al.. 1992). The cells were grown in Ultraculture media (500 
ml. Bio-Whittaker. Walkersville, Maryland) with supplements o f HEPES (5 ml. 1 M. 
Sigma. St. Louis. Missouri), gentamicin (1 ml. 50 mg/ml. Bio-Whittaker. Walkersville, 
Maryland), sodium bicarbonate (5 ml. 7.5%. Sigma. St. Louis. Missouri), fungizone (2 
ml. 250 mg/ml, GIBCO, Grand Island, New York) and glutamine (10.3 ml. 200 mM. 
Sigma. St. Louis. Missouri). The media was further supplemented with 10 units of IL- 
6/mI and 50 pM o f 2-mercaptoethanol to maintain the cells.
The cells were washed three times in assay media that did not contain IL-6. A 
standard curve was prepared for each 96-well microplate (Costar. Cambridge. 
Massachusetts). A standard curve (33.3, 25, 10. 5. 3.33. 2.5. 1 and 0 units per/ml) was 
prepared for each microplate by dilutions. Specific activity o f the human IL-6 standard
o
was 1.375 x 10 units/mg o f protein. The samples were diluted 1: 39 with assay media
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and 100 pi of the diluted sample or standard was added, in duplicate, to the appropriate 
wells. The 7TD1 cells were diluted with assay media to a concentration o f 2-10 cells x 
104 cells/ml and 100 pi of cells was added to each well of the microplate. The plates 
were incubated for 68 hour at 37°C in 5% C 0 2. Four hours before termination. 20 pi of 
Alamar blue dye (Alamar Biosciences, Sacramento, California) was added to each well 
and the plate was incubated at 37°C for 4 hours. The activity of the IL-6 was assessed 
by use of a fluorometer (Cytofluor 2350. Millipore. New Bedford. Massachusetts) with 
settings o f 530 nm excitation and 590 nm emission.
The standard curve was plotted as a log-logit transformation using Cytocalc 
(Millipore. New Bedford. Massachusetts). The log-logit transformations gave 12 linear 
response curves. ”y" (absorbance) versus "c" (concentration, pg/ml). for each plate: 
y = l.57 c - 5.34. R=0.95; v=l.49 c - 5.12. R=0.94; y=1.41 c - 4.82. R=0.91; y = l.50 c - 
4.95. R=0.92; y=1.38 c - 4.70. R=0.91: y=1.40 c - 4.76. R=0.90; v=1.27 c -4.45. 
R=0.98; y=l .44 c - 4.98. R=0.99; y=l .38 c -4.72. R=0.99; v=1.45 c -5.05. R=0.98: 
y=l .33 c - 4.63. R=0.98 and y=1.38 c - 4.81. R=0.99. The sample values were 
interpolated from the standard curve on each o f the microplates and the data was plotted 
using SigmaPlot (Version 3.0. Jandel Scientific. San Rafael. California).
Interleukin-ip ELISA assay
Microplates that were coated with mouse monoclonal antibody to IL-1 p 
(Interleukin-ip ELISA Test K.it. Genzyme Diagnostics. Cambridge, Massachusetts) 
were used to measure IL-1P in pig plasma at 0, 2. 6 and 12 hours. A 100 pi aliquot of 
standard or sample was added to each well in duplicate. A standard curve was prepared
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to include 0. 4. 64. 256, 512 and 1024 pg/ml o f IL -1 p using polypropylene culture 
tubes. The serial dilutions o f the standards were accomplished with sample diluent that 
was supplied in the kit and were mixed by vortexing. The undiluted plasma was added 
directly to the test wells.
The test wells were covered with plate sealer and incubated for 30 minutes at 
37°C to allow IL-1P to bind with the monoclonal antibody. The liquid was aspirated 
from the test wells after incubation. The wells were washed five times with wash 
reagent followed by aspiration after each wash. After the last wash, the plates were 
blotted with paper towels to remove excess liquid. Reconstituted IL-1P rabbit 
polyclonal antibody (100 pi) was added to each well. The plates were covered with 
plate sealer and incubated for 30 minutes at 37°C. The test wells were washed and 
aspirated five times and 100 pi of IL-1 (3 conjugate (peroxidase anti-rabbit IgG reagent) 
was added to each well. The plates were incubated for 15 minutes at 37°C and washed 
five times.
Finally. 100 pi o f peroxidase substrate and chromagen (tetramethylbenzidine) 
reagent was added to each well and the plates were incubated for 30 minutes at room 
temperature. A blue color was produced in the presence of the peroxide enzyme. The 
color reaction was stopped by the addition of acid (50 pi) which changes the blue color 
to yellow. The intensity of the yellow color was directly proportional to the amount of 
IL-ip present in the sample or standard. The plates were read at 450 nm absorbance on 
a microplate spectrophotometer (Spectra Max 250. Molecular Devices. Sunnyvale. 
California) within 30 minutes after stopping the reaction. A standard curve was plotted
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using Softmax Pro (Version 1.2, Molecular Devices. Sunnyvale. California) and the 
plasma sample concentrations of IL-ip were interpolated from the standard curve on 
each plate. The response curves of the standard dilutions were nonlinear, "y” 
(absorbance) versus "c” (concentration, pg/ml): y=0.12 + 0.006 c - (2.5 x 10-6)c\ 
R=0.9995 and y=0.175 + 0.009 c - (5 x 10-6)c2. R=0.9995.
Health observations, necropsies and histopathology
Health observations were made during the entire study period of 4 days. Gross 
necropsies were performed on all animals in the infection study. The pigs were 
euthanized with Euthasol® which contained sodium pentobarbital (Delmarva 
Laboratories. Inc.. Bristol. Tennessee). Brain and spinal cord were not examined. Fresh 
liver (100 to 200 grams) was collected and frozen at -80°C if required to perform 
Northern or Western blots. Lung weights and gross necropsy observations were 
recorded on a necropsy form. The color, texture, location and size o f gross lesions were 
also noted on the necropsy form. After trimming the trachea from the lung at the level 
of the cranial bronchi the lung was weighed before sampling for histopathology.
The following tissues (1-2 mm thick up to 4 x 4 cm) were collected for 
histopathology: right bronchial lymph node, middle mediastinal lymph node, mesenteric 
lymph node, lung, two sections of heart from the left ventricle and septum, three 
sections of liver from different lobes, one section o f the middle region of the spleen and 
one section o f each kidney. The lungs were covered with a paper towel during fixation 
in the specimen jar. If gross abnormalities were observed in other organs or tissues, a 
sample was collected for histopathology. The tissues were placed in a 4 L specimen jar
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containing 10% buffered formalin. pH 7.4. (Sigma. St. Louis. Missouri) in a 1: 20 ratio 
of tissues to formalin. The tissues were allowed to fix in the formalin for 24 hours and 
the spent formalin was decanted and replaced with fresh formalin. The tissues were 
allowed to completely fix for at least one week before transporting to the Department of 
Veterinary Pathology. College of Veterinary Medicine. Louisiana State University, 
Baton Rouge. Louisiana for processing and microscopic examination. The tissues were 
sealed and shipped to Louisiana State University in whirl pack plastic bags with a 
minimum of formalin. Selected tissues were processed by routine methods for light 
microscopy.
Statistics
Pharmacokinetic parameters, urine enrofloxacin and ciprofloxacin 
concentrations. IL -1 and IL-6 plasma concentrations and lung weights were analyzed by 
Two-Way ANOVA. General Linear Model, using SigmaStat. Version 2.0 and 
SigmaPlot. Version 3.0 (Jandel Scientific. San Rafael. California). Pharmacokinetic 
parameters that were statistically analyzed were: : Area Under Curve. 0 h to last 
sample. (AUCq.* pg h /L); Area Under Curve. 0 h to infinity. ( A U C , p g  h /L); 
Mean Residence Time, (MRT. h ); Terminal half-life. ( t1/2 h ); Total Body Clearance 
(Cltot. L/hr/kg); Volume o f Distribution at Steady State (Vss. L/kg) and Volume of 
Distribution of the elimination phase (Vp, L/kg)) and Elimination Rate Constant (p.
1/h). Bacterial infection and dexamethasone treatments were the main effects with 
infection by dexamethasone as the interaction. Two-way ANOVA was performed after 
ranking the raw data, P<0.01. except for the comparison of total urine creatinine.
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ciprofloxacin and enrofloxacin. Urine for the control and dexamethasone groups was 
collected and the volume measured, but urine volumes for the infected and infected- 
dexamethasone groups were not measured. AH pairwise multiple comparisons were 
made using the Student-Newman-Keuls test with P<0.01. except for total urine 
creatinine, ciprofloxacin and enrofloxacin which was done using the t-Test. P<0.01. 
after ranking the raw data.
Results 
Animal observations and pathology
The infected pigs became lethargic and dyspnic within 2 hours after inoculation 
with Actinobacillus pleuropneumoniae. Three infected pigs vomited and all infected 
pigs were anorectic. After 24 hours, the infected pigs were still depressed but ate some 
of their ration. Breathing was labored in all of the infected pigs until the time of 
necropsy. In contrast, all o f the non-infected pigs were eating and drinking and did not 
exhibit labored breathing after sham inoculation.
Five of the non-infected pigs showed focal to extensive areas of hemorrhage and 
the lesions were raised above the surface of the lung. The remaining 7 non-infected 
pigs had normal lungs (Figure 2.1). Gross pathology observations in all of the infected 
pigs included fibrinous pleuropneumonia with necrosis and hemorrhage in a focal to 
multifocal pattern (Figure 2.2). The pulmonary lesions were raised above the surface 
and observed predominately on the right lung in the middle and caudal lobes. The rank 
means of the lung/body weight (g/kg) ratio of the infected pigs was increased and 
significantly different (PO .O l) from the non-infected pigs (Table 2.2; Figure 2.3).
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Histopathology of the non-infected pigs revealed slight to moderate, chronic 
interstitial pneumonia that was not indicative o f Actinobacillus pleuropneumoniae 
infection (Figure 2.4). The infected pigs had necrotizing extensive, severe, 
fibrinopurulent pneumonia with edema and fibrinopurulent pleuritis (Figures 2.5 and 
2.6). One of the infected pigs died within 24 hours after inoculation. The cytokine 
results were analyzed for this pig. but not the pharmacokinetic changes because plasma 
samples were not collected. The gross and microscopic lesions in the infected pigs were 
compatible with Actinobacillus pleuropneumoniae infection. Lung cultures o f the 
infected and non-infected pigs on agar plates provided only isolates that were 
contaminants instead of the characteristic Actinobacillus pleuropneumoniae colonies. 
Enrofloxacin administration at 24 h after infection may have prevented the recovery of 
viable bacteria from the lung..
Plasma interleukin-6
Plasma interleukin-6 concentrations were elevated and significantly different in 
the non-infected pigs versus the infected pigs based on area under the curve form 0 to 
72 h (PO .O l) (Table 2.3; Figures 2.7 and 2.8). Comparison of the infected group 
versus infected-dexamethasone group was not significantly different (P O .O l) (Figure 
2.8). Control group and dexamethasone group interleukin-6 concentrations remained at 
baseline over the 72 h period (Figure 2.7).
Plasma interleukin-1
Plasma interleukin-1 concentrations were not statistically different among the four 
treatment groups in the endotoxin study. The IL-1 plasma concentrations of
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STUDY 318.14 PIG 27 
12/7/95 
GROUP I NON-INFECTED 
NO DEXAMETHASONE
Figure 2.1. Dorsal view of the trachea, heart and lungs of a control pig (non-infected. 
no-dexamethasone).
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STUDY 318.14 PIG 1 11/8/95 
GROUP III INFECTED 
NO DEXAMETHASONE
Figure 2.2. Dorsal view of the trachea, heart and lung in an infected pig (no- 
dexamethasone). The gross lesion (5 x 6 cm) on the right caudal lung lobe (arrow) 
described as necrotizing fibrinopurulent pneumonia that is consistent with 
Actinobacillus pleuropneumoniae infection.
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Table 2.2. Lung/body weight (g/kg) ratios in control, dexamethasone. infected and 
infected-dexamethasone treatment groups.
Control Dexamethasone Infected Infected-
Dexamethasone
LW/BW (g/kg) 8.49 8.82 12.3 12.7
(min-max) (7.41-9.44) (7.58-20.3) (10.3-14.7) (9.5-16.7)
The lungs weights were normalized with body weights.
LW/BW; the ratio o f the lung weight/total body weight.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
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Figure 2.3. Rank means±SD of iung/body weight ratios in control, infected, 
dexamethasone and infected-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare non-infected pigs with infected pigs, (n= 12) (Two-way analysis of
variance performed after ranking the raw data. P O .O l).
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Figure 2.4. Photomicrograph of a normal section o f lung from a control pig with slight, 
chronic interstitial pneumonia.
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Figure 2.5. Photomicrograph o f a section o f lung from an infected pig with necrotizing, 
fibrinopurulent pneumonia.
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Figure 2.6. Photomicrograph of a section of lung from an infected pig with necrotizing, 
fibrinopurulent pneumonia with alveolar edema, bronchitis and bronchopneumonia.
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control, dexamethasone, endotoxin and endotoxin-dexamethasone groups remained at 
baseline levels over the 12 h period after endotoxin administration.
Plasma enrofloxacin pharmacokinetic changes 
Area under the curve
The rank means of no-dexamethasone pigs versus dexamethasone treated pigs 
were significantly different for both area under the curve for zero to infinity AUC(inf) 
and area under the curve from zero to the last measured time point AUC(last) (Table 
2.4: Figure 2.9). The no-dexamethasone pigs rank means were greater (PO .O l) than the 
dexamethasone treated pigs rank means (Figure 2.10). The ratio of AUC(last) to 
AUC(inf) was lower for the control group compared to the dexamethasone. infected and 
infected-dexamethasone groups, 0.76, 0.82. 0.86 and 0.91 respectively (Figure 2.11). 
This is expected, because the control group has a longer half-life than the other three 
treatment groups which increases the percentage of the AUC from the last measured 
time point to infinity within the area of AUC(inf) (Table 2.4: Figures 2.10 and 2.11).
The larger area under the curve from the last measured time point to infinity in the non- 
infected and infected pigs should not bias pharmacokinetic calculations because the last 
measured time point at 36 and 48 h are above the 0.05 mg/L limit of detection for 
plasma enrofloxacin and the elimination phase was determined over four time points 
from a beginning time point of 3 to 12 h to an ending time point of 36 to 48 h.
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Clearance, volume of distribution, mean residence time, half-life and elimination rate
constant
Clearance was significantly greater (P O .O l) for the dexamethasone treated pigs 
compared to the no-dexamethasone pigs (Table 2.5: Figure 2.12). Volume of 
distribution based on the elimination phase (Vp) and volume of distribution at steady 
state (Vss) were both significantly less (PO .O l) for the infected pigs compared to the 
non-infected pigs (Table 2.5: Figures 2.13 and 2.14). Mean residence time and half-life 
were significantly less (P O .0 1) for the infected pigs compared to non-infected pigs 
(Table 2.5: Figure 2.15). The elimination rate constant (P) was significantly greater 
(P O .O l) for the dexamethasone treated pigs compared to the no-dexamethasone pigs 
(Table 2.5). The elimination rate constant (P) was also significantly greater (P O .0 1) 
for the infected pigs compared to the non-infected pigs (Table 2.5).
Urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios 
Ciprofloxacin and enrofloxacin were both detected in the 24 and 48 h urine samples 
(Tables 2.6 and 2.7). The ciprofloxacin and enrofloxacin peaks did not appear in the 0 h 
blank sample (Figure 2.16). Ciprofloxacin was the only metabolite that was measured 
in the urine of the infection study pigs (Figure 2.16). The four other possible lesser 
metabolites were oxo-ciprofloxacin. desethylene-ciprofloxacin. oxo-enrofloxacin and 
desethylene-enrofloxacin (Figure 2.17). Oxo-enrofloxacin is a suspect peak found in 
the urine of a control pig between the pipemidic acid and ciprofloxacin at about 7 
minutes retention time in the infection study (Figures 2.16 and 2.17). The oxo- 
enrofloxacin suspect peak corresponded to a peak detected in a separate analysis using a
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Figure 2.7. Mean plasma concentration o f interleukin-6 collected at 0, 1. 2. 3. 4. 6. 8, 
10. 12. 24. 36. 48, 60. and 72 hours after infection or sham infection.
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Table 2.3. Area under the curv e for plasma interleukin-6 in pigs.
Control Dexamethasone Infected Infected-
Dexamethasone
AUC0_>72 hr 32.3 38.6 467 1158
(units/ml x h) (0-340.1) (0-335.6) (2.11-946.7) (39.27-6014.9)
(min-max)
A U C o ^  hr: area under the curve from 0 to 72 h.
Values are raw data medians and (min-max) represents the range o f raw data within a 
group.
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Figure 2.8. Rank means o f  area under the curve for plasma interleukin-6.
Values with identical superscripts are not significantly different. P< 0.01.
*\B wUsed to compare non-infected pigs with infected pigs. (n=12) (Two-way analysis of 
variance performed after ranking the raw data. P<0.01).
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Figure 2.9. Semilogrithmic plot of mean plasma concentrations o f enrofloxacin 
measured at 0. 0.25. 0.5. 1. 2, 3, 4, 6, 8. 12. 24. 36. and 48 h after i.v. enrofloxacin (5 
mg/kg BW) administration and 24 h after infection or sham infection.
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Table 2.4. Area under the curve (mg/L x h) for plasma enrofloxacin in control, 
dexamethasone. infected and infected-dexamethasone treatment groups.
Area Under the Control Dexamethasone Infected Infected-
Curve Dexamethasone
(mg/L x h)
AUC(inf) 31.1 19.5 31.1 14.2
(min-max) (21.3-32.2) (12.2-27.1) (23.1-45.0) (11.3-32.4)
AUC(last) 22.8 14.8 28.3 13.0
(min-max) (17.1-25.3) (10.4-22.8) (19.9-34.5) (10.4-26.7)
AUC(inf) area under the curve from zero to infinity
AUC(last). area under the curve from zero to the last measured hour.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
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Figure 2.10. Rank means±SD of area under the curve for plasma enrofloxacin in 
control, infected, dexamethasone and infected-dexamethasone treatment groups. 
AUC(inf) area under the curve from zero to infinity.
AUC(last). area under the curve from zero to the last measured hour.
Values with identical superscripts are not significantly different. P< 0.01. 
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs for 
AUC(inf) (n—12) (Two-way analysis of variance performed after ranking the raw data. 
PO.Ol).
^Used to compare no-dexamethasone pigs with dexamethasone treated pigs for 
AUC(last) (n=12) (Two-way analysis of variance performed after ranking the raw data. 
P<0.01).
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Figure 2.11. Means of area under the curve ratios for plasma enrofloxacin in control, 
infected, dexamethasone and infected-dexamethasone treatment groups.
AUC(inf). area under the curve from zero to infinity.
AUC(Iast), area under the curve from zero to the last measured hour.
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Control Dexamethasone Infected lnfected-Dexamethasone
C \„  (L/h/kg) 0.161 0.259 0.161 0.359
(min-max) (0.155-0.234) (0.185-0.409) (0.111-0.216) (0.154-0.443)
V ptfA g) 5.47 7.75 3.20 5.13
(min-max) (4.25-6.73) (4.32-9.52) (2.59-4.71) (3.50-6.42)
V«(L/kg) 5.52 7.61 3.04 4.85
(min-max) (4.33-6.89) (4.40-8.60) (2.60-4.84)) (3.33-5.97)
MRTinr(h) 31.3 24.2 21.2 13.6
(min-max) (26,1-44.2) (20.5-36.9) (18.5-30.1) (11.3-27.3)
l i/2 (h) 21.4 17.2 14.6 10.2
(min-max) (17.7-29.9) (15.9-25.8) (12.8-19.2) (8.25-19.1)
P ( 1/h) 0.0360“a 0.0516bA 0.0560aU 0.0679bH
(min-max) (0.0261-0.0414) (0.0318-0.0744) (0.0472-0.0706) (0.0369-0.0840)
Cll01, total body clearance; V() volume of distribution based on the terminal phase; Vss, volume of distribution at steady state; MR r il)t, 
mean residence time from zero to infinity; t1/2, half-life of the terminal phase and |), elimination rate constant.
Values are raw data medians and (min-max) represents the range of raw data within a group.
Values with identical superscripts are not significantly different, P< 0.01.
,lbUsed to compare the no-dexamethasone pigs with the dexamethasone treated pigs after ranking the data (n= 12) ( Two-way analysis of
variance performed after ranking the raw data, P<0.01). 
AHUsed to compare the non-inlected 
after ranking the raw data, P<0.01).
pigs with the infected pigs after ranking the data (n=12) ('Two-way analysis of variance performed
Figure 2.12. Rank means±SD of clearance for plasma enrofloxacin in control, infected, 
dexamethasone and infected-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01. 
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=12) 
(Two-way analysis of variance performed after ranking the raw data. P O .O l).
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Figure 2.13. Rank means±SD for volume of distribution o f the elimination phase for 
plasma enrofloxacin in control, infected, dexamethasone and infected-dexamethasone 
treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
Used to compare non-infected pigs with infected pigs. (n=12) (Two-way analysis of 
variance performed after ranking the raw data, P<0.01).
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Figure 2.14. Rank means±SD of volume of distribution at steady state for plasma 
enrofloxacin in control, infected, dexamethasone and infected-dexamethasone treatment 
groups.
Values with identical superscripts are not significantly different, P< 0.01.
Used to compare non-infected pigs with infected pigs (n=l2) (Two-way analysis of 
variance performed after ranking the raw data. P<0.01).
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Figure 2.15. Rank means±SD o f mean residence time (MRT) and half-life (tt/2) for 
plasma enrofloxacin in control, infected, dexamethasone and infected-dexamethasone 
treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
ABUsed to compare non-infected pigs with infected pigs for mean residence time (h) 
(n=12) (Two-way analysis o f variance performed after ranking the raw data, PO .O l).
CD " wUsed to compare non-infected pigs with infected pigs for half-life (h) (n=12) (Two- 
way analysis of variance performed after ranking the raw data. PO .O l).
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Figure 2.16. Chromatographs of standards (ciprofloxacin and enrofloxacin) and the 
internal standard (pipemidic acid); 0 h urine sample; and 48 h urine samples in a control 
pig.
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Enrofloxacin






Figure 2.17. Enrofloxacin and the major metabolite, ciprofloxacin, with four minor 
metabolites.
155
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 2.6. Total urine creatinine, enrofloxacin and ciprofloxacin in control and 
dexamethasone treatment groups for the infection study.
Control Dexamethasone
24 h Creat (mg) 510a OO o 00
(min-max) (139-962) (336-1037)
48 h Creat (mg) 1204a 1002a
(min-max) (798-1417) (459-1044)
24 h Enro (mg) 10.7° 13.5°
(min-max) (6.64-14.3) (8.28-17.7)
48 h Enro (mg) 8.46c 4.45d
(min-max) (5.08-19.0) (2.91-6.12)
24 h Cipro (mg) 11.0e 9.92°
(min-max) (4.24-12.9) (7.50-23.6)
48 h Cipro (mg) 8.45c 3.45f
(min-max) (4.74-11.1) (3.04-6.53)
Creat (mg), total urine creatinine: Enro (mg), total urine enrofloxacin: and Cipro (mg), 
total urine ciprofloxacin.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
Values with identical superscripts are not significantly different. P< 0.01.
“Used to compare the control group with the dexamethasone group for total urine 
creatinine at 24 and 48 h (n=6) (t Test after ranking the raw' data. P O .O l). 
cdUsed to compare the control group with the dexamethasone group for total urine 
enrofloxacin at 24 and 48 h (n=6) (t Test after ranking the raw data. PO .O l). 
ctUsed to compare the control group with the dexamethasone group for total urine 
ciprofloxacin at 24 and 48 h (n=6) (t Test after ranking the raw data, PO .O l).
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Table 2.7. Urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios in control, 
infected, dexamethasone and infected-dexamethasone treatment groups.




(pg/mg) 22.5 16.5 18.2 14.7
(min-max) (14.1-47.8) (14.5-28.4) (11.5-25.8) (7.28-32.0)
48 h
Enro/Creat
(pg/mg) 8.58 4.75 9.17 3.81




18.5 19.3 20.4 13.1




7.52 4.46 10.8 6.41
(min-max) (5.32-47.6) (0.575-6.69) (4.27-14.2) (1.11-9.69)
Enro/Creat (pg/mg). ratio o f urine ciprofloxacin to urine creatinine.
Cipro/Creat (pg/mg), ratio of urine enrofloxacin to urine creatinine.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
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Figure 2.18. Rank means±SD of urine enrofloxacin/creatinine ratios in control, 
infected, dexamethasone and infected-dexamethasone treatment groups at 24. and 48 h 
after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01. 
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and non- 
infected pigs with infected pigs at 24 h (n= 12) (Two-way analysis of variance 
performed after ranking the raw data. P<0.01).
cdUsed to compare no-dexamethasone pigs with dexamethasone treated pigs at 48 h 
(n=12) (Two-way analysis of variance performed after ranking the raw data. PO .O l)
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8
Figure 2.19. Rank means±SD of urine ciprofloxacin/creatinine (pg/mg) ratios in 
control, infected, dexamethasone and infected-dexamethasone treatment groups at 24 
and 48 h after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01. 
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and non- 
infected with infected pigs at 24 h (n=12) (Two-way analysis o f variance performed 
after ranking the raw data. P<0.01).
'’Used to compare no-dexamethasone pigs with dexamethasone treated pigs and non- 
infected pigs with infected pigs at 48 h (n=12) (Two-way analysis o f variance 
performed after ranking the raw data. P O .O l).
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different column and mobile phase, but using a control urine sample from this study 
(Dr. Joseph Kawalek. unpublished data). Desethylene-ciprofloxacin was used to make a 
previous standard curve, but was not detected in the urine samples. A peak in the 24 
and 48 h urine samples did co-elute at the same time (6.3 min) as desethylene- 
ciprofloxacin and was between the unknown peak (7 minutes retention time) and 
pipemidic acid. This peak was an endogenous product, because it appeared in the zero 
hour urine samples and had an absorption maxima at 250 nm. Flouroquionolones have 
a characteristic absorption maxima at about 280 nm. but not at 250 nm. In vitro studies 
with liver microsomes have supported this observation where oxo-ciprofloxacin. 
desethylene-ciprofloxacin and desethylene-enrofloxacin were not detected (Dr. Joseph 
Kawalek. unpublished. FDA/CVM final report 275.16). Ciprofloxacin was detected in 
urine after a short incubation and oxo-enrofloxacin was detected after a prolonged 
incubation of porcine hepatic microsomes from pigs unrelated to this study (Dr. Joseph 
Kawalek. unpublished. FDA/C VM final report 275.16).
Total urine creatinine is not significantly different for the control group 
compared to the dexamethasone group (Table 2.6). Total urine enrofloxacin is not 
significantly different at 24 h. but the total urine enrofloxacin was significantly less for 
the dexamethasone group compared to the control group at 48 h (Table 2.6). Total urine 
ciprofloxacin is not significantly different at 24 h. but the total urine ciprofloxacin was 
significantly less for the dexamethasone group compared to the control group at 48 h 
(Table 2.6).
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The urine enrofloxacin/creatinine ratios are not significantly different in the 24 h 
urine samples (Table 2.7; Figure 2.18). The urine enrofloxacin/creatinine ratios were 
significantly less in the dexamethasone treated pigs compared to the no-dexamethasone 
pigs at 48 h (Table 2.7; Figure 2.18). The urine ciprofloxacin/creatinine ratios are not 
significantly different in the 24 and 48 h urine samples (Table 2.7; Figure 2.19)
Discussion
The infected animals developed signs of APP infection within 2 h which was 
verified by gross pathology and histopatholgy (Figures 2.1-2.6). The establishment of 
APP infection was further supported by increased lung weights and increased plasma 
interleukin-6 in the infected pigs (Table 2.2; Figure 2.3). There was only a slight but 
statistically different elevation of plasma IL-6 in infected pigs. This proved that IL-6 
was released systemically. but returned to baseline by 48 (Table 2.3; Figures 2.7 and 
2.8). The intensity and duration of IL-6 release was much less than expected and it is 
unlikely that cytochrome P450's w'ere suppressed. Nonetheless, the signs, pathology 
and systemic IL-6 release all demonstrated that the APP disease model was standardized 
and reproducible in this study.
Statistical analysis was a challenge because many pharmacokinetic parameters, 
such as volume of distribution, half-life, mean residence time and clearance, do not have 
a normal distribution which prevents parametric testing (Dyke & Sams. 1994). 
Parametric tests are based on larger sample sizes of 30 or more observations (Dyke & 
Sams. 1994). The infection study data had 6 animals per group or 11 to 12 animals. If 
there was no interaction, the two infected groups, and two dexamethasone groups could
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be pooled which allowed two-way analysis of variance. The ranking o f raw data was 
necessary, because the two by two factorial designs could not be applied to the non- 
parametric Kruskal-Wallis test to detect differences among three or more groups. A 
distribution free test was not available that would allow analysis o f a two by two 
factorial by non-parametric methods. Therefore, a compromise approach was used to 
rank the data and perform two-way analysis of variance on the ranked data with a 
P<0.01 to guard against Type II error or false positives.
Pharmacokinetic parameters were calculated on the assumption that the 
extrapolated area under the curve from the last measured time point to infinity did not 
bias the calculation of clearance, volume of distribution, mean residence time and half- 
life. When the AUC(inf) was compared to AUC(last). the outcome o f the statistical 
analysis was the same (Table 2.3; Figure 2.10). The ratios o f AUC(last)/AUC(inf) 
among the control, dexamethasone. endotoxin and endotoxin-dexamethasone treatment 
groups were acceptable, because the area under the curve from the last measured time 
points to infinity was calculated based on values above the limit o f detection for 
enrofloxacin (Figure 2.11). A long half-life may be associated with a large extrapolated 
area under the curve which is not important provided that the error o f the last measured 
time point is minimal. Error around the last measured time point may be of little 
consequence because an extrapolated area under the curve could contribute 10% of the 
total area under the curve, but only contribute 5% error with a bias o f 50% (Purves. 
1992). This means that the subsequent calculations of pharmacokinetic parameters were
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not strongly biased due to error associated with enrofloxacin plasma concentrations 
around the limit of detection.
Pharmacokinetic parameters were calculated from the dose. AUC(inf). 
AUCM(inf) and P (elimination constant) for clearance. Cl=dose/AUC; volume of 
distribution of the elimination phase; Vp=dose/(P x AUC); volume of distribution at 
steady state. Vss=(dose/AUC) x (AUMC/AUC)=C1 x MRT; mean residence time. 
MRT=AUMC/AUC: and terminal half-life, t 1/r>=0.693/p=(0.693 x Vp)/Cl. Clearance is 
a measure o f efficiency of removal of a chemical from an organ or the body. The 
volume of distribution during the terminal phase. Vp. is the proportionality constant 
between the amount of drug in the body post distribution and the plasma concentration 
during the elimination phase. Volume of distribution based on the terminal phase (Vp) 
depends on the rate of elimination from the central compartment (Ritschel & Denson. 
1991). Volume of distribution at steady state. Vss. is the proportionality constant 
between the amount of drug in the body and the plasma concentration at steady state for 
intravenous bolus or constant-rate infusion administration of a drug. Mean residence 
time is the average amount o f  time that all molecules spend in the body or the mean 
transit time. Plasma half-life is the amount of time for a 50% reduction in the 
concentration of a xenobiotic in the plasma which is a constant if elimination is 
independent from the dose.
Volume of distribution based on the elimination phase will be influenced in 
disease-altered elimination, whereas distribution changes independent of elimination are 
reflected by Vss (Ritschel & Denson, 1991). With decreasing Vp, the concentration in
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plasma increases (Ritschel & Denson. 1991). The volume of distribution at steady state 
is affected by both plasma and tissue binding, decreasing as the free fraction in plasma 
and tissues increases and the bound fraction decreases. The volume of distribution for 
both the elimination phase and steady state were decreased for the infected animals but 
not for dexamethasone treated animals (Table 2.5; Figures 2.13 and 2.14). Volume of 
distribution of the elimination phase. Vp decreases as plasma concentration increases 
(Ritschel & Denson. 1991). Decreased Vss would indicate decreased plasma and tissue 
protein binding and increased plasma and tissue free fraction (Ritschel & Denson.
1991). As the free fraction in plasma increases, plasma clearance should increase 
(Ritschel & Denson. 1991). At steady state, distribution is in equilibrium with 
elimination and the amount o f drug bound to plasma and tissue protein is at a 
maximum. At ail other times, the amount o f drug bound to tissue protein depends upon 
the time course of the drug during distribution or elimination phases.
The infected pigs had a significantly larger elimination rate constant compared 
to the non-infected pigs (Table 2.5). The elimination rate constant increased while the 
AUC remained the same, and the volume o f distribution of the elimination phase 
decreased for the infected pigs (Figures 2.10 and 2.13). This explanation is further 
supported by the decreased half-life o f the infected pigs versus the non-infected pigs 
where the elimination rate constant is related to half-life by the equation: t|/2=0.693/p 
(Figure 2.15). As the elimination rate constant increases, the half-life decreases. Mean 
residence time would be expected to parallel half-life where the MRT of the infected 
pigs was less than the non-infected pigs. The literature value for ciprofloxacin half-life
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was 6 to 8 h in pigs , which is much less than the enrofloxacin median half-life (21.4 h) 
or MRT (31.3 h) of the control group (Table 2.5; Figure 2.15) (Rung et a i. 1993a.b).
Clearance in the infected pigs was not altered as expected if there was an 
increase in the free fraction o f plasma enrofloxacin with a decreased volume of 
distribution. The free fraction o f enrofloxacin may have increased without an increase 
in clearance because a decrease in volume of distribution could have offset an increase 
in the elimination rate constant, p. where clearance is mathematically related to volume 
of distribution and elimination rate constant by the equation: Cl=Vyp (Table 2.5). The 
elimination rate constant, p. was significantly greater for the infected pigs compared to 
the non-infected pigs (Table 2.5). Thus, volume of distribution of the elimination phase 
in the infected pigs was affected by an increase in the elimination rate constant 
(Vp=dose/(P x AUC). However, volume of distribution at steady state was also 
significantly decreased for the infected pigs, but is independent o f the elimination rate 
constant. This suggests that some other factor, such as decreased protein binding in 
tissues and increased protein binding in plasma, is also a component of the decreased 
volume of distribution for the infected pigs. The loss o f plasma proteins to the alveolar 
space may also account for the decreased volume o f distribution as observed in the 
photomicrograph of a section o f lung from an infected pig (Figure 2.6).
In addition to protein binding, several disease conditions can affect the 
elimination rate constant and Vp such as alterations in blood flow and pH changes for 
healthy and diseased animals (Ritschel & Denson, 1991). The onset and duration of 
action of a drug is dependent on the rate or extent o f  distribution and a change in the
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apparent volume of distribution may change the drug concentration in plasma, tissues 
and at the receptor site. The volume of distribution may be reduced by reduced blood 
supply to peripheral tissues in shock and the concentration at the site o f action may be 
diminished. The infected pigs may have had poor pulmonary perfusion and respiratory 
acidosis due to labored breathing caused by pulmonary infection (Figures 2.5 and 2.6). 
Enrofloxacin is amphoteric with acid and base properties. A small change in acid-base 
balance may have an amplified effect on the degree of ionization of weak organic acids 
and bases. Increased ionization could reduce the tissue penetration by affecting the 
solubility of enrofloxacin and result in decreased volume of distribution. Depending on 
pH. enrofloxacin could bind to albumin as an acid or to a,-glycoprotein as a base and be 
displaced in plasma or tissues. However, neither the blood concentration, nor pH 
affected the low serum protein binding of other fluoroquinolones (Greene & Budberg.
1993). Low serum protein binding would promote rapid elimination by renal and 
extrarenal mechanisms. In pigs, low plasma protein binding (23.6%) of ciprofloxacin 
was previously attributed to interference by fatty acids with albumin or more binding 
sites on plasma proteins such as albumin and a  |-acid glycoprotein (Nouws et al.. 1988: 
Belpaire. 1986). In humans. AGP plasma concentration can increase as much as two­
fold during the acute-phase respose (Kremer et. al., 1988). Although AGP has an 
affinity for basic drugs, it can bind acidic drugs (Kremer et. a*.. 1988). The acidic drugs 
which exhibit a high or intermedicate affinity to AGP do not contain a carboxyl moiety 
and share a common binding site on human serum albumin, called site I or the warfarin 
site. In comparison, all drugs having a low affinity or no affinity to AGP exhibit
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carboxyl groups and bind specifically to another human serum albumin site, called site 
II or the diazepam site (Kremer et. al.. 1988). Enrofloxacin is an amphoteric compound 
with a basic nitrogen in the piperazinyl ring and an acidic carboxyl group on the other 
end of the molecule (Figure 1.2). The decreased volumes of distribution in the infected 
pigs may occur subsequent to the release of AGP. The basic nitrogens on the 
piperazinyl ring may preferentially bind to AGP molecules because it takes longer for 
albumin to decrease in the acute-phase response while AGP is increasing.
While enrofloxacin volumes of distribution are not altered in pigs receiving 
dexamethasone. clearance for the dexamethasone treated pigs compared to the no- 
dexamethasone pigs was increased (Table 2.5; Figures 2.13 and 2.14). The reason for 
the increase in clearance may be related to increased glomerular filtration rate. A five 
day regimen of adrenocorticotropin (ACTH) and glucocorticoids (GC) raised blood 
pressure, caused marked antinatriuresis. expansion of extracellular fluid and plasma 
volume, and altered renal function in humans (Connell, et al.. 1987). Both treatments 
raised glomerular filtration rate (GFR). as demonstrated by inulin clearance. Creatinine 
clearance was not changed and it proved to be an unreliable index of GFR during steroid 
administration. Filtration fraction also increased during both ACTH and GC treatment, 
and renal blood flow fell only during cortisol treatment. Effective renal plasma flow, 
measured by para-aminohippurate clearance, remained unchanged. The mechanism for 
changes in GFR may be a reduction in the availability of angiotensin II at glomerular 
receptor sites, because dexamethasone increases the activity o f aminopeptidase as 
shown in human glomerluar epithelial cells (Stefanovic et al.. 1991). Aminopeptidase
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splits off the N-terminal Asp from angiotensin II and inactivates angiotensin II. 
Therefore, the increased clearance o f  enrofloxacin in the dexamethasone treated pigs 
could be due to increased GFR and filtration fraction.
The major metabolite, ciprofloxacin and a suspect peak, oxo-enrofloxacin. were 
found in the urine (Figures 2.16 and 2.17). The peak corresponding to oxo- 
enrofloxacin. a minor metabolite, is intriguing because it contradicts the absence of 
metabolites in another investigation where ciprofloxacin was administered to pigs 
(Nouws et. al., 1988) (Figures 2.16 and 2.17). There was no statistical difference 
among the treatment groups at 24 h for the total urine enrofloxacin and ciprofloxacin; 
and urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios (Tables 2.6 and 2.7 
Figures 2.18 and 2.19). However, the 48 h sample had a reduced 
enrofloxacin/creatinine ratio for the dexamethasone treated pigs compared to the no- 
dexamethasone pigs, but the 48 h ciprofloxacin/creatinine ratio was unchanged. The 
reduced enrofloxacin/creatinine ratio could be due to the depletion o f enrofloxacin in 
the first 24 h of urine collection, because the clearance of enrofloxacin is increased in 
dexamethasone treated pigs. Creatinine clearance would be expected to increase with 
increased GFR after dexamethasone treatment, but total urine creatinines were not 
significantly different (Table 2.6). However, it has already been stated that creatinine 
clearance is an unreliable index during steroid treatment (Connell et al.. 1987). It is 
curious that a concomitant decrease in the ciprofloxacin/creatinine ratio was not seen in 
the dexamethasone treated pigs, where a lack of statistical significance could be due to 
small sample size or lack o f biological significance.
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Apparently, there was no effect o f APP infection on either the 
enrofloxacin/creatinine ratio or the ciprofloxacin/creatinine ratio in infected pigs (Tables 
2.6 and 2.7; Figures 2.18 and 2.19). The hypothesis in this study included the alteration 
of metabolism in conjunction with other pharmacokinetic changes that have already- 
been described. There was a small systemic elevation of interleukin-6, but interleukin-1 
was not systemically elevated. Therefore, it is probable that metabolism of enrofloxacin 
to ciprofloxacin was not affected by infection, because there was no increase in the 
enrofloxacin/creatinine ratio and a decrease in the ciprofloxacin/creatinine ratio in 
infected pigs. Any changes in metabolism of enrofloxacin to ciprofloxacin would have 
been easily observed because of the large amount of ciprofloxacin excreted in the urine 
of control animals. Whatever the metabolic pathway, cytochrome P450 or flavin- 
containing monooxygenase, is responsible for the dealkylation of enrofloxacin to 
ciprofloxacin, it is still intact in the APP infected and dexamethasone treated pigs.
In contrast to the absence o f metabolic changes in this study, a previous 
investigation reported the suppression of oxidative hepatic biotransformation in pigs 
infected with APP (Monshouwer et al., 1995a). The hepatic clearance of antipyrine and 
caffeine were decreased by 72 and 68%, respectively. Renal function and hepatic blood 
flow were not affected. The APP infected pigs in the Netherlands did not exhibit a 
change in microsomal uridine diphosphate glucuronyl transferase activities 
(Monshouwer et al.. 1995b). No glucuronide conjugates o f ciprofloxacin or its 
metabolites were detected in the urine o f calves and piglets (Nouws et. al.. 1988). 
Additionally, the urine samples were subjected to a mixture of 0.05 N sodium hydroxide
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and acetonitrile in a two to one ratio, respectively. This may have been sufficient to 
hydrolyze any enrofloxacin and ciprofloxacin urine conjugates as reported in a study of 
fenoprofen and oxprenolol in horses (Delbeke & Debackere. 1994). Hydrolysis of 
fenoprofen conjugates was accomplished by treating urine samples with a final sodium 
hydroxide concentration of 0.025 N. The final concentration of sodium hydroxide that 
was used to prepare urine samples for HPLC analysis in this study was 0.032 N. 
Therefore, glucuronated enrofloxacin and ciprofloxacin metabolites were not measured 
in this study.
The different results found in the present study compared to the Netherlands 
study are not necessarily contradictory. The previous study was done at a different 
location using a different genetic base of pigs that were infected with a different 
serotype of APP that may have differed in virulence. No change in clearance and 
metabolism was found in this study compared to decreased oxidative metabolism of 
antipyrine and caffeine in the Netherlands study. The antipyrine and caffeine were used 
as model drugs to test oxidative biotransformation in the infected pigs. Instead of 
model drugs, a therapeutic drug, enrofloxacin. was tested in this study. Enrofloxacin 
clearance was not altered by APP infection. Enrofloxacin can be biotransformed to 
oxygenated metabolites but this is not an important pathway in pigs (Dr. Joseph 
Kawalek. unpublished; Nouws et al.. 1988). Dealkylation results in the major 
metabolite, ciprofloxacin. Oxidation of enrofloxacin to the suspect minor metabolite, 
oxo-enrofloxacin. requires confirmation by mass-spectroscopy.
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Endotoxin derived form Eschericia coli has been used as a model for septic 
shock in swine (Myers et. al. 1997; Monshouwer et al., 1996a). The administration of 
intravenous endotoxin in this study and any associated pharmacokinetic changes was 
intended to provide a comparison to Actinobacillus pleuropneumoniae infection and the 
subsequent plueropneumonia. Drug disposition and metabolism can both be affected by 
infection and endotoxin challenge. Other toxins besides endotoxins are certainly 
present in porcine pleuropneumonia and may contribute to pathological changes. 
However, endotoxin has been used extensively as a model of septic shock and the acute- 
phase response. Endotoxin is not directly cytotoxic to tissue, but it does induce release 
of TNF-a and IL-6 (Edwards et al.. 1994). A CD14 leukocyte receptor appears to 
initiate TNF-a release after binding endotoxin to LPS binding protein.
Viral, bacterial or parasitic infections and inflammatory stimuli from endotoxin 
or turpentine induce physiological, hematological and metabolic changes that 
characterize the acute-phase response (Ballmer et al.. 1991; van Miert. 1990). The 
acute-phase response may be triggered by cytokines released from macrophages- 
monocytes. Interleukins l a  and ip. TNFs a  and P and interferons a  and P are 
cytokines that inhibit oxidative and conjugative drug metabolism in laboratory animals 
(Craig et al.. 1989b; Ghezzi et al., 1986a.b; Morgan & Norman. 1990; Renton & 
Knickle. 1990). Furthermore, active infection with bacterial proliferation is not
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necessary for changes to occur in drug biotransformation. Endotoxins from Gram- 
negative and positive bacterial cell walls are potent inhibitors of hepatic mixed-function 
oxidase (Azri & Renton. 1987: Gorodischer et al.. 1976; Lavicky et al.. 1988: Sasaki et 
al.. 1984: Sonawane et al.. 1982; Stanley et al.. 1988; Williams & Szentivanyi. 1983: 
Yoshida et al., 1982). Escherichia coli. Bordatellapertussis. diphtheria toxoid and 
tetanus toxoid all contain cell wall endotoxins that alter P450 activity (Ashner et al.. 
1992: Fantuzzi et al.. 1994a.b).
A previous study compared an LPS model to an Actinobacillus 
pleuropneumoniae model and demonstrated a distinct similarity with respect to effects 
on hepatic drug metabolism (Monshouwer et. al.. 1996a). The experimentally induced 
APP infection in pigs was reported to induce a mild acute-phase response and inhibition 
of P450. The plasma clearance of caffeine and antipyrine were shown to be decreased 
by 70% at 24 h after inoculation (Monshouwer et al.. 1995a.b).
The goal of the endotoxin study was 1) to characterize pharmacokinetic changes 
associated with endotoxin administration in swine after receiving enrofloxacin and 2) to 
evaluate the endotoxin model as a substitute for the APP infection model or other Gram- 
negative-pathogens. Plasma concentrations of IL-6 were determined from 0 to 9 h after 
endotoxin administration. Aspartate aminotransferase plasma concentrations were 
determined for 0. 24 and 96 h after endotoxin infusion. Plasma concentrations of 
enrofloxacin and ciprofloxacin were determined for pharmacokinetic analysis from 24 
to 96 h after endotoxin infusion. Urine enrofloxacin and ciprofloxacin were also
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measured and normalized with urine creatinine concentrations. Gross necropsies were 
performed and included lung weights.
Materials and Methods 
Animal management
The experiment utilized 24 crossbred. Hampshire x Yorkshire, castrated pigs 
that were procured from a local vendor. All of the pigs were weighed prior to 
intravenous catheterization and were within a 25 to 35 kg weight range. Housing 
consisted of a heated building with a concrete floor and all animals were fed 3 kg/day 
from a single batch o f a commercial com-based ration without antibiotics. The pigs had 
been fed a commercial ration that was medicated with tylosin before procurement. All 
pigs were examined upon arrival and were clinically healthy at the start of the study. 
Experimental design
The design consisted of a 2 x 2 factorial of treatment groups (Table 3.1). 
Eschericici coli 055: B5 endotoxin (2 pg/kg. Sigma. St. Louis. Missouri) was dissolved 
in about 5 ml of phosphate buffered saline (0.0067 M of phosphate. 0.15 M sodium 
chloride. pH 7.4; Sigma. St. Louis. Missouri) as the first treatment. This endotoxin dose 
(2 pg/kg) was previously determined by previous studies at the Center for Veterinary 
Medicine. The second treatment was dexamethasone (0.5 mg/kg. Phoenix 
Pharmaceuticals. St. Joseph Missouri). Endotoxin was infused by i.v. bolus at zero hour 
into two of the four groups as a comparison to APP infection. Two groups (12 pigs) 
were procured at a time and one group was placed in stainless steel metabolism cages
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Table 3.1. Experimental design for the endotoxin study.
Treatment Sham Infusion Endotoxin
No Dexamethasone
Sham Infusion Endotoxin
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for four days followed by the second group. This process was repeated with another 
two groups of pigs over a one month period. The endotoxin treatment was administered 
as single i.v. injection to two groups while the other two groups received a sham saline 
infusion (Table 3.1). One endotoxin group and one sham group received i.v. 
dexamethasone at -18 h . 0 h and 12 h. A bolus dose o f 5 mg/kg enrofloxacin (Baytril . 
Bayer. Shawnee Mission. Kansas) was administered intravenously 24 h after saline or 
endotoxin infusion to all four groups of pigs.
Blood collection
Intravenous cannulation and blood collection was identical to the infection 
study. Cytokine blood samples were collected in heparin tubes (Monovette. Sarstedt. 
Germany) at 0. I. 3. 6 and 9 h after endotoxin and sham infusion. Plasma samples for 
HPLC analysis were collected in EDTA tubes (Monovette. Sarstedt. Germany) at 0. 
0.25. 0.5. 1. 2. 3. 4. 6. 8. 12, 24. 36. 48. 60 and 72 h after enrofloxacin infusion. 
Pharmacokinetic analysis 
Urine and plasma sample preparation
Plasma sample preparation was identical to the infection study. Urine samples 
were collected at 24 hour intervals starting 24 h after endotoxin infusion or saline at 0. 
24. 48 and 96 hours.
Urine creatinine
Urine creatinine preparation was identical to the infection study. A plot o f the 
standard curves for creatinine gave a linear response, “y” (absorbance) versus "c” 
(concentration. mg/L): y=0.007 c + 0.197. R= 1.0. y=0.008 c + 0.219. R=0.9995.
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y=0.007 c + 0.203. R=1.0. y=0.007 c + 0.21. R= 1.0 and y=0.008 c + 0.207. R=0.9995 
where the coefficient of variation was less than 5% and 10% for the standards and 
samples, respectively.
Aqueous standard curves for urine and plasma
Aqueous standard curves for plasma and urine were constructed by first 
preparing desethylene-ciprofloxacin, enrofloxacin and ciprofloxacin stock standards 
which was similar to the infection study.
The linearity of the response, "y“ (ratio o f peak height counts using the internal 
standard, pipemidic acid) versus "c" (concentration. mg/L) were tested over eight 
standard solutions of desethylene-ciprofloxacin, ciprofloxacin and enrofloxacin. The 
typical response standard curves for plasma samples were represented by the linear 
equations: y=17.1 c - 0.00478. R=0.9997 for enrofloxacin; y=12.3 c - 0.0216. R=0.9997 
for ciprofloxacin: and y=127 c + 0.0366, R=0.9997 for desethylene-ciprofloxacin. The 
typical response standard curves for urine samples were linear and represented by the 
same equations that were presented in the infection study: y=16.0 c - 0.00379.
R=0.9996 for enrofloxacin: y= 11 .8c- 0.00253, R=0.9997 for ciprofloxacin and y=124 
c + 0.0434. R=0.9997 for desethylene-ciprofloxacin.
Five replicates of each of the 8 concentrations (3.9 - 500 pg/L for ciprofloxacin 
and enrofloxacin and 1.22 - 156 pg/L for desethylene-ciprofloxacin) o f standard 
resulted in a coefficient of variation ranging from 0.7% to 9% for the plasma standard 
curves and 0.7% to 11% for the urine standards curves to include enrofloxacin. 
ciprofloxacin and desethylene-ciprofloxacin.
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High-performance liquid chromatography
High-performance liquid chromatography analysis was identical to the infection 
study for urine and plasma.
Interleukin-6 bioassay
Interleukin-6 assay was performed as previously described in the infection 
study. The standard curve was plotted as a log-logit transformation using Cytocalc 
(Millipore. New Bedford. Massachusetts). The log-logit transformations gave linear 
response, "y" (absorbance) versus “c" (concentration, pg/ml). curves for each of the five 
microplates: y=2.74 c - 9.48. R=0.9180; y —1.52 c - 1.01. R=0.986; y=2.76 c - 9.85. 
R=0.917; y=2.51 c - 8.85. R=0.903 and y=2.42 c - 8.67. R=0.903.
Plasma aspartate aminotransferase assay
The plasma aspartate aminotransferase (AST) assay was performed using an 
AST/GOT Transaminase Diagnostic Test Kit to measure plasma AST at 0. 24 and 48 h 
after endotoxin (Sigma. St. Louis. Missouri). The AST assay was undertaken as an 
indicator of liver damage after endotoxin administration. All four groups were tested by 
adding 50 pi of plasma or standard to 250 pi of substrate reagent. The mixture was 
vortexed and placed in a 37°C water bath for 1 hour. A color reagent (250 pi) was 
added after incubation. The mixture was vortexed and incubated at room temperature 
for twenty minutes. Next, a 2.5 ml aliquot of 0.4 N sodium hydroxide was added and 
the test tube was mixed by inversion. After waiting 5 minutes, a 200 pi aliquot sample 
mixture was pipetted, in triplicate, into a 96 well microplate. The results were read at
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503 nm absorbance using a microplate spectrophotometer (Spectra Max 250. Molecular 
Devices. Sunnyvale. California).
A standard curve was prepared for each microplate by diluting standards with 
water and substrate to the following concentrations: 0. 9.6. 26.4. 45.6. 69.6 and 103.7 
lU/ml where 0.48 international unit (IU) was equivalent to one Sigmund-Frankel unit. 
The standards were prepared for reading on the microplate spectrophotometer by adding 
50 pi of standard to 250 pi o f substrate reagent. The mixture was vortexed and 
incubated at room temperature for 20 minutes. A 2.5 ml aliquot o f 0.4 N sodium 
hydroxide was added and the test tube was mixed by inversion. After a 5 minute wait, 
triplicate 300 pi aliquots of each standard were transferred into the microplates. The 
resulting standard curves were nonlinear, "y” (absorbance) versus "c" (concentration. 
lU/ml): y={-0.603/[l + (c/255)0827]} + 0.801. R=0.999: y={-0.607)/[l + (c/273)0 723]} + 
0.801. R=0.999; y={-0.573)/[l + (c /227)0856]} + 0.741. R=0.9995 and y={-0.641/[l +
(c /283)0 8-9]} + 0.831. R=0.999. The coefficient of variation for the standards and 
samples was less than 3% and 11%, respectively. The sample values were interpolated 
from the standard curves using Softmax Pro (Version 1.2. Molecular Devices.
Sunnyvale. California).
Health observations and necropsies
Health observations were made during the entire study period of 4 days. Gross 
necropsies were performed on all animals in the infection study. The pigs were 
euthanized with Euthasol® which contained sodium pentobarbital (Delmarva 
Laboratories, Inc.. Bristol. Tennessee). Brain and spinal cord were not examined. Fresh
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liver (100 to 200 grams) was collected and frozen at -80°C for Northern or Western 
blots, if required. Lung weights and gross necropsy observations were recorded on a 
necropsy form. The color, texture. location and size of gross lesions were also noted on 
the necropsy form. After trimming the trachea from the lung at the level o f the cranial 
bronchi, the lung was weighed.
Statistics
Statistical analyses of pharmacokinetic parameters, urine creatinine, 
enrofloxacin and ciprofloxacin concentrations. IL-6 plasma concentrations, plasma 
aspartate transaminase and lung weights were similar to the infection study. One-way 
analysis o f variance was performed where the predominant statistical difference was due 
t the endotoxin group or an endotoxin and dexamethasone interaction.
Results 
Animal observations and pathology
The endotoxin treated pigs became depressed and dyspnic within 30 to 60 
minutes after i.v. injection. One endotoxin treated pig vomited. Signs of labored 
breathing and depression were reduced 24 h after endotoxin administration, but all pigs 
were anorectic. At 48 h. all pigs were more active and consumed almost all o f their 
ration. At 72 h, all endotoxin treated pigs appeared normal and had finished their ration.
There were no gross lesions present in the lungs at necropsy. No significant 
differences (PO .O l) in the lung/body weight ratio (g/kg) were found among control, 
dexamethasone, endotoxin and endotoxin-dexamethasone treatment groups (Table 3.2;
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Figure 3.1). However, there was a significant interaction (P<0.01) between 
dexamethasone and endotoxin. Histopathology was not done in the endotoxin study.
Plasma aspartate aminotransferase was elevated in endotoxin treated pigs at 24 h 
and returned to baseline levels at 96 h after endotoxin administration (Table 3.3). The 
rank means at 0 and 96 h for plasma aminotransferase were not significantly different 
for no-dexamethasone pigs versus dexamethasone treated pigs, and no-endotoxin pigs 
versus endotoxin treated pigs (Figure 3.2). The rank means for plasma aminotransferase 
at 24 h were significantly greater (PO.Ol) for the no-dexamethasone pigs versus 
dexamethasone treated pigs and the endotoxin treated pigs versus no-endotoxin pigs. 
Plasma interleukin-6
The mean plasma interleukin-6 concentration was markedly elevated for the 
endotoxin treatment group compared to the control, dexamethasone and endotoxin- 
dexamethasone treatment groups (Figure 3.3). Rank means o f area under the curve 
from zero to 9 h (A U C o^) were significantly greater (P<0.01) for the endotoxin versus 
the no-endotoxin pigs (Table 3.4; Figure 3.4).
Interleukin-6 synthesis is increased by tumor necrosis factor-a (Edwards et al.,
1994). Usually, tumor necrosis factor is released from macrophages and monocytes as a 
proximal-mediator before the release IL-1 and IL-6 in septic shock. Endotoxin 
increases serum TN F-a concentrations by enhancing TN F-a gene transcription 
approximately 10-fold, cellular TNF-a mRNA 100-fold and a 10,000-fold increase in 
the quantity o f protein secreted from activated monocytes. Dexamethasone and other 
glucocorticoids inhibit TNF-a mRNA accumulation (Beutler et al., 1986; Han et al.,
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1990b; Luedke et al.. 1990). Glucocorticoids act both at the transcriptional and post- 
transcriptional level to block TNF-a synthesis (Han et al.. 1990a; Trinchieri. 1991). 
This mechanism of TN F-a release that is stimulated by endotoxin and inhibited by 
glucocorticoids can explain why the IL-6 plasma concentration was decreased in the 
endotoxin-dexamethasone group compared to the endotoxin group (Figures 3.3 and 
3.4).
Plasma enrofloxacin pharmacokinetic changes
Area under the curve
The area under the curve for the endotoxin treatment groups was significantly 
greater (P<0.01) compared to control, dexamethasone and endotoxin-dexamethasone 
treatment groups for both area under the curve from zero to infinity, AUC(inf), and area 
under the curve from zero to the last measured time point AUC(last) (Table 3.5: Figures 
3.5 and 3.6). There was a significant interaction (PO .O l) between endotoxin and 
dexamethasone for AUC(last) values. The AUC(last)/AUC(inf) ratios were 0.86. 0.92. 
0.89, 0.93 and 0.86 for control, dexamethasone. endotoxin and endotoxin- 
dexamethasone groups, respectively (Figure 3.7). Therefore, the area o f the 
extrapolated curve from the last measured time point to infinity was less than 14%. 
which should not bias pharmacokinetic calculations. Furthermore, the one-way analysis 
o f variance of AUC(last) and AUC(inf) produced identical results where the endotoxin 
group was significantly different from the control, dexamethasone and endotoxin- 
dexamethasone groups.
183
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Clearance, volume of distribution, mean residence time, half-life and elimination rate
constant
Clearance was significantly greater (PO .O l) for the dexamethasone treated pigs 
compared to the no-dexamethasone pigs by two-way analysis o f variance (Table 3.6: 
Figure 3.8). Clearance was significantly greater (P O .O l) for the endotoxin group 
compared to the control, dexamethasone and endotoxin-dexamethasone groups by one­
way analysis o f variance (Figure 3.8). Volume of distribution based on the elimination 
phase (Vp) and volume o f distribution at steady state (Vss) were both significantly 
greater (PO .O l) for dexamethasone treated pigs compared to the no-dexamethasone 
pigs (Table 3.6; Figures 3.9 and 3.10). Mean residence time was significantly greater 
(PO.Ol) for the endotoxin group compared to control, dexamethasone and endotoxin- 
dexamethasone groups and there was a significant interaction (PO .O l) between 
endotoxin and dexamethasone (Table 3.6: Figure 3.11). There was no significant 
difference (PO .O l) in half-life among the control, dexamethasone. endotoxin and 
endotoxin-dexamethasone treatment groups (Table 3.6: Figure 3.11).
Urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios
Ciprofloxacin was the major enrofloxacin metabolite that was detected in the 
urine of the endotoxin study pigs as observed in the infection study (Figures 2.17 and 
3.12). The minor metabolite, oxo-enrofloxacin. was a suspect peak in the urine but oxo- 
enrofloxacin ratios were not calculated (Figure 2.17 and 3.12). The suspect oxo- 
enrofloxacin peak had a similar retention time (7 min) as the suspect oxo-enrofloxacin 
peak in the infection study (Figures 2.17 and 3.12). Ciprofloxacin and enrofloxacin
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were both detected in the 24. 48 and 72 h urine samples (Tables 3.7 and 3.8). The 
ciprofloxacin, oxo-enrofloxacin and enrofloxacin peaks did not appear in the 0 h blank 
samples (Figure 3.12). Desethylene-ciprofloxacin was not detected in the urine samples 
even though an unknown endogenous product co-eluted at the same time (6.3 min) as 
desethylene-ciprofloxacin (Figure 3.12). As in the infection study, this unknown peak 
was determined not to be desethylene-ciprofloxacin because it co-eluted with an 
endogenous peak in the 0 h urine sample and had an ultraviolet absorption maximum at 
250 nm. The characteristic fluoroquinolone absorption maxima occurs around 280 nm.
Total urine creatinine was not significantly different among the control, 
dexamethasone. endotoxin and endotoxin-dexamethasone groups at 24, 48 and 72 h 
(Table 3.7). Total urine enrofloxacin and ciprofloxacin were not significantly different 
at 24 and 48 h (Table 3.7). Total urine enrofloxacin and ciprofloxacin were 
significantly greater (P<0.01) for the endotoxin group compared to the control, 
dexamethasone and endotoxin-dexamethasone groups at 72 h by one-way analysis of 
variance (Table 3.7).
The urine enrofloxacin/creatinine ratios were not significantly different (PO .O l) 
for the 24 h urine samples (Table 3.7; Figure 3.13). The enrofloxacin/creatinine ratio of 
the 48 h urine samples for the endotoxin group was significantly greater (P O .O l) than 
the control, dexamethasone. and endotoxin-dexamethasone treatment groups. There 
was a significant interaction (P O .O l) between endotoxin and dexamethasone (Table 
3.7; Figure 3.13). The 48 h urine samples also had a significantly lower (P O .O l)
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Table 3.2. Lung/body weight (g/kg) ratios in control, dexamethasone. endotoxin and 
endotoxin-dexamethasone treatment groups. The lung weights were normalized with 
body weights.
Control Dexamethasone Endotoxin Endotoxin-
Dexamethasone
LW/BW (g/kg) 10.8 9.36 10.1 10.5
(min-max)_______ (8.84-11.9) (8.38-10.5) (8.21-10.5) (9.68-12.2)
LW/BW; the ratio o f the lung weight to total body weight.
Values are raw data medians and (min-max) represents the range of raw data within a 
treatment group.
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Figure 3.1. Rank means±SD of lung/body weight ratios in control, endotoxin, 
dexamethasone and endotoxin-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01 
*. indicates a significant interaction between endotoxin and dexamethasone. 
aUsed to compare control, dexamethasone, endotoxin and endotoxin-dexamethasone 
treatment groups (n=6) (One-way analysis of variance performed after ranking the raw 
data. P<0.01).
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Control Dexamethasone Endotoxin Endotoxin-
Dexamethasone
Oh 13.9 10.2 17.1 13.4
(min-max) (9.74-25.4) (3.72-12.7) (12.3-20.1) (9.27-23.3)
24 h 18.9 11.4 41.2 16.2
(min-max) (13.5-21.7) (6.80-13.9) (17.7-708) (11.4-33.9)
96 h 16.7 13.3 18.1 15.9
(min-max) (8.76-21.9) (6.64-16.8) (13.5-29.6) (10.9-18.6)
AST (IU/ml). plasma aspartate aminotransferase
Values are means and (min-max) represents the range of raw data within a group.
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Figure 3.2. Rank means±SD of plasma aspartate aminotransferase in control, 
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups at 0. 24 and 
72 h after endotoxin administration.
Values with identical superscripts are not significantly different. P< 0.01 
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no­
endotoxin pigs with endotoxin treated pigs at 0 h (n=12) (Two-way analysis of variance 
performed after ranking the raw data. P.0.01).
tdUsed to compare no-dexamethasone pigs with dexamethasone treated pigs at 24 h 
(n=12) (Two-way analysis of variance performed after ranking the raw data. P<0.01).
CD Used to compare no-endotoxin pigs with endotoxin treated pigs at 24 h (n=12) (Two- 
way analysis o f variance performed after ranking the raw data. P<0.01). 
eUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no­
endotoxin pigs with endotoxin treated pigs at 96 h (n=l2) (Two-way analysis of 
variance performed after ranking the raw data. PO .O l).
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Figure 3.3. Mean plasma concentration o f interleukin-6 measured at 0. 1. 3.6 and 9 
hours after endotoxin (2 pg/kg BW) administration at 0 h.
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Table 3.4. Area under the curve for plasma interleukin-6 in pigs in control,
dexamethasone. endotoxin and endotoxin-dexamethasone treatment groups.
Area Under the Control Dexamethasone Endotoxin Endotoxin-
Curve Dexamethasone
(units/ml x h)
AUCo_9h 387 203 17243 1100
(min-max) (44.4-489) (131-440) (1447-23579) (483-16748)
AUCq̂ q h; area under the curve from 0 to 9 h.
Values are raw data medians and (min-max) represents the range o f raw data within a 
group.
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Figure 3.4. Rank means±SD of area under the curve for plasma interleukin-6 in control, 
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01).
Used to compare no-endotoxin pigs with endotoxin treated pigs (n=12) (Two-way 
analysis of variance performed after ranking the raw data. P<0.01).
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Figure 3.5. Semilogrithmic plot of mean plasma concentrations of enrofloxacin 
measured at 0. 0.25. 0.5. 1. 2, 3, 4, 6, 8. 12. 24. 36. 48. 60. and 72 h after i.v. 
enrofloxacin (5 mg/kg BW) administration and 24 h after endotoxin or sham endotoxin
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Table 3.5. Area under the curve (mg/L x h) for plasma enrofloxacin in control,
dexamethasone. endotoxin and endotoxin-dexamethasone treatment groups.
Area Under the Control Dexamethasone Endotoxin Endotoxin- 
Curve (mg/L x h) Dexamethasone
AUC(in0 11.2 9.43 22.4 9.22
(min-max) (9.13-14.2) (8.41-13.7) (18.7-36.6) (6.20-13.2)
A U C d^ 10.4 8.47 21.2 7.71
(min-max) (8.02-13.2) (7.05-12.0) (16.0-34.6) (5.65-11.7)
AUC,inr). area under the curve from zero to infinity
AUC(Iast). area under the curve from zero to the last measured hour.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
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Figure 3.6. Rank means±SD of area under the curve for plasma enrofloxacin in control, 
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups, comparing 
AUC(last) with AUC(inf).
AUC(inf). area under the curve from zero to infinity
AUC(last). area under the curve from zero to the last measured hour.
Values with identical superscripts are not significantly different. P<0.01.
* indicates an interaction between endotoxin and dexamethasone. 
abUsed to compare the endotoxin group with the control, dexamethasone and endotoxin- 
dexamethasone group for AUC(inf) (n=6) (One-way analysis o f variance performed 
after ranking the raw data. P<0.01).
cd •Used to compare the endotoxin group with the control, dexamethasone and endotoxin- 
dexamethasone group for AUC(last) (n=6) (One-way analysis o f variance performed 
after ranking the raw data, P<0.01).
CD wUsed to compare endotoxin-dexamethasone group with control and dexamethasone 
groups for AUC(last) (n=6).(One-way analysis o f variance performed after ranking the 
raw data. P<0.01).
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Figure 3.7. Means of area under the curve ratios for plasma enrofloxacin in control, 
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups. 
AUC(inf) area under the curve from zero to infinity 
AUC(last), area under the curve from zero to the last measured hour.
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Table 3.6. Plasma pharmacokinetic parameters of enrofloxacin in control, endotoxin, dexamethasone and endotoxin-dexamethasone 
treatment groups.
Pharmacokinetic Control Dexamethasone Endotoxin Endotoxin-
Parameters Dexamethasone
Cll0, (L/li/kg) 0.447 0.531 0.223 0.542
(min-max) (0.353-0.548) (0.366-0.594) (0.137-0.267) (0.379-0.806)
V„(L/kg) 6.11 8.64 4.62 9.21
(min-max) (4.60-8.56) (6.03-10.5) (2.52-7.13) (7.24-11.6)
Vss(L/kg) 5.12 7.16 4.37 7.07
(min-max) (4.01-6.14) (5.52-7.42) (2.59-6.25) (5.69-9.55)
MRT (h) 12.0 12.7 21.6 13.3
(min-max) (8.75-13.6) (10.8-16.9) (14.1-28.0) (9.07-17.4)
11/2 (h) 10.5 12.7 16.2 11.8
(min-max) (6.96-11.3) (8.22-14.1) (9.70-20.4) (8.46-14.7)
P(1/h) 0.0658“ 0.0624“ 0.0432“ 0.0589“
(min-max) (0.062-0.100) (0.0491-0.0844) (0.0340-0.0714) (0.0473-0.0819)
CIU)1, total body clearance; V,, volume of distribution based on the terminal phase; Vss, volume of distribution at steady state; MRT, 
mean residence time; t !/2, half-life and (i, elimination rate constant.
Values are raw data medians and (min-max) represents the range of raw data within a group.
Values with identical superscripts are not significantly different, P< 0.01.
“Used to compare the endotoxin group with the control, dexamethasone and endotoxin-dexamethasone groups after ranking the data 
(n=6) (One-way analysis of variance performed after ranking the raw data, P<0.01).
Figure 3.8. Rank means±SD o f clearance for plasma enrofloxacin in control, endotoxin, 
dexamethasone and endotoxin-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01. 
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=12) 
(Two-way analysis o f variance performed after ranking the raw data. P<0.01).
■\B * wUsed to compare the endotoxin group with the control, dexamethasone and 
endotoxin-dexamethasone groups (n=6) (One-way analysis o f variance performed after 
ranking the raw data. PO .O l).
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Figure 3.9. Rank means±SD o f volume of distribution of the elimination phase for 
plasma enrofloxacin in control, endotoxin, dexamethasone and endotoxin- 
dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01. 
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=l2) 
(Two-way analysis o f variance performed after ranking the raw data. P O .O l).
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Figure 3.10. Rank means±SD of volume of distribution at steady state for plasma 
enrofloxacin in control, endotoxin, dexamethasone and endotoxin-dexamethasone 
treatment groups.
Values with identical superscripts are not significantly different. P< 0.01. 
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=12) 
(Two-way analysis of variance performed after ranking the raw data. P.O.01).
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Figure 3.11. Rank means±SD o f mean residence time (MRT) and half-life (tl/2) for 
plasma enrofloxacin in control, endotoxin, dexamethasone and endotoxin- 
dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
*. indicates a significant interaction between endotoxin and dexamethasone. 
abUsed to compare the endotoxin group with control, dexamethasone and endotoxin- 
dexamethasone groups for mean residence time (n=6) (One-way analysis of variance 
performed after ranking the raw data, PO.Ol).
cUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no­
endotoxin pigs with endotoxin treated pigs for half-life (n=12) (Two-way analysis of 
variance performed after ranking the raw data. P<0.01).
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Figure 3.12. Chromatographs of standards (ciprofloxacin and enrofloxacin) and the 
internal standard (pipemidic acid); 0 h urine sample: and 72 h urine samples in an 
endotoxin treated pig.
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Table 3.7. Total urine creatinine, enrofloxacin and ciprofloxacin in control, endotoxin, 
dexamethasone and endotoxin-dexamethasone treatment groups.
Creat (mg), total urine creatinine; Enro (mg), total urine enrofloxacin; and Cipro (mg), 
total urine ciprofloxacin.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
Values with identical superscripts are not significantly different. P< 0.01. 
aUsed to compare control, dexamethasone. endotoxin and endotoxin-dexamethasone 
treatment groups for total urine creatinine at 24. 48 and 72 h (n=6) (One-way analysis of 
variance performed after ranking the raw data. P<0.01).
 ̂ Used to compare the endotoxin group with the control, dexamethasone and endotoxin- 
dexamethasone groups for total urine enrofloxacin at 24. 48 and 72 h (n=6) (One-way 
analysis of variance performed after ranking the raw data. P<0.01). 
uUsed to compare the endotoxin group with the control, dexamethasone and endotoxin- 
dexamethasone groups for total urine ciprofloxacin at 24. 48 and 72 h (n=6) (One-way 
analysis of variance performed after ranking the raw data. P<0.01).
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Control Dexamethasone Endotoxin Endotoxin-
Dexamethasone
24 h Creat (mg) I223a 832a 751a 1042a
(min-max) (60.8-1539) (354-1292) (6.94-1161) (289-1409)
48 h Creat (mg) 987a 1128a 856a 1022a
(min-max) (723-1488) (854-1697) (218-1148) 879-1373)
72 h Creat (mg) 922a 73 2a 1209a III  4a
(min-max) (353-1414) (445-1241) (488-1790) (580-1843)
24 h Enro (mg) 10.4° 8.14° 8.86° 7.60°
(min-max) (8.82-13.0) (5.59-15.6) (0.003-16.3) (4.09-8.87)
48 h Enro (mg) 4.15c 4.03c 5.39° 2.04c
(min-max) (2.31-4.98) (1.74-9.06) (0.951-11.3) (1.13-3.31)
72 h Enro (mg) 1.19C 1.04c 2.38d 0.746°
(min-max) (0.468-1.49) (0.715-1.92) (1.60-4.57) (0.589-0.957)
24 h Cipro (mg) 11.3° 12.5° 6.37c 15.4°
(min-max) (8.36-14.0) (7.90-18.6) (0.027-18.2) (8.75-17.2)
48 h Cipro (mg) 4.54e 5.07e 8.60° 4.32e
(min-max) (3.39-5.52) (3.40-9.86) (1.91-11.0) (2.49-6.25)
72 h Cipro (mg) 1.23e 1.15C 4.311' 1.88°
(min-max) (0.468-2.27) (0.201-2.11) (3.38-5.93) (0.743-4.72)
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Table 3.8. Urine ciprofloxacin/creatinine and enrofloxacin/creatinine ratios in control.
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups.




(pg/mg) 9.84 14.4 10.7 6.77
(min-max) (5.73-11.4) (5.15-19.5) (0.383-14.1) (2.91-30.7)
48 h
Enro/Creat
(pg/mg) 3.78 3.53 6.45 2.06
(min-max) (2.89-5.38) (2.03-5.87) (4.36-9.85) (0.826-3.26)
72 h
Enro/Creat
(pg/mg) 1.23 1.07 2.19 0.586
(min-max) (0.923-3.03) (1.00-1.71) (1.50-4.99) (0.378-1.40)
24 h
Cipro/Creat
(pg/mg) 9.22 20.3 8.31 15.7
(min-max) (6.91-12.1) (7.81-22.3) (3.85-15.7) (6.21-50.3)
48 h
Cipro/Creat
(pg/mg) 4.01 4.07 9.16 4.17
(min-max) (3.01-7.02) (3.83-6.40) (7.01-11.2) (2.07-7.11)
72 h
Cipro/Creat
(pg/mg) 1.99 1.07 4.34 2.31
(min-max) (0-2.70) (0.451-1.70) (2.40-6.92) (0.705-2.90)
Enro/Creat (pg/mg). ratio of urine enrofloxacin/urine creatinine.
Cipro/Creat (pg/mg). ratio o f urine enrofloxacin to urine creatinine.
Values are raw data medians and (min-max) represents the range of raw data within a 
group.
214
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 3.13. Rank means±SD of urine enrofloxacin/creatinine ratios in control, 
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups at 24.48 
and 72 h after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01 
*. indicates a significant interaction between endotoxin and dexamethasone. 
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no­
endotoxin pigs with endotoxin treated pigs at 24 h (n=12) (Two-way analysis of 
variance performed after ranking the raw data. P<0.01).
udUsed to compare the endotoxin group with control, dexamethasone and endotoxin- 
dexamethasone groups at 48 h (n=6) (One-way analysis o f variance performed after 
ranking the raw data. P<0.01).
CD wUsed to compare the endotoxin-dexamethasone group with the control group at 48 h 
(n=6) (One-way analysis o f variance performed after ranking the raw data. PO .O l). 
l' tUsed to compare the endotoxin-dexamethasone group with the control, dexamethasone 
and endotoxin groups at 72 h (n=6) (One-way analysis of variance performed after 
ranking the raw data. P<0.01).
215











































Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8
Figure 3.14. Rank means±SD o f urine ciprofloxacin/creatinine ratios in control, 
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups at 24. 48 
and 72 h after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01. 
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs at 24 h 
(n=12) (Two-way analysis of variance performed after ranking the raw data. P<0.01). 
LliUsed to compare the endotoxin group with the control, dexamethasone and endotoxin- 
dexamethasone groups at 48 h (n=6) (One-way analysis of variance performed after 
ranking the raw data. P<0.01).
dUsed to compare endotoxin group with control, dexamethasone and endotoxin- 
dexamethasone groups at 72 h (n=6) (One-way analysis of variance performed after 
ranking the raw data. P<0.01).
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enrofloxacin/creatinine ratio for the endotoxin-dexamethasone group compared to the 
control group (Table 3.7; Figure 3.13). The 72 h enrofloxacin/creatinine ratios for the 
endotoxin-dexamethasone group were significantly less (P<0.01) for the endotoxin- 
dexamethasone group compared to the control, dexamethasone and endotoxin groups 
(Table 3.7; Figure 3.13). There was a significant interaction (P<0.01) between 
endotoxin and dexamethasone (Table 3.7; Figure 3.13).
The ciprofloxacin/creatinine ratios were significantly greater (P<0.01) for the 
dexamethasone treated pigs compared to no-dexamethasone pigs in the 24 h urine 
samples (Table 3.8; Figure 3.14). The ciprofloxacin/creatinine ratio was significantly 
greater (P O .O l) for the endotoxin group compared to the control, dexamethasone and 
endotoxin-dexamethasone groups in the 48 and 72 h urine samples (Table 3.8; Figure 
3.14).
Discussion
All o f the endotoxin treated pigs exhibited signs of labored breathing and 
lethargy within two hours which confirmed that the pigs received enough endotoxin to 
induce systemic illness. The plasma AST concentrations were elevated at 24 hours and 
returned to baseline by 96 h after endotoxin administration. This meant that the liver 
injury present at 24 h was repaired by 96 h. Transient liver injury is logical because the 
plasma interleukin-6 concentrations were significantly elevated in the endotoxin treated 
pigs at 3 h but had decreased to near baseline by 9 h (Table 4.3; Figures 3.3 and 3.4). 
Therefore, the stimulus for liver injury and possible suppression of cytochrome P450's 
was absent after 9 h.
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Pharmacokinetic parameters were calculated on the assumption, similar to the 
infection study, that the extrapolated area under the curve from the last measured time 
point to infinity did not bias the calculation o f clearance, volume o f distribution, mean 
residence time and half-life. When the AUC(inf) was compared to AUC(last). the 
outcome of the statistical analysis was the same, based on one-way analysis of variance 
(Table 3.5: Figures 3.5 and 3.6. Unlike the infection study for AUC(last) and AUC(inf). 
the endotoxin group was significantly greater than the control, dexamethasone and 
endotoxin-dexamethasone groups (Figure 3.6). The biological significance of the 
endotoxin and dexamethasone interaction for AUC(last) can not be readily explained 
based on AUC data (Figure 3.6). The dexamethasone treatment seems to counteract the 
endotoxin response. The ratios o f AUC(last)/AUC(inf) among the control, 
dexamethasone. endotoxin and endotoxin-dexamethasone treatment groups were 
acceptable because less than 10% of the total area was extrapolated (Figure 3.7). The 
calculation of pharmacokinetic parameters based on AUC(inf) is still valid .
The volume of distribution of enrofloxacin for both the elimination phase and 
steady state was increased for the dexamethasone treated animals but not the endotoxin 
treated animals compared to the no dexamethasone and no-endotoxin pigs (Table 3.5: 
Figures 3.9 and 3.10). Increased Vp may indicate decreased plasma protein binding and 
increased free fraction while the increased Vss could indicate increased plasma and 
tissue protein binding and decreased free fraction for enrofloxacin (Ritschel & Denson. 
1991). Thus, the free fraction in the plasma and tissues should decrease and the 
clearance of enrofloxacin in the endotoxin group should increase for the dexamethasone
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treated pigs (Figures 3.8 - 3.10). The increased clearance in the dexamethasone treated 
pigs is more likely due to increased GFR and filtration fraction as a glucocorticoid 
effect on the kidney (Connell et al.. 1987: Stefanovic et al.. 1991). The rate o f 
elimination from the central compartment and the AUC could both contribute to a 
change in Vp in the dexamethasone treated pigs, because the elimination rate constant 
and AUC are both inversely related to the volume of distribution o f the elimination 
phase by the equation: Vp=dose/([3 x AUC). A decrease in one or both parameters could 
increase Vp. The AUC did decrease for the dexamethasone treated pigs but the 
elimination rate constant did not change, which could account for the increase in Vp 
(Table 3.6: Figures 3.9 and 3.10).
The half-life for the endotoxin group was not significantly different from the 
control, dexamethasone and endotoxin-dexamethasone groups (Figure 3.11). Mean 
residence time would be expected to parallel half-life., but MRT o f the endotoxin group 
is greater than the control, dexamethasone and endotoxin-dexamethasone groups 
(Figure 3.11). The graphical profiles are similar even though the statistical outcomes 
are different (Figure 3.11).
The most likely explanation for increased protein binding in tissues leading to 
increased volumes of distribution in dexamethasone treated pigs would be lack of 
interference by fatty acids with albumin and more binding sites on albumin or a,-acid 
glycoprotein (Greene & Budberg, 1993). This assumes that other factors, such as 
enrofloxacin blood concentration or pH. did not affect the serum protein binding of 
enrofloxacin. While volumes of distribution were altered for the dexamethasone treated
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pigs, the volumes o f  distribution are not altered for the endotoxin treated pigs compared 
to the no-endotoxin pigs (Table 3.5; Figures 3.9 and 3.10). In the infection study, the 
volumes o f distribution were decreased in the infected pigs and unchanged for the 
dexamethasone treated pigs (Figures 2.13 and 2.14). In comparison to the infection 
study, the failure o f endotoxin to change the volume of distribution in the endotoxin 
treated pigs can not be readily explained. There are many more toxins associated with 
APP infection than would be associated with endotoxin administration, and the 
endotoxin was administered as a single i.v. dose.
Ciprofloxacin and suspect oxo-enrofloxacin were found in the urine(Figures 
2.17 and 3.12). This is consistent with the infection study where the suspect lesser 
metabolite, oxo-enrofloxacin. was also detected in the urine after i.v. administration of 
enrofloxacin. There was no significant difference among the treatment groups at 24 h 
for the urine enrofloxacin/creatinine ratio, but the urine ciprofloxacin/creatinine ratio 
was significantly greater for the dexamethasone treated pigs compared to the no- 
dexamethasone pigs at 24 h (Table 3.7 and 3.8; Figures 3.13 and 3.14). The effect of 
dexamethasone on GFR and clearance was not evident at 24 h for the urine 
enrofloxacin/creatinine ratio, but the increased urine ciprofloxacin/creatinine ratio in the 
dexamethasone treated pigs at 24 h might be explained by increased clearance related to 
augmented GFR (Figures 3.13 and 3.14).
At 48 h. the urine enrofloxacin/creatinine ratio was greatest for the endotoxin 
group compared to control, dexamethasone and endotoxin-dexamethasone groups; and 
the endotoxin-dexamethasone was less than the control and dexamethasone groups.
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(Table 3.7; Figure 3.13). The interaction between endotoxin and dexamethasone in the 
48 h urine enrofloxacin/creatinine ratios was probably due to GFR “washout” in the 
dexamethasone group and peripheral vasodilatation followed by renal vasoconstriction 
in the endotoxin group (Figure 3.13). In other words, the endotoxin group may have 
developed hypotension associated with endotoxic shock, with a subsequent renal 
vasoconstriction to maintain homeostasis. In fact, endotoxin treated pigs had a flushed, 
red skin until they were necropsied. This supports a physiological effect o f endotoxin 
on enrofloxacin clearance rather than a metabolic effect. The urine 
ciprofloxacin/creatinine ratio in the endotoxin group should have decreased relative to 
the control group, if metabolism of enrofloxacin had been decreased (Tables 3.7 and 
3.8; Figure 3.14). The ciprofloxacin/creatinine ratio for the endotoxin group was 
actually increased at 48 and 72 h which means that there was no liver injury present to 
cause a decrease in total cytochrome P450 protein (Figure 3.14). Liver damage for the 
endotoxin treated pigs was transient as indicated by plasma AST (Figure 3.2). At 24 h 
after endotoxin administration, the dexamethasone treated pigs had decreased plasma 
AST concentrations compared to the no-dexamethasone pigs while the endotoxin 
treated pigs had increased plasma AST concentrations compared to no-endotoxin pigs. 
This implies a sparing effect o f dexamethasone on liver damage.
Two or more AST isozymes are located in the cytosol and the mitochondria and 
catalyze the conversion o f aspartate and alpha-ketoglutarate to glutamate and 
oxaloacetate (Duncan & Prasse. 1986). The enzyme occurs in almost all cells. It is 
considered to be a diagnostic enzyme for liver and muscle disease, because of high
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activity in these tissues. The plasma AST half-life for swine is about 18 hours. Plasma 
AST activity increases with changes in heptocellular permeability due to sublethal 
injury and necrosis. The magnitude of the increase approximates the number of cells 
affected in acute disease. In acute hepatic sublethal injury or necrosis and high serum 
AST. hepatic insufficiency may be minimal. Consequently, the 24 h 
enrofloxacin/creatinine and ciprofloxacin/creatinine ratios were elevated for the 
endotoxin group 48 h after endotoxin administration which is 24 h after AST elevation. 
By 48 h. liver damage (plasma AST concentration) was on the decline which would 
suggest that any depression o f total cytochrome P450 protein content was increasing. 
This seems reasonable, because total cytochrome P450 content and enzyme activities 
were decreased 24 h after five doses of endotoxin (17 pg/kg) in the Netherlands study 
(Monshouwer et. al.. 1996a) compared to a single i.v. dose (2 pg/kg) used in this study. 
Resolving liver damage and elevated urine ciprofloxacin/creatinine ratio point to a 
physiological mechanism for decreased enrofloxacin clearance in the endotoxin group. 
A decrease in enrofloxacin conversion to ciprofloxacin is not likely in the endotoxin 
treated pigs.
Dexamethasone depressed IL-6 concentrations after endotoxin administration 
(Table 3.4; Figures 3.3 and 3.4). Then, the effect o f  endotoxin could have depended 
upon concurrent dexamethasone concentration. Therefore, the endotoxin treated pigs 
showed no changes in clearance or volume of distribution of enrofloxacin. The changes 
in urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios at 48 h may be the
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result of enrofloxacin and ciprofloxacin "washout7' due to increased GFR (Figures 3.13 
and 3.14).
At 72 h, the urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios 
were greatest for the endotoxin group compared to the control, dexamethasone and 
endotoxin-dexamethasone groups (Tables 3.7 and 3.8; Figures 3.13 and 3.14). Again, 
there was a significant interaction at 72 h between endotoxin and dexamethasone in the 
enrofloxacin/creatinine ratios (Figure 3.13). Presumably, the interaction may have 
occurred for the same reasons as in the 48 h urine enrofloxacin/creatinine ratios. The 
prolonged enrofloxacin/creatinine and ciprofloxacin/creatinine ratios were most likely 
due to physiological mechanisms rather than reduced metabolism o f ciprofloxacin.
It is also possible that dexamethasone could induce cytochrome P450 
metabolism of enrofloxacin to ciprofloxacin and contribute to the clearance of 
enrofloxacin. Endotoxin could suppress P450's and decrease enrofloxacin clearance, 
but endotoxin did not have an effect on clearance. Endotoxin decreased clearance of 
enrofloxacin compared to control, dexamethasone and endotoxin-dexamethasone groups 
(One-way analysis of variance) (Figure 3.8).
While the enrofloxacin clearance was not decreased and the volume of 
distribution was not increased for the endotoxin group, the mean residence time was 
significantly increased for the endotoxin group compared to the control, dexamethasone 
and endotoxin-dexamethasone groups with no effect on half-life ( Table 4.5; Figure 
3.11). This verifies that the transit time for enrofloxacin is increased by endotoxin. 
Assuming that biliary excretion or transenteric secretion remains the same as healthy
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animals, the most likely cause for the increased transit time is renal vasoconstriction. 
Dexamethasone did not inhibit enrofloxacin clearance in both the infection and 
endotoxin studies. Therefore, a direct effect of dexamethasone on enrofloxacin 
metabolism is doubtful. Liver injury was transient at 24 h after endotoxin 
administration and returned to baseline by 96 h. as measured by plasma AST. This was 
not long enough to promote suppression of cytochrome P450 by systemic cytokine 
release and cause a subsequent reduction of enrofloxacin biotransformation to 
ciprofloxacin or oxo-enrofloxacin. Then, the direct effect o f endotoxin on enrofloxacin 
metabolism is also doubtful. In female rats. IL-1 and dexamethasone significantly 
depressed total P450. and P450IIC12 apoenzyme. and mRNA (Wright & Morgan.
1991). Induction of IL-1 and IL-6 was inhibited by dexamethasone which would 
prevent the cytokine induced suppression of cytochrome P450's (Menzozzi et al..
1994). In this study, dexamethasone did suppress the endotoxin induced release of IL-6 
(Figures 3.3 and 3.4) but did not increase urine enrofloxacin/creatinine ratio with a 
concomitant decrease o f the ciprofloxacin/creatinine ratio in the endotoxin and 
dexamethasone pigs. This strongly suggests that metabolism of enrofloxacin was not 
affected by dexamethasone.
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SUMMARY AND CONCLUSIONS
Previous pharmacokinetic studies have used healthy animals while diseased 
animals were used in efficacy studies. The lack o f pharmacokinetic studies in diseased 
animals was not through scientific neglect, but the fact that the drug or antimicrobial 
must be tested in healthy animals who may be screened for age. weight, medical history, 
blood chemistry and receive the test article at the same time of day. with similar 
conditions o f fasting, food, and activity. The performance of a drug or antimicrobial or 
its formulation is a tested in healthy animals by keeping all variables that might affect 
pharmacokinetics parameters constant. However, many veterinary drugs are not 
intended for healthy animals, but rather for those animals with one or more pathological 
conditions that are manifested as disease processes. These disease processes alter the 
normal function of the body. Consequently, the normal functions involved in 
distribution and elimination of a drug may be altered by disease.
Because the body handles many drugs and endogenous substances similarly, 
diseases that alter the pharmacodynamics of endogenous substances may also alter the 
pharmacodynamics o f drugs. Diseases that alter pharmacodynamics can also alter 
pharmacokinetic parameters. The onset and duration o f action of a drug is dependent on 
the rate and extent of distribution. A change in the apparent volume of distribution may 
change the drug concentration in blood or plasma and at the receptor site. Diseases can 
modify a number of kinetic parameters and alter steady state concentrations and. 
thereby, influence efficacy or toxicity. Unfortunately, it is not easy to standardize 
disease models. Disease models are ever changing and never constant, dependent on the
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state of the disease, which makes it difficult to find a population o f animals who are 
homogenous for the disease, disease state, therapy, age, weight, genetics, diet, housing 
and stress factors.
One o f the objectives o f this investigation was to determine whether a 
Actinobacillus pleuropneumoniae pulmonary infection model could be standardized. 
This goal was accomplished as demonstrated by the pigs becoming ill within 2 hours of 
inoculation with APP. where signs o f labored breathing and lethargy were observed. 
Systemic interleukin-6 concentrations were highly elevated in the infected pigs. This 
was another indication that APP infection was accomplished. Infection was verified by 
gross pathology observations, increased lung weights and microscopic pathology results 
of necrotizing, fibrinopurulent pneumonia.
The second objective was to examine the effect of infection and dexamethasone 
on pharmacokinetic parameters in swine after administering enrofloxacin. Clearance 
was reduced for the dexamethasone treated pigs, but clearance was not altered in 
infected pigs. This change was attributed to increased glomerular filtration rate and 
filtration fraction. The volume o f distribution based on the elimination phase was 
decreased in the infected pigs, and was influenced by the elimination rate constant. The 
volume of distribution at steady state was also decreased in the infected pigs and is 
independent of the elimination rate constant. This means that decreased volumes of 
distribution may be due to not only an increased elimination rate constant but could also 
be to decreased protein binding in plasma and tissues and/or changes in blood pH or 
flow. Mean residence time and half-life were decreased in the dexamethasone treated
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pigs. The changes in mean residence time and half-life reflected the change of 
increased clearance in the dexamethasone treated pigs. The urine 
enrofloxacin/creatinine ratio was decreased for the dexamethasone treated pigs which 
demonstrated a "washout” effect of dexamethasone by increasing the glomerular 
filtration rate and filtration fraction. The ciprofloxacin/creatinine ratio and clearance in 
the infected pigs were not changed which means that enrofloxacin metabolism was not 
altered by infection. Finding the suspect oxo-enrofloxacin peak in the urine samples of 
the control, dexamethasone. infected and non-infected dexamethasone pigs was 
completely unexpected. Other investigators not did not find metabolites or conjugates 
after ciprofloxacin administration (Nouws et al., 1988). The presence of oxo- 
enrofloxacin should be confirmed by mass-spectroscopy before HPLC analysis o f the 
urine peaks. Dexamethasone could have depressed metabolism by cytochrome P450's 
but this would not be obvious from the data because excretion and metabolism are 
components o f clearance. Infection may change the appropriate dosage of enrofloxacin 
because the volume o f distribution is changed. Decreased volume of distribution could 
mean less drug at the receptor site. Withdrawal times should not be altered because 
infection did not change enrofloxacin clearance.
The third objective was to compare the results of the infection study to an 
endotoxin study. It was postulated that the use o f endotoxin would mimic the 
Actinobacillus pleuropneumoniae infection and induce similar pharmacokinetic 
changes. The endotoxin treated pigs became ill within 30 minutes as shown by very 
elevated interleukin-6 plasma concentrations, which proves that systemic signs were
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initiated. As observed in the infection study, clearance o f enrofloxacin was increased in 
the dexamethasone treated pigs. The volumes of distribution o f the elimination phase 
and at steady state were also increased in the dexamethasone treated pigs which was not 
observed in the infection study. The combined effect of volume of distribution increase 
and clearance increase resulted in no change in half-life in the dexamethasone treated 
pigs. Mean residence time was increased for the endotoxin group. Clearance was 
decreased for the endotoxin group which was further manifested as increased urine 
enrofloxacin/creatinine and ciprofloxacin/creatinine ratios. In the endotoxin study, the 
washout of enrofloxacin and ciprofloxacin was evident in the urine samples of 
dexamethasone treated pigs as in the infection study. If the clearance of enrofloxacin 
was decreased by reduced metabolism of enrofloxacin. it is assumed that renal function, 
hepatic function and blood flow were not altered. However, it is more probable that 
renal blood flow was decreased as a response to endotoxic shock and hypotension.
Dexamethasone enhanced enrofloxacin clearance and suppressed IL-6 plasma 
concentrations which suggests that cytochrome P450 activity was not decreased in 
endotoxin treated pigs. Therefore, dexamethasone had a positive influence on 
enrofloxacin clearance, rather than producing a blockade o f cytochrome P450 
metabolism and decreased clearance, along with its anti-inflammatory role.
Additionally, the transient liver injury caused by endotoxin may not have been 
substantial enough to depress hepatic metabolism of enrofloxacin as indicated by 
aspartate aminotransferase plasma concentrations. It is not likely that cytochrome 
P450’s are involved in the decreased clearance and increased mean residence time of
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enrofloxacin in the endotoxin group for the following reasons: 1) urine 
ciprofloxacin/creatinine ratios were not elevated; 2) liver injury was transient as 
indicated by plasma aspartate aminotransferase concentrations. However, the presence 
of a suspect oxo-enrofloxacin peak in the endotoxin study may prove interesting after 
mass-spectroscopy confirmation and HPLC analysis as already mentioned for the 
infection study. If the oxo-enrofloxacin ratios are not decreased for the endotoxin group 
compared to the control, dexamethasone and endotoxin-dexamethasone groups, this 
would support the physiological explanation for decreased enrofloxacin clearance as 
opposed to reduced metabolism.
The infection and endotoxin studies confirm that the use of dexamethasone in 
conjunction with enrofloxacin may result in reduced efficacy because of increased 
clearance. Furthermore, the infected pigs had a decreased volume of distribution which 
may reduce the concentration of enrofloxacin at the receptor site and decrease efficacy. 
The contradiction o f no effect of dexamethasone on volumes of distribution in the 
infection study but increased volumes of distribution in the endotoxin study can not be 
readily explained, except that the genetic make up of the pigs was different between the 
two studies; Landrace x Yorkshire in the infection and Hampshire x Yorkshire in the 
endotoxin study.
The use o f model drugs, such as antipyrine, to investigate pharmacokinetic 
parameters with diseased animals is a useful screening tool but can only viewed as 
preliminary information prior to testing therapeutic agents. However, the variables 
involved in the disease process, compared to healthy animals, make interpretation of the
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results with model drugs difficult and the prediction of efficacy and toxicity impractical. 
Thus, the best way to assess the influence of disease on pharmacokinetic parameters is 
to use a specific therapeutic drug or antimicrobial instead of a model drug in the 
presence of a disease model with a particular gene pool of domestic animals. This study 
showed that Actinobacillus pleuropneumoniae. serotype 1. could be used as a disease 
model in United States domestic pigs (Yorkshire crosses) to test the effects of infection 
on pharmacokinetic parameters of enrofloxacin. a therapeutic fluoroquinolone.
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